@article{abdel-qadirContributionFamilialHeritable2007,
  title = {The Contribution of Familial and Heritable Risks in Heart Failure},
  author = {{Abdel-Qadir}, Husam M. and Lee, Douglas S.},
  year = {2007},
  month = may,
  journal = {Current Opinion in Cardiology},
  volume = {22},
  number = {3},
  pages = {214--219},
  issn = {0268-4705},
  doi = {10.1097/HCO.0b013e3280d9e855},
  abstract = {PURPOSE OF REVIEW: The purpose of this review is to summarize the recent literature regarding the familial heritability of heart failure and to discuss the possible mechanisms through which this risk is mediated. RECENT FINDINGS: Data from the Framingham Heart Study recently showed that the parental occurrence of heart failure increases the risk of heart failure in offspring. Although the mechanisms mediating this increased risk are not elucidated, heritable risks of heart failure may result from genes affecting the cardiac or vascular systems. Alternatively, familial risk may be mediated partly through the inheritance of recognized or as yet unidentified risk factors for heart failure. Heritable components or genetic loci for quantitative traits contribute to the development of hypertension, coronary artery disease, cardiomyopathies, valvular heart disease, and metabolic conditions, which collectively increase the risk of heart failure. SUMMARY: A careful assessment of the family history of heart failure and associated risk factors may identify treatable targets that can potentially reduce the likelihood of developing heart failure, and can assist in the implementation of preventive strategies for risk populations with stages A and B heart failure.},
  langid = {english},
  pmid = {17413278},
  keywords = {Genetic Diseases Inborn,Genetic Predisposition to Disease,Genotype,Heart Failure,Humans,Insulin Resistance,Obesity,Phenotype,Risk Assessment,Risk Factors}
}

@article{alebnaUpdateObesityObesity2024,
  title = {Update on Obesity, the Obesity Paradox, and Obesity Management in Heart Failure},
  author = {Alebna, Pamela L. and Mehta, Anurag and Yehya, Amin and {daSilva-deAbreu}, Adrian and Lavie, Carl J. and Carbone, Salvatore},
  year = {2024},
  journal = {Progress in Cardiovascular Diseases},
  volume = {82},
  pages = {34--42},
  issn = {1873-1740},
  doi = {10.1016/j.pcad.2024.01.003},
  abstract = {Obesity is a major public health challenge worldwide. It is costly, predisposes to many cardiovascular (CV) diseases (CVD), is increasing at an alarming rate, and disproportionately affects people of low-socioeconomic status. It has a myriad of deleterious effects on the body, particularly on the CV system. Obesity is a major risk factor for heart failure (HF) and highly prevalent in this population, particularly in those with HF with preserved ejection fraction (HFpEF), to the extent that an obesity HFpEF phenotype has been proposed in the literature. However, once HF is developed, an obesity paradox exists where those with obesity have better short- and mid-term survival than normal or underweight individuals, despite a greater risk for hospitalizations. It may be argued that excess energy reserve, younger patient population, higher tolerability of HF therapy and better nutritional status may account for at least part of the obesity paradox on survival. Furthermore, body mass index (BMI) may not be an accurate measure of body composition, especially in HF, where there is an excess volume status. BMI also fails to delineate fat-free mass and its components, which is a better predictor of functional capacity and cardiorespiratory fitness (CRF), which particularly is increasingly being recognized as a risk modifier in both healthy individuals and in persons with comorbidities, particularly in HF. Notably, when CRF is accounted for, the obesity paradox disappears, suggesting that improving CRF might represent a therapeutic target with greater importance than changes in body weight in the setting of HF. In this narrative review, we discuss the current trends in obesity, the causal link between obesity and HF, an update on the obesity paradox, and a description of the major flaws of BMI in this population. We also present an overview of the latest in HF therapy, weight loss, CRF, and the application of these therapeutic approaches in patients with HF and concomitant obesity.},
  langid = {english},
  pmid = {38199320},
  keywords = {Body mass index,Body Mass Index,Cardiovascular disease,Cardiovascular Diseases,Heart failure,Heart Failure,Humans,Obesity,Obesity Management,Obesity paradox,Obesity Paradox,Prognosis,Risk Factors,Stroke Volume},
  file = {/Users/xx20081/Zotero/storage/SIDTIEV6/Alebna et al. - 2024 - Update on obesity, the obesity paradox, and obesit.pdf}
}

@article{aronneContinuedTreatmentTirzepatide2024,
  title = {Continued {{Treatment With Tirzepatide}} for {{Maintenance}} of {{Weight Reduction}} in {{Adults With Obesity}}: {{The SURMOUNT-4 Randomized Clinical Trial}}},
  shorttitle = {Continued {{Treatment With Tirzepatide}} for {{Maintenance}} of {{Weight Reduction}} in {{Adults With Obesity}}},
  author = {Aronne, Louis J. and Sattar, Naveed and Horn, Deborah B. and Bays, Harold E. and Wharton, Sean and Lin, Wen-Yuan and Ahmad, Nadia N. and Zhang, Shuyu and Liao, Ran and Bunck, Mathijs C. and Jouravskaya, Irina and Murphy, Madhumita A. and {SURMOUNT-4 Investigators}},
  year = {2024},
  month = jan,
  journal = {JAMA},
  volume = {331},
  number = {1},
  pages = {38--48},
  issn = {0098-7484},
  doi = {10.1001/jama.2023.24945},
  urldate = {2025-01-21},
  abstract = {The effect of continued treatment with tirzepatide on maintaining initial weight reduction is unknown.To assess the effect of tirzepatide, with diet and physical activity, on the maintenance of weight reduction.This phase 3, randomized withdrawal clinical trial conducted at 70 sites in 4 countries with a 36-week, open-label tirzepatide lead-in period followed by a 52-week, double-blind, placebo-controlled period included adults with a body mass index greater than or equal to 30 or greater than or equal to 27 and a weight-related complication, excluding diabetes.Participants (n\,=\,783) enrolled in an open-label lead-in period received once-weekly subcutaneous maximum tolerated dose (10 or 15 mg) of tirzepatide for 36 weeks. At week 36, a total of 670 participants were randomized (1:1) to continue receiving tirzepatide (n\,=\,335) or switch to placebo (n\,=\,335) for 52 weeks.The primary end point was the mean percent change in weight from week 36 (randomization) to week 88. Key secondary end points included the proportion of participants at week 88 who maintained at least 80\% of the weight loss during the lead-in period.Participants (n\,=\,670; mean age, 48 years; 473 [71\%] women; mean weight, 107.3 kg) who completed the 36-week lead-in period experienced a mean weight reduction of 20.9\%. The mean percent weight change from week 36 to week 88 was -5.5\% with tirzepatide vs 14.0\% with placebo (difference, -19.4\% [95\% CI, -21.2\% to -17.7\%]; P\,\&lt;\,.001). Overall, 300 participants (89.5\%) receiving tirzepatide at 88 weeks maintained at least 80\% of the weight loss during the lead-in period compared with 16.6\% receiving placebo (P\,\&lt;\,.001). The overall mean weight reduction from week 0 to 88 was 25.3\% for tirzepatide and 9.9\% for placebo. The most common adverse events were mostly mild to moderate gastrointestinal events, which occurred more commonly with tirzepatide vs placebo.In participants with obesity or overweight, withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction.ClinicalTrials.gov Identifier: NCT04660643},
  file = {/Users/xx20081/Zotero/storage/2N5WHJAW/Aronne et al. - 2024 - Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity The.pdf;/Users/xx20081/Zotero/storage/66WYJRMG/2812936.html}
}

@article{atherImpactNoncardiacComorbidities2012,
  title = {Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population with Heart Failure and Preserved versus Reduced Ejection Fraction},
  author = {Ather, Sameer and Chan, Wenyaw and Bozkurt, Biykem and Aguilar, David and Ramasubbu, Kumudha and Zachariah, Amit A. and Wehrens, Xander H. T. and Deswal, Anita},
  year = {2012},
  month = mar,
  journal = {Journal of the American College of Cardiology},
  volume = {59},
  number = {11},
  pages = {998--1005},
  issn = {1558-3597},
  doi = {10.1016/j.jacc.2011.11.040},
  abstract = {OBJECTIVES: The aim of this study was to evaluate the prevalence and prognostic impacts of noncardiac comorbidities in patients with heart failure (HF) with preserved ejection fraction (HFpEF) compared with those with HF with reduced ejection fraction (HFrEF). BACKGROUND: There is a paucity of information on the comparative prognostic significance of comorbidities between patients with HFpEF and those with HFrEF. METHODS: In a national ambulatory cohort of veterans with HF, the comorbidity burden of 15 noncardiac comorbidities and the impacts of these comorbidities on hospitalization and mortality were compared between patients with HFpEF and those with HFrEF. RESULTS: The cohort consisted of 2,843 patients with HFpEF and 6,599 with HFrEF with 2-year follow-up. Compared with patients with HFrEF, those with HFpEF were older and had higher prevalence of chronic obstructive pulmonary disease, diabetes, hypertension, psychiatric disorders, anemia, obesity, peptic ulcer disease, and cancer but a lower prevalence of chronic kidney disease. Patients with HFpEF had lower HF hospitalization, higher non-HF hospitalization, and similar overall hospitalization compared with those with HFrEF (p {$<$} 0.001, p {$<$} 0.001, and p = 0.19, respectively). An Increasing number of noncardiac comorbidities was associated with a higher risk for all-cause admissions (p {$<$} 0.001). Comorbidities had similar impacts on mortality in patients with HFpEF compared with those with HFrEF, except for chronic obstructive pulmonary disease, which was associated with a higher hazard (1.62 [95\% confidence interval: 1.36 to 1.92] vs. 1.23 [95\% confidence interval: 1.11 to 1.37], respectively, p = 0.01 for interaction) in patients with HFpEF. CONCLUSIONS: There is a higher noncardiac comorbidity burden associated with higher non-HF hospitalizations in patients with HFpEF compared with those with HFrEF. However, individually, most comorbidities have similar impacts on mortality in both groups. Aggressive management of comorbidities may have an overall greater prognostic impact in HFpEF compared to HFrEF.},
  langid = {english},
  pmcid = {PMC4687406},
  pmid = {22402071},
  keywords = {Aged,Aged 80 and over,Comorbidity,Female,Heart Failure,Humans,Male,Middle Aged,Prevalence,Retrospective Studies,Stroke Volume,United States}
}

@article{badveEffectsGLP1Receptor2025,
  title = {Effects of {{GLP-1}} Receptor Agonists on Kidney and Cardiovascular Disease Outcomes: A Meta-Analysis of Randomised Controlled Trials},
  shorttitle = {Effects of {{GLP-1}} Receptor Agonists on Kidney and Cardiovascular Disease Outcomes},
  author = {Badve, Sunil V. and Bilal, Anika and Lee, Matthew M. Y. and Sattar, Naveed and Gerstein, Hertzel C. and Ruff, Christian T. and McMurray, John J. V. and Rossing, Peter and Bakris, George and Mahaffey, Kenneth W. and Mann, Johannes F. E. and Colhoun, Helen M. and Tuttle, Katherine R. and Pratley, Richard E. and Perkovic, Vlado},
  year = {2025},
  month = jan,
  journal = {The Lancet. Diabetes \& Endocrinology},
  volume = {13},
  number = {1},
  pages = {15--28},
  issn = {2213-8595},
  doi = {10.1016/S2213-8587(24)00271-7},
  abstract = {BACKGROUND: GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains uncertain. We aimed to comprehensively assess the effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes by performing a meta-analysis of randomised controlled trials. METHODS: For this meta-analysis, we searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for randomised controlled trials that included at least 500 participants with type 2 diabetes, compared a GLP-1 receptor agonist with placebo with at least 12 months of follow-up, and reported a primary clinical kidney or cardiovascular outcome, from database inception to March 26, 2024. Post hoc, we included the SELECT trial (NCT03574597), which enrolled participants with cardiovascular disease and a BMI of 27 kg/m2 or more without diabetes. Study-level summary data were extracted independently by two authors for inclusion in this random-effects analysis. The main kidney outcome was a composite outcome, consisting of kidney failure (kidney replacement therapy or a persistent estimated glomerular filtration rate [eGFR] {$<$}15 mL/min per 1{$\cdot$}73 m2), a sustained reduction in eGFR by at least 50\% or the nearest equivalent, or death from kidney failure. The main cardiovascular outcome was MACE, consisting of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. This study is registered with PROSPERO, CRD42024528864. FINDINGS: Of the 5140 records identified through the literature search, 11 trials, involving 85\,373 participants (29\,386 female, 55\,987 male), were included in the meta-analysis. In participants with type 2 diabetes (67\,769), GLP-1 receptor agonists reduced the composite kidney outcome by 18\% compared with placebo (hazard ratio [HR] 0{$\cdot$}82, 95\% CI 0{$\cdot$}73-0{$\cdot$}93; I2 =26{$\cdot$}41\%), kidney failure by 16\% (HR 0{$\cdot$}84, 0{$\cdot$}72-0{$\cdot$}99; I2 =0\%), MACE by 13\% (HR 0{$\cdot$}87, 0{$\cdot$}81-0{$\cdot$}93; I2 =49{$\cdot$}75\%), and all-cause death by 12\% (HR 0{$\cdot$}88, 0{$\cdot$}83-0{$\cdot$}93; I2 =0\%). The effect on the composite kidney outcome (HR 0{$\cdot$}81, 95\% CI 0{$\cdot$}72-0{$\cdot$}92; I2 =23{$\cdot$}11\%), kidney failure (HR 0{$\cdot$}84, 0{$\cdot$}72-0{$\cdot$}98; I2 =0\%), MACE (HR 0{$\cdot$}86, 0{$\cdot$}80-0{$\cdot$}92; I2 =48{$\cdot$}9\%), and all-cause death (HR 0{$\cdot$}87, 0{$\cdot$}82-0{$\cdot$}91; I2 =0\%) was similar when the SELECT trial was included, with no evidence of heterogeneity between this trial and those including participants with type 2 diabetes (pheterogeneity {$>$}0{$\cdot$}05). There was no difference in the risk of serious adverse events, including acute pancreatitis and severe hypoglycaemia, between the GLP-1 receptor agonist and placebo groups (risk ratio [RR] 0{$\cdot$}95, 95\% CI 0{$\cdot$}90-1{$\cdot$}01; I2 =88{$\cdot$}5\%). However, treatment discontinuation due to adverse events occurred more frequently in the GLP-1 receptor agonist groups (RR 1{$\cdot$}51, 95\% CI 1{$\cdot$}18-1{$\cdot$}94; I2 =96{$\cdot$}3\%). INTERPRETATION: We found evidence that GLP-1 receptor agonists significantly reduce clinically important kidney events, kidney failure, and cardiovascular events. FUNDING: None.},
  langid = {english},
  pmid = {39608381},
  keywords = {Cardiovascular Diseases,Diabetes Mellitus Type 2,Glucagon-Like Peptide-1 Receptor Agonists,Humans,Hypoglycemic Agents,Randomized Controlled Trials as Topic,Treatment Outcome}
}

@article{banackBadWorseCollider2015,
  title = {From Bad to Worse: Collider Stratification Amplifies Confounding Bias in the "Obesity Paradox"},
  shorttitle = {From Bad to Worse},
  author = {Banack, Hailey R. and Kaufman, Jay S.},
  year = {2015},
  month = oct,
  journal = {European Journal of Epidemiology},
  volume = {30},
  number = {10},
  pages = {1111--1114},
  issn = {1573-7284},
  doi = {10.1007/s10654-015-0069-7},
  abstract = {Smoking is often identified as a confounder of the obesity-mortality relationship. Selection bias can amplify the magnitude of an existing confounding bias. The objective of the present report is to demonstrate how confounding bias due to cigarette smoking is increased in the presence of collider stratification bias using an empirical example and directed acyclic graphs. The empirical example uses data from the Atherosclerosis Risk in Communities (ARIC) study, a prospective cohort study of 15,792 men and women in the United States. Poisson regression models were used to examine the confounding effect of smoking. In the total ARIC study population, smoking produced a confounding bias of {$<$}3 percentage points. This result was obtained by comparing the incidence rate ratio (IRR) for obesity from a model adjusted for smoking was 1.07 (95~\% CI 1.00, 1.15) with one that did not adjust for smoking was 1.10 (95~\% CI 1.03, 1.18). However, among smokers with CVD, the obesity IRR was 0.89 (95~\% CI 0.81, 0.99), while among non-smokers with CVD the obesity IRR was 1.20 (95~\% CI 1.03, 1.41). The empirical and graphical explanations presented suggest that the magnitude of the confounding bias induced by smoking is greater in the presence of collider stratification bias.},
  langid = {english},
  pmid = {26187718},
  keywords = {Bias,Causality,Confounding bias,Confounding Factors Epidemiologic,Humans,Linear Models,Models Statistical,Obesity,Obesity paradox,Selection bias,Selection Bias,Smoking},
  file = {/Users/xx20081/Zotero/storage/MWB7IKJ8/Banack and Kaufman - 2015 - From bad to worse collider stratification amplifi.pdf}
}

@article{banerjeeEpicardialFatParadox2023,
  title = {Epicardial {{Fat Paradox}} and {{Differential Effects}} of {{GLP-1 Receptor Agonists Across Heart Failure Phenotypes}}},
  author = {Banerjee, Mainak},
  year = {2023},
  month = dec,
  journal = {Circulation: Heart Failure},
  volume = {16},
  number = {12},
  pages = {e010966},
  publisher = {American Heart Association},
  doi = {10.1161/CIRCHEARTFAILURE.123.010966},
  urldate = {2024-04-04},
  keywords = {adiposity,diabetes type 2,heart failure,mortality,obesity paradox}
}

@article{bergmannSemaglutideTreatmentOverweight2023,
  title = {Semaglutide for the Treatment of Overweight and Obesity: {{A}} Review},
  shorttitle = {Semaglutide for the Treatment of Overweight and Obesity},
  author = {Bergmann, Natasha Chidekel and Davies, Melanie J. and Lingvay, Ildiko and Knop, Filip K.},
  year = {2023},
  month = jan,
  journal = {Diabetes, Obesity \& Metabolism},
  volume = {25},
  number = {1},
  pages = {18--35},
  issn = {1462-8902},
  doi = {10.1111/dom.14863},
  urldate = {2025-01-21},
  abstract = {Obesity is a chronic, relapsing disease associated with multiple complications and a substantial morbidity, mortality and health care burden. Pharmacological treatments for obesity provide a valuable adjunct to lifestyle intervention, which often achieves only limited weight loss that is difficult to maintain. The Semaglutide Treatment Effect in People with obesity (STEP) clinical trial programme is evaluating once-weekly subcutaneous semaglutide 2.4~mg (a glucagon-like peptide-1 analogue) in people with overweight or obesity. Across STEP 1, 3, 4 and 8, semaglutide 2.4~mg was associated with mean weight losses of 14.9\%-17.4\% in individuals with overweight or obesity without type 2 diabetes from baseline to week 68; 69\%-79\% of participants achieved {$\geq$}10\% weight loss with semaglutide 2.4~mg (vs. 12\%-27\% with placebo) and 51\%-64\% achieved {$\geq$}15\% weight loss (vs. 5\%-13\% with placebo). In STEP 5, mean weight loss was -15.2\% with semaglutide 2.4~mg versus -2.6\% with placebo from baseline to week 104. In STEP 2 (individuals with overweight or obesity, and type 2 diabetes), mean weight loss was -9.6\% with semaglutide 2.4~mg versus -3.4\% with placebo from baseline to week 68. Improvements in cardiometabolic risk factors, including high blood pressure, atherogenic lipids and benefits on physical function and quality of life were seen with semaglutide 2.4~mg. The safety profile of semaglutide 2.4~mg was consistent across trials, primarily gastrointestinal adverse events. The magnitude of weight loss reported in the STEP trials offers the potential for clinically relevant improvement for individuals with obesity-related diseases.},
  pmcid = {PMC10092086},
  pmid = {36254579},
  file = {/Users/xx20081/Zotero/storage/ZS7HFI7R/Bergmann et al. - 2023 - Semaglutide for the treatment of overweight and obesity A review.pdf}
}

@article{bmSaxagliptinCardiovascularOutcomes2013,
  title = {Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus},
  author = {Bm, Scirica and Dl, Bhatt and E, Braunwald and Pg, Steg and J, Davidson and B, Hirshberg and P, Ohman and R, Frederich and Sd, Wiviott and Eb, Hoffman and Ma, Cavender and Ja, Udell and Nr, Desai and O, Mosenzon and Dk, McGuire and Kk, Ray and La, Leiter and I, Raz},
  year = {2013},
  month = mar,
  journal = {The New England journal of medicine},
  volume = {369},
  number = {14},
  publisher = {N Engl J Med},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1307684},
  urldate = {2023-12-08},
  abstract = {DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes. (Fun {\dots}},
  langid = {english},
  pmid = {23992601},
  file = {/Users/xx20081/Zotero/storage/92E2FC95/Bm et al. - 2013 - Saxagliptin and cardiovascular outcomes in patient.pdf;/Users/xx20081/Zotero/storage/TVK4WY7F/23992601.html}
}

@article{borlaugEffectInorganicNitrite2018,
  title = {Effect of {{Inorganic Nitrite}} vs {{Placebo}} on {{Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction}}: {{The INDIE-HFpEF Randomized Clinical Trial}}},
  shorttitle = {Effect of {{Inorganic Nitrite}} vs {{Placebo}} on {{Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction}}},
  author = {Borlaug, Barry A. and Anstrom, Kevin J. and Lewis, Gregory D. and Shah, Sanjiv J. and Levine, James A. and Koepp, Gabe A. and Givertz, Michael M. and Felker, G. Michael and LeWinter, Martin M. and Mann, Douglas L. and Margulies, Kenneth B. and Smith, Andrew L. and Tang, W. H. Wilson and Whellan, David J. and Chen, Horng H. and {Davila-Roman}, Victor G. and McNulty, Steven and {Desvigne-Nickens}, Patrice and Hernandez, Adrian F. and Braunwald, Eugene and Redfield, Margaret M. and {National Heart, Lung, and Blood Institute Heart Failure Clinical Research Network}},
  year = {2018},
  month = nov,
  journal = {JAMA},
  volume = {320},
  number = {17},
  pages = {1764--1773},
  issn = {1538-3598},
  doi = {10.1001/jama.2018.14852},
  abstract = {IMPORTANCE: There are few effective treatments for heart failure with preserved ejection fraction (HFpEF). Short-term administration of inorganic nitrite or nitrate preparations has been shown to enhance nitric oxide signaling, which may improve aerobic capacity in HFpEF. OBJECTIVE: To determine the effect of 4 weeks' administration of inhaled, nebulized inorganic nitrite on exercise capacity in HFpEF. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled, 2-treatment, crossover trial of 105 patients with HFpEF. Participants were enrolled from July 22, 2016, to September 12, 2017, at 17 US sites, with final date of follow-up of January 2, 2018. INTERVENTIONS: Inorganic nitrite or placebo administered via micronebulizer device. During each 6-week phase of the crossover study, participants received no study drug for 2 weeks (baseline/washout) followed by study drug (nitrite or placebo) at 46 mg 3 times a day for 1 week followed by 80 mg 3 times a day for 3 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was peak oxygen consumption (mL/kg/min). Secondary end points included daily activity levels assessed by accelerometry, health status as assessed by the Kansas City Cardiomyopathy Questionnaire (score range, 0-100, with higher scores reflecting better quality of life), functional class, cardiac filling pressures assessed by echocardiography, N-terminal fragment of the prohormone brain natriuretic peptide levels, other exercise indices, adverse events, and tolerability. Outcomes were assessed after treatment for 4 weeks. RESULTS: Among 105 patients who were randomized (median age, 68 years; 56\% women), 98 (93\%) completed the trial. During the nitrite phase, there was no significant difference in mean peak oxygen consumption as compared with the placebo phase (13.5 vs 13.7 mL/kg/min; difference, -0.20 [95\% CI, -0.56 to 0.16]; P\,=\,.27). There were no significant between-treatment phase differences in daily activity levels (5497 vs 5503 accelerometry units; difference, -15 [95\% CI, -264 to 234]; P\,=\,.91), Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (62.6 vs 61.9; difference, 1.1 [95\% CI, -1.4 to 3.5]; P\,=\,.39), functional class (2.5 vs 2.5; difference, 0.1 [95\% CI, -0.1 to 0.2]; P\,=\,.43), echocardiographic E/e' ratio (16.4 vs 16.6; difference, 0.1 [95\% CI, -1.2 to 1.3]; P\,=\,.93), or N-terminal fragment of the prohormone brain natriuretic peptide levels (520 vs 533 pg/mL; difference, 11 [95\% CI, -53 to 75]; P\,=\,.74). Worsening heart failure occurred in 3 participants (2.9\%) during the nitrite phase and 8 (7.6\%) during the placebo phase. CONCLUSIONS AND RELEVANCE: Among patients with HFpEF, administration of inhaled inorganic nitrite for 4 weeks, compared with placebo, did not result in significant improvement in exercise capacity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02742129.},
  langid = {english},
  pmcid = {PMC6248105},
  pmid = {30398602},
  keywords = {Administration Inhalation,Aged,Cross-Over Studies,Double-Blind Method,Exercise Test,Exercise Tolerance,Female,Heart Failure,Humans,Inorganic Chemicals,Male,Middle Aged,Nitrites,Oxygen Consumption,Stroke Volume,Treatment Failure}
}

@article{bozkurtContributoryRiskManagement2016,
  title = {Contributory {{Risk}} and {{Management}} of {{Comorbidities}} of {{Hypertension}}, {{Obesity}}, {{Diabetes Mellitus}}, {{Hyperlipidemia}}, and {{Metabolic Syndrome}} in {{Chronic Heart Failure}}},
  shorttitle = {Contributory {{Risk}} and {{Management}} of {{Comorbidities}} of {{Hypertension}}, {{Obesity}}, {{Diabetes Mellitus}}, {{Hyperlipidemia}}, and {{Metabolic Syndrome}} in {{Chronic Heart Failure}}},
  author = {Bozkurt, Biykem and Aguilar, David and Deswal, Anita and Dunbar, Sandra B. and Francis, Gary S. and Horwich, Tamara and Jessup, Mariell and Kosiborod, Mikhail and Pritchett, Allison M. and Ramasubbu, Kumudha and Rosendorff, Clive and Yancy, Clyde},
  year = {2016},
  month = dec,
  journal = {Circulation},
  volume = {134},
  number = {23},
  pages = {e535-e578},
  issn = {1524-4539},
  doi = {10.1161/CIR.0000000000000450},
  langid = {english},
  pmid = {27799274},
  keywords = {AHA Scientific Statements,American Heart Association,Cardiology,cardiovascular diseases,Chronic Disease,comorbidity,Comorbidity,Consensus,diabetes mellitus,Diabetes Mellitus,Evidence-Based Medicine,heart failure,Heart Failure,Humans,hyperlipidemia,Hyperlipidemias,hypertension,Hypertension,Incidence,Metabolic Syndrome,obesity,Obesity,Prognosis,Risk Assessment,risk factors,Risk Factors,United States},
  file = {/Users/xx20081/Zotero/storage/YZ4S7LHW/Bozkurt et al. - 2016 - Contributory Risk and Management of Comorbidities .pdf}
}

@article{burgessAddressingCredibilityCrisis2024,
  title = {Addressing the Credibility Crisis in {{Mendelian}} Randomization},
  author = {Burgess, Stephen and Woolf, Benjamin and Mason, Amy M. and {Ala-Korpela}, Mika and Gill, Dipender},
  year = {2024},
  month = sep,
  journal = {BMC Medicine},
  volume = {22},
  number = {1},
  pages = {374},
  issn = {1741-7015},
  doi = {10.1186/s12916-024-03607-5},
  urldate = {2025-03-22},
  abstract = {Genome-wide association studies have enabled Mendelian randomization analyses to be performed at an industrial scale. Two-sample summary data Mendelian randomization analyses can be performed using publicly available data by anyone who has access to the internet. While this has led to many insightful papers, it has also fuelled an explosion of poor-quality Mendelian randomization publications, which threatens to undermine the credibility of the whole approach.},
  keywords = {Bias evaluation,Causal inference,Evidence synthesis,Genetic epidemiology,Instrumental variables,Risk of bias},
  file = {/Users/xx20081/Zotero/storage/2PAX2Q3V/Burgess et al. - 2024 - Addressing the credibility crisis in Mendelian randomization.pdf;/Users/xx20081/Zotero/storage/R663AXZF/s12916-024-03607-5.html}
}

@article{burgessSensitivityAnalysesRobust2017,
  title = {Sensitivity {{Analyses}} for {{Robust Causal Inference}} from {{Mendelian Randomization Analyses}} with {{Multiple Genetic Variants}}},
  author = {Burgess, Stephen and Bowden, Jack and Fall, Tove and Ingelsson, Erik and Thompson, Simon G.},
  year = {2017},
  month = jan,
  journal = {Epidemiology (Cambridge, Mass.)},
  volume = {28},
  number = {1},
  pages = {30--42},
  issn = {1531-5487},
  doi = {10.1097/EDE.0000000000000559},
  abstract = {Mendelian randomization investigations are becoming more powerful and simpler to perform, due to the increasing size and coverage of genome-wide association studies and the increasing availability of summarized data on genetic associations with risk factors and disease outcomes. However, when using multiple genetic variants from different gene regions in a Mendelian randomization analysis, it is highly implausible that all the genetic variants satisfy the instrumental variable assumptions. This means that a simple instrumental variable analysis alone should not be relied on to give a causal conclusion. In this article, we discuss a range of sensitivity analyses that will either support or question the validity of causal inference from a Mendelian randomization analysis with multiple genetic variants. We focus on sensitivity analyses of greatest practical relevance for ensuring robust causal inferences, and those that can be undertaken using summarized data. Aside from cases in which the justification of the instrumental variable assumptions is supported by strong biological understanding, a Mendelian randomization analysis in which no assessment of the robustness of the findings to violations of the instrumental variable assumptions has been made should be viewed as speculative and incomplete. In particular, Mendelian randomization investigations with large numbers of genetic variants without such sensitivity analyses should be treated with skepticism.},
  langid = {english},
  pmcid = {PMC5133381},
  pmid = {27749700},
  keywords = {C-Reactive Protein,Causality,Coronary Artery Disease,Genetic Variation,Genome-Wide Association Study,Humans,Mendelian Randomization Analysis,Odds Ratio,Reproducibility of Results},
  file = {/Users/xx20081/Zotero/storage/RPNYHT5X/Burgess et al. - 2017 - Sensitivity Analyses for Robust Causal Inference f.pdf}
}

@article{burmeisterHypothalamicGlucagonLikePeptide2017,
  title = {The {{Hypothalamic Glucagon-Like Peptide}} 1 {{Receptor Is Sufficient}} but {{Not Necessary}} for the {{Regulation}} of {{Energy Balance}} and {{Glucose Homeostasis}} in {{Mice}}},
  author = {Burmeister, Melissa A. and Ayala, Jennifer E. and Smouse, Hannah and {Landivar-Rocha}, Adriana and Brown, Jacob D. and Drucker, Daniel J. and Stoffers, Doris A. and Sandoval, Darleen A. and Seeley, Randy J. and Ayala, Julio E.},
  year = {2017},
  month = feb,
  journal = {Diabetes},
  volume = {66},
  number = {2},
  pages = {372--384},
  issn = {0012-1797},
  doi = {10.2337/db16-1102},
  urldate = {2024-08-15},
  abstract = {Pharmacological activation of the hypothalamic glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) promotes weight loss and improves glucose tolerance. This demonstrates that the hypothalamic GLP-1R is sufficient but does not show whether it is necessary for the effects of exogenous GLP-1R agonists (GLP-1RA) or endogenous GLP-1 on these parameters. To address this, we crossed mice harboring floxed Glp1r alleles to mice expressing Nkx2.1-Cre to knock down Glp1r expression throughout the hypothalamus (GLP-1RKD{$\Delta$}Nkx2.1cre). We also generated mice lacking Glp1r expression specifically in two GLP-1RA--responsive hypothalamic feeding nuclei/cell types, the paraventricular nucleus (GLP-1RKD{$\Delta$}Sim1cre) and proopiomelanocortin neurons (GLP-1RKD{$\Delta$}POMCcre). Chow-fed GLP-1RKD{$\Delta$}Nkx2.1cre mice exhibited increased food intake and energy expenditure with no net effect on body weight. When fed a high-fat diet, these mice exhibited normal food intake but elevated energy expenditure, yielding reduced weight gain. None of these phenotypes were observed in GLP-1RKD{$\Delta$}Sim1cre and GLP-1RKD{$\Delta$}POMCcre mice. The acute anorectic and glucose tolerance effects of peripherally dosed GLP-1RA exendin-4 and liraglutide were preserved in all mouse lines. Chronic liraglutide treatment reduced body weight in chow-fed GLP-1RKD{$\Delta$}Nkx2.1cre mice, but this effect was attenuated with high-fat diet feeding. In sum, classic homeostatic control regions are sufficient but not individually necessary for the effects of GLP-1RA on nutrient homeostasis.},
  pmcid = {PMC5248999},
  pmid = {27908915},
  file = {/Users/xx20081/Zotero/storage/7MKF9WR6/Burmeister et al. - 2017 - The Hypothalamic Glucagon-Like Peptide 1 Receptor .pdf}
}

@article{buttAnthropometricMeasuresAdverse2023,
  title = {Anthropometric Measures and Adverse Outcomes in Heart Failure with Reduced Ejection Fraction: Revisiting the Obesity Paradox},
  shorttitle = {Anthropometric Measures and Adverse Outcomes in Heart Failure with Reduced Ejection Fraction},
  author = {Butt, Jawad H and Petrie, Mark C and Jhund, Pardeep S and Sattar, Naveed and Desai, Akshay S and K{\o}ber, Lars and Rouleau, Jean L and Swedberg, Karl and Zile, Michael R and Solomon, Scott D and Packer, Milton and McMurray, John J V},
  year = {2023},
  month = mar,
  journal = {European Heart Journal},
  volume = {44},
  number = {13},
  pages = {1136--1153},
  issn = {0195-668X},
  doi = {10.1093/eurheartj/ehad083},
  urldate = {2024-01-16},
  abstract = {Structured Graphical AbstractThe upper part of the figure describes the calculation of each of the anthropometric measures. The lower part of the figure shows the risk of outcomes according to continuous body mass index (left panel) and waist-to-height ratio (right panel). The solid line represents the hazard ratio and the shaded area the 95\% confidence interval. The blue spline is adjusted for treatment and region. The red spline is adjusted for treatment, age, sex, region, systolic blood pressure, heart rate, estimated glomerular filtration rate, left ventricular ejection fraction, log of n-terminal pro-B-type natriuretic peptide, body mass index (only in the waist-to-height ratio analyses), New York Heart Association functional class, heart failure aetiology, duration of heart failure, prior heart failure hospitalization, a history of diabetes, and atrial fibrillation. BMI, body mass index; BRI, body roundness index; BSA, body surface area; BSI, body shape index; CI, confidence interval; HF, heart failure; HR, hazard ratio; RFM, relative fat mass; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio; WWI, weight-adjusted-waist index.},
  pmcid = {PMC10111968},
  pmid = {36944496},
  file = {/Users/xx20081/Zotero/storage/9VHJGDEY/Butt et al. - 2023 - Anthropometric measures and adverse outcomes in he.pdf}
}

@article{caiAdjustingColliderBias2022,
  title = {Adjusting for Collider Bias in Genetic Association Studies Using Instrumental Variable Methods},
  author = {Cai, Siyang and Hartley, April and Mahmoud, Osama and Tilling, Kate and Dudbridge, Frank},
  year = {2022},
  month = jul,
  journal = {Genetic Epidemiology},
  volume = {46},
  number = {5-6},
  pages = {303--316},
  issn = {1098-2272},
  doi = {10.1002/gepi.22455},
  abstract = {Genome-wide association studies have provided many genetic markers that can be used as instrumental variables to adjust for confounding in epidemiological studies. Recently, the principle has been applied to other forms of bias in observational studies, especially collider bias that arises when conditioning or stratifying on a variable that is associated with the outcome of interest. An important case is in studies of disease progression and survival. Here, we clarify the links between the genetic instrumental variable methods proposed for this problem and the established methods of Mendelian randomisation developed to account for confounding. We highlight the critical importance of weak instrument bias in this context and describe a corrected weighted least-squares procedure as a simple approach to reduce this bias. We illustrate the range of available methods on two data examples. The first, waist-hip ratio adjusted for body-mass index, entails statistical adjustment for a quantitative trait. The second, smoking cessation, is a stratified analysis conditional on having initiated smoking. In both cases, we find little effect of collider bias on the primary association results, but this may propagate into more substantial effects on further analyses such as polygenic risk scoring and Mendelian randomisation.},
  langid = {english},
  pmcid = {PMC9544531},
  pmid = {35583096},
  keywords = {ascertainment bias,Bias,Genome-Wide Association Study,Humans,index event bias,Least-Squares Analysis,Mendelian randomisation,Mendelian Randomization Analysis,selection bias,Waist-Hip Ratio},
  file = {/Users/xx20081/Zotero/storage/QXC5MJFQ/Cai et al. - 2022 - Adjusting for collider bias in genetic association.pdf}
}

@article{cappolaLossoffunctionDNASequence2011,
  title = {Loss-of-Function {{DNA}} Sequence Variant in the {{CLCNKA}} Chloride Channel Implicates the Cardio-Renal Axis in Interindividual Heart Failure Risk Variation},
  author = {Cappola, Thomas P. and Matkovich, Scot J. and Wang, Wei and {van Booven}, Derek and Li, Mingyao and Wang, Xuexia and Qu, Liming and Sweitzer, Nancy K. and Fang, James C. and Reilly, Muredach P. and Hakonarson, Hakon and Nerbonne, Jeanne M. and Dorn, Gerald W.},
  year = {2011},
  month = feb,
  journal = {Proceedings of the National Academy of Sciences of the United States of America},
  volume = {108},
  number = {6},
  pages = {2456--2461},
  issn = {1091-6490},
  doi = {10.1073/pnas.1017494108},
  abstract = {Common heart failure has a strong undefined heritable component. Two recent independent cardiovascular SNP array studies identified a common SNP at 1p36 in intron 2 of the HSPB7 gene as being associated with heart failure. HSPB7 resequencing identified other risk alleles but no functional gene variants. Here, we further show no effect of the HSPB7 SNP on cardiac HSPB7 mRNA levels or splicing, suggesting that the SNP marks the position of a functional variant in another gene. Accordingly, we used massively parallel platforms to resequence all coding exons of the adjacent CLCNKA gene, which encodes the K(a) renal chloride channel (ClC-K(a)). Of 51 exonic CLCNKA variants identified, one SNP (rs10927887, encoding Arg83Gly) was common, in linkage disequilibrium with the heart failure risk SNP in HSPB7, and associated with heart failure in two independent Caucasian referral populations (n = 2,606 and 1,168; combined P = 2.25 {\texttimes} 10(-6)). Individual genotyping of rs10927887 in the two study populations and a third independent heart failure cohort (combined n = 5,489) revealed an additive allele effect on heart failure risk that is independent of age, sex, and prior hypertension (odds ratio = 1.27 per allele copy; P = 8.3 {\texttimes} 10(-7)). Functional characterization of recombinant wild-type Arg83 and variant Gly83 ClC-K(a) chloride channel currents revealed {$\approx$} 50\% loss-of-function of the variant channel. These findings identify a common, functionally significant genetic risk factor for Caucasian heart failure. The variant CLCNKA risk allele, telegraphed by linked variants in the adjacent HSPB7 gene, uncovers a previously overlooked genetic mechanism affecting the cardio-renal axis.},
  langid = {english},
  pmcid = {PMC3038744},
  pmid = {21248228},
  keywords = {Alleles,Amino Acid Substitution,Chloride Channels,Cohort Studies,Exons,Female,Genotype,Heart Failure,HSP27 Heat-Shock Proteins,Humans,Kidney,Male,Mutation Missense,Myocardium,Polymorphism Single Nucleotide,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/5WJWZ8BG/Cappola et al. - 2011 - Loss-of-function DNA sequence variant in the CLCNK.pdf}
}

@misc{chazaraAssessingRoleRare2023a,
  title = {Assessing the Role of Rare Pathogenic Variants in Heart Failure Progression by Exome Sequencing in 8,089 Patients},
  author = {Chazara, Olympe and Dub{\'e}, Marie-Pierre and Wang, Quanli and Middleton, Lawrence and Vitsios, Dimitrios and Walentinsson, Anna and Wang, Qing-Dong and Hansson, Kenny M. and Granger, Christopher B. and Kjekshus, John and Haefliger, Carolina and Tardif, Jean-Claude and Paul, Dirk S. and Carss, Keren},
  year = {2023},
  month = aug,
  pages = {2023.07.28.23293350},
  publisher = {medRxiv},
  doi = {10.1101/2023.07.28.23293350},
  urldate = {2025-01-13},
  abstract = {Most therapeutic development is targeted at slowing disease progression, often long after the initiating events of disease incidence. Heart failure is a chronic, life-threatening disease and the most common reason for hospital admission in people over 65 years of age. Genetic factors that influence heart failure progression have not yet been identified. We performed an exome-wide association study in 8,089 patients with heart failure across two clinical trials, CHARM and CORONA, and one population-based cohort, the UK Biobank. We assessed the genetic determinants of the outcomes `time to cardiovascular death' and `time to cardiovascular death and/or hospitalisation', identifying seven independent exome-wide-significant associated genes, FAM221A, CUTC, IFIT5, STIMATE, TAS2R20, CALB2 and BLK. Leveraging public genomic data resources, transcriptomic and pathway analyses, as well as a machine-learning approach, we annotated and prioritised the identified genes for further target validation experiments. Together, these findings advance our understanding of the molecular underpinnings of heart failure progression and reveal putative new candidate therapeutic targets.},
  archiveprefix = {medRxiv},
  copyright = {{\copyright} 2023, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/DHUW8ZP4/Chazara et al. - 2023 - Assessing the role of rare pathogenic variants in heart failure progression by exome sequencing in 8.pdf}
}

@article{cohnRandomizedTrialAngiotensinreceptor2001,
  title = {A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure},
  author = {Cohn, J. N. and Tognoni, G. and {Valsartan Heart Failure Trial Investigators}},
  year = {2001},
  month = dec,
  journal = {The New England Journal of Medicine},
  volume = {345},
  number = {23},
  pages = {1667--1675},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa010713},
  abstract = {BACKGROUND: Actions of angiotensin II may contribute to the progression of heart failure despite treatment with currently recommended drugs. We therefore evaluated the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard therapy for heart failure. METHODS: A total of 5010 patients with heart failure of New York Heart Association (NYHA) class II, III, or IV were randomly assigned to receive 160 mg of valsartan or placebo twice daily. The primary outcomes were mortality and the combined end point of mortality and morbidity, defined as the incidence of cardiac arrest with resuscitation, hospitalization for heart failure, or receipt of intravenous inotropic or vasodilator therapy for at least four hours. RESULTS: Overall mortality was similar in the two groups. The incidence of the combined end point, however, was 13.2 percent lower with valsartan than with placebo (relative risk, 0.87; 97.5 percent confidence interval, 0.77 to 0.97; P=0.009), predominantly because of a lower number of patients hospitalized for heart failure; 455 (18.2 percent) in the placebo group and 346 (13.8 percent) in the valsartan group (P{$<$}0.001). Treatment with valsartan also resulted in significant improvements in NYHA class, ejection fraction, signs and symptoms of heart failure, and quality of life as compared with placebo (P{$<$}0.01). In a post hoc analysis of the combined end point and mortality in subgroups defined according to base-line treatment with angiotensin-converting-enzyme (ACE) inhibitors or beta-blockers, valsartan had a favorable effect in patients receiving neither or one of these types of drugs but an adverse effect in patients receiving both types of drugs. CONCLUSIONS: Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy. However, the post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a beta-blocker raises concern about the potential safety of this specific combination.},
  langid = {english},
  pmid = {11759645},
  keywords = {Adrenergic beta-Antagonists,Angiotensin Receptor Antagonists,Angiotensin-Converting Enzyme Inhibitors,Chronic Disease,Double-Blind Method,Drug Therapy Combination,Female,Heart Failure,Hospitalization,Humans,Male,Middle Aged,Probability,Quality of Life,Stroke Volume,Survival Analysis,Tetrazoles,Valine,Valsartan}
}

@article{connerForwardGeneticAnalysis2008,
  title = {Forward Genetic Analysis of {{Toll-like}} Receptor Responses in Wild-Derived Mice Reveals a Novel Antiinflammatory Role for {{IRAK1BP1}}},
  author = {Conner, James R. and Smirnova, Irina I. and Poltorak, Alexander},
  year = {2008},
  month = feb,
  journal = {The Journal of Experimental Medicine},
  volume = {205},
  number = {2},
  pages = {305--314},
  issn = {0022-1007},
  doi = {10.1084/jem.20071499},
  urldate = {2024-04-12},
  abstract = {Although inflammatory cytokines produced by activation of Toll-like receptors (TLRs) are essential for early host defense against infection, they also mediate a vast array of pathologies, including autoimmune disease, hypersensitivity reactions, and sepsis. Thus, numerous regulatory mechanisms exist in parallel with proinflammatory pathways to prevent excessive release of these potent effector molecules. We report elucidation of a novel regulatory function for interleukin receptor--associated kinase (IRAK)-1 binding protein 1 (IRAK1BP1, also known as SIMPL) through quantitative trait locus mapping of the TLR response in wild-derived mouse strains. This gene emerged as a negative regulator of TLR2-mediated interleukin (IL)-6 production in MOLF/Ei mice, which expressed IRAK1BP1 mRNA in an allele-specific manner when crossed with the C57BL/6J strain. Human peripheral blood mononuclear cells and primary macrophages from two other wild-derived mouse strains also induced IRAK1BP1 mRNA by 4 hours after stimulation with agonists of various TLRs. Examination of its effects on IL-6 and other cytokines demonstrated that IRAK1BP1 regulates transcription of a specific subset of TLR-responsive genes, producing an overall antiinflammatory profile. Our results reveal that IRAK1BP1 is a critical factor in preventing dangerous overproduction of proinflammatory cytokines by the innate immune system and in influencing the specificity of TLR responses. Furthermore, these results show that the genetic diversity of wild-derived mouse strains makes them a valuable model of important human gene functions that have been lost in some laboratory-inbred strains.},
  pmcid = {PMC2271017},
  pmid = {18268037},
  file = {/Users/xx20081/Zotero/storage/JGXQRDIX/Conner et al. - 2008 - Forward genetic analysis of Toll-like receptor res.pdf}
}

@article{connerIRAK1BP1InhibitsInflammation2010,
  title = {{{IRAK1BP1}} Inhibits Inflammation by Promoting Nuclear Translocation of {{NF-$\kappa$B}} P50},
  author = {Conner, James R. and Smirnova, Irina I. and Moseman, Annie Park and Poltorak, Alexander},
  year = {2010},
  month = jun,
  journal = {Proceedings of the National Academy of Sciences of the United States of America},
  volume = {107},
  number = {25},
  pages = {11477--11482},
  issn = {0027-8424},
  doi = {10.1073/pnas.1006894107},
  urldate = {2024-04-12},
  abstract = {An orchestrated balance of pro- and antiinflammatory cytokine release is critical for an innate immune response sufficient for pathogen defense without excessive detriment to host tissues. By using an unbiased forward genetic approach, we previously reported that IL-1R--associated kinase 1 binding protein 1 (IRAK1BP1) down-modulates Toll-like receptor-mediated transcription of several proinflammatory cytokines. To gain insights into the physiological relevance of the inhibitory role of IRAK1BP1 in inflammation, we generated mutant mice lacking IRAK1BP1. Here we report that IRAK1BP1 does not inhibit signaling pathways generally but rather changes the transcriptional profile of activated cells, leading to an increase in IL-10 production and promoting LPS tolerance. This shift in cytokine transcription correlates with an increased ratio of functional NF-{$\kappa$}B subunit dimers comprised of p50/p50 homodimers relative to p50/p65 heterodimers. The increase in nuclear p50/p50 was consistent with the ability of IRAK1BP1 to bind to the p50 precursor molecule and I{$\kappa$}B family member p105. We conclude that IRAK1BP1 functions through its effects on NF-{$\kappa$}B as a molecular switch to bias innate immune pathways toward the resolution of inflammation.},
  pmcid = {PMC2895073},
  pmid = {20534545},
  file = {/Users/xx20081/Zotero/storage/SL2H4NG2/Conner et al. - 2010 - IRAK1BP1 inhibits inflammation by promoting nuclea.pdf}
}

@article{daviesReadingMendelianRandomisation2018,
  title = {Reading {{Mendelian}} Randomisation Studies: A Guide, Glossary, and Checklist for Clinicians},
  shorttitle = {Reading {{Mendelian}} Randomisation Studies},
  author = {Davies, Neil M. and Holmes, Michael V. and Davey Smith, George},
  year = {2018},
  month = jul,
  journal = {BMJ (Clinical research ed.)},
  volume = {362},
  pages = {k601},
  issn = {1756-1833},
  doi = {10.1136/bmj.k601},
  abstract = {Mendelian randomisation uses genetic variation as a natural experiment to investigate the causal relations between potentially modifiable risk factors and health outcomes in observational data. As with all epidemiological approaches, findings from Mendelian randomisation studies depend on specific assumptions. We provide explanations of the information typically reported in Mendelian randomisation studies that can be used to assess the plausibility of these assumptions and guidance on how to interpret findings from Mendelian randomisation studies in the context of other sources of evidence},
  langid = {english},
  pmcid = {PMC6041728},
  pmid = {30002074},
  keywords = {Causality,Confounding Factors Epidemiologic,Effect Modifier Epidemiologic,Genetic Variation,Genome-Wide Association Study,Humans,Mendelian Randomization Analysis,Observational Studies as Topic,Outcome Assessment Health Care,Public Health},
  file = {/Users/xx20081/Zotero/storage/3LEU6Y2A/Davies et al. - 2018 - Reading Mendelian randomisation studies a guide, .pdf}
}

@article{deanfieldSemaglutideCardiovascularOutcomes2024,
  title = {Semaglutide and Cardiovascular Outcomes in Patients with Obesity and Prevalent Heart Failure: A Prespecified Analysis of the {{SELECT}} Trial},
  shorttitle = {Semaglutide and Cardiovascular Outcomes in Patients with Obesity and Prevalent Heart Failure},
  author = {Deanfield, John and Verma, Subodh and Scirica, Benjamin M and Kahn, Steven E and Emerson, Scott S and Ryan, Donna and Lingvay, Ildiko and Colhoun, Helen M and Plutzky, Jorge and Kosiborod, Mikhail N and Hovingh, G Kees and {Hardt-Lindberg}, S{\o}ren and Frenkel, Ofir and Weeke, Peter E and Rasmussen, S{\o}ren and Goudev, Assen and Lang, Chim C and {Urina-Triana}, Miguel and Pietil{\"a}, Mikko and Lincoff, A Michael and Abe, Mitsunori and Abhaichand, Rajpal K and Abhayaratna, Walter P and Abhyankar, Atul and Abidin, Imran B Zainal and Abou Assi, Hiba and Accini Mendoza, Jose L and Adas, Mine and Agaiby, John M and Agarwal, Devendra K and Agha, Maher and Ahmed, Azazuddin and Ahtiainen, Petteri and Aigner, Elmar and Ajay, Naik and Ali, Norsiah and {Al-Karadsheh}, Amer and Allison, Roy and Allison, Dale C and Alpenidze, Diana and Altuntas, Yuksel and {Al-Zoebi}, Ayham and Ambuj, Roy and Amerena, John and Anderson, Robert J and Ando, Toshiaki and Andrews, Robert and Antonova, Elizaveta and Appel, Karl-Friedrich and Arantes, Fl{\'a}via B and Araz, Mustafa and Arbel, Yaron and Arenas Le{\'o}n, Jos{\'e} L and Argyrakopoulou, Georgia and Ariani, Mehrdad and Arias Mendoza, Maria A and Arif, Ahmed A and Arneja, Jaspal and Aroda, Vanita R and Aronne, Louis J and Arstall, Margaret and Asamoah, Njaimeh and Asanin, Milika and Audish, Hanid and Avram, Rodica and Badat, Aysha and Badiu, Corin V and Bakdash, Wa'el and Bakiner, Okan S and Bandezi, Vuyokazi N and Bang, Liew H and Bansal, Sandeep and Baranyai, Marietta and Barbarash, Olga and Barber, Mark and Barnum, Otis and Barone Rochette, Gilles and Bashkin, Amir and Baum, Seth and Bays, Harold E and Bazzoni Ruiz, Alberto E and Beckowski, Maciej and Beerachee, Yaswin and Bellary, Srikanth and Belousova, Lidia and Berk, Martin and Bernstein, Marc and Berra, Cesare and Beshay, Isaac and Bhagwat, Ajit and Bhan, Arti and Biggs, William C and Billings, Liana and Bitar, Fahed and Block, Bradley and Bo, Simona and Bogdanski, Pawel and Bolshakova, Olga O and Boshchenko, Alla A and Bosworth, Hayden and Botero Lopez, Rodrigo and B{\^o}ttcher, Morten and Bourgeois, Ronald and Brautigam, Donald and Breton, Cristian F and Broadley, Andrew and Brockmyre, Andrew P and Brodie, Steven K and Bucci, Marco and Budincevic, Hrvoje and Budoff, Matthew J and Buffman, Barry and Buljubasic, Nediljka and Buranapin, Supawan and Burgess, Lesley and Burguera, Bartolom{\'e} and Buriakovska, Olena and Buscemi, Silvio and Busch, Robert and Buse, John B and Buynak, Robert and Byrne, Maria and Caceaune, Elena and Cadena Bonfanti, Alberto J and Calinescu, Cornell V and Call, Robert S and Canecki Varzic, Silvija and Cannon, Kevin and Capehorn, Matt and Cariou, Bertrand and Carr, Jeffrey and {Carrillo-Jimenez}, Rodolfo and Casas, Marcelo and Castro, Almudena and Celik, Ahmet and Cercato, Cintia and Cermak, Ondrej and Cha, James Y and Chacon, Carolina and {Chaicha-Brom}, Tira and Chandra, Sandeep and Chettibi, Mohamed and Chevts, Julia and Christopher, Johann and Chrustowski, Witold and Cif, Adriana and Clark, Rebecca and Clark, Wayne and Clifford, Piers and Coetzee, Kathleen and Cogni, Giulia and Colao, Anna Maria and Colquhoun, David M and Concha, Mauricio and Condit, Jonathan and Constance, Christian and Constantin, Ciprian and Constantinescu, Silviana and Corbett, Clive and Cornett, George M and Correia, Marcelo and Cortinovis, Fiorenzo and Cosma, Dana and Creely, Steven and Cross, David and Curtis, Brian and Czochra, Wojciech and Daboul, Nizar Y and Dagdelen, Selcuk and D'agostino, Ronald and Dang, Cuong and Datta, Sudip and Davuluri, Ashwini K and Dawood, Saleem Y and De Jong, Douwe M and De La Cuesta, Carmen and De Los Rios Ibarra, Manuel O and De Pablo, Carmen and De Pauw, Michel and Dela Llana, Alexander and Delibasic, Maja and {Delic-Brkljacic}, Diana and Demicheli, Thibaud and Denger, Ralf J and Desai, Devang and Desai, Piyush and Desouza, Cyrus V and Dicker, Dror and Djenic, Nemanja and Dobson, Simon and Doi, Masayuki and Doran, Jesse A and Dorman, Reinhart and Dotta, Francesco and Dukes, Carl E and Duronto, Ernesto and Durst, Ronen and Dvoryashina, Irina V and Ebrahim, Iftikhar O and Eggebrecht, Holger and Egstrup, Kenneth and Ekinci, Elif I and Eliasson, Bj{\"o}rn and Eliasson, Ken and Enache, Georgiana and Enculescu, Dan and English, Patrick and Ermakova, Polina and Ershova, Olga and Ezaki, Hirotaka and Ezhov, Marat and Farias, Eduardo and Farias, Javier M and Farsky, Pedro S and Ferreira, Daniel and Filteau, Pierre and Finneran, Matthew P and Folkens, Eric M and Fonseca, Alberto G and Fonseca, Luisa and Fordan, Steven and Fourie, Nyda and Fran{\c c}a, Sara and Franco, Denise R and Franek, Edward and Friedman, Keith and Frittitta, Lucia and Froer, Michael and Fuckar, Krunoslav and Fujii, Kenshi and Fujita, Ryoko and Fukushima, Yasushi and Fulat, Mohamed and Fulwani, Mahesh and Gajos, Grzegorz and Galyavich, Albert and Gambill, Michael L and Gandotra, Dheeraj and Winston, Gandy and Garcia Hernandez, Pedro A and Garc{\'i}a Reza, Raymundo and Garg, Naveen and Garg, Sandeep and Garvey, William T and Garza, Juan C and {Gatta-Cherifi}, Blandine and Gelev, Valeri and Geller, Steven A and Geohas, Jeffrey G and Georgiev, Borislav and Ghazi, Adline and Gilbert, Matthew P and Gilinskaya, Olga and Gislason, Gunnar and Gogas Yavuz, Dilek and Gonz{\'a}lez Albarr{\'a}n, Olga and Gordeev, Ivan G and Gorton, Sidney C and Goudev, Assen and Gretland Valderhaug, Tone and Groenemeijer, Bjorn and Gul, Ibrahim and Gullestad, Lars and Gurieva, Irina and Guseva, Galina N and Hagenow, Andreas and Haluzik, Martin and Halvorsen, Sigrun and Hammoudi, Naima and Hanaoka, Keiichi and Hancu, Nicolae and Hanusch, Ursula and Harris, Kathleen and Harris, Barry and Hartleib, Michael and Hartman, Aaron N and Hata, Yoshiki and Heimer, Brian and Herman, Lee and Herzog, William and Hewitt, Eric and Heymer, Peter and Hiremath, Shirish and Hjelmesaeth, Joeran and H{\o}galmen, Rasmus Geir and H{\o}ivik, Hans Olav and Holmer, Helene and Horoshko, Olha and Houser, Patricia M and Hove, Jens D and Hsieh, I-Chang and Hulot, Jean-S{\'e}bastien and Hussein, Zanariah and Ilashchuk, Tetiana and Ilveskoski, Erkki and Ipatko, Irina and Iranmanesh, Ali and Isawa, Tsuyoshi and Issa, Moises and Iteld, Bruce and Iwasawa, Takamasa and Jabbar, Danish and Jackson, Richard A and {Jackson-Voyzey}, Ewart and Jacob, Stephan and Jaffrani, Naseem A and Jardula, Michael F and Jastreboff, Ania and Jensen, Svend E and Jerkins, Terri and {Jimenez-Ramos}, Silvia A and Jitendra Pal Singh, Sawhney and Johnson, Wallace and Joyce, John M and Jozefowska, Malgorzata and Jugnundan, Prakash and Jungmair, Wolfgang and Jurowiecki, Jaroslaw and Kadokami, Toshiaki and Kahali, Dhiman and Kahrmann, Gerd and Kaiser, Sergio E and Kalmucki, Piotr and Kanadasi, Mehmet and Kandath, David and Kania, Grzegorz and Kannan, J and Kapp, Cornelia and Karczmarczyk, Agnieszka and Kartalis, Athanasios and Kaser, Susanne and Kasim, Sazzli Shahlan and Kastelic, Richard and Kato, Toshiaki and Katova, Tzvetana and Kaul, Upendra and {Kautzky-Willer}, Alexandra and Kawanishi, Masahiro and Kayikcioglu, Meral and Kazakova, Elena E and Keeling, Philip and Kempe, Hans-Peter and Kereiakes, Dean J and Kerneis, Mathieu and {Keski-Opas}, Tiina and Khadra, Suhail and Khaisheva, Larisa and Kharakhulakh, Marina and Khlevchuk, Tatiana and Khoo, Jeffrey and Kiatchoosakun, Songsak and Kinoshita, Noriyuki and Kinoshita, Masaharu and Kitamura, Ryoji and Kiyosue, Arihiro and Klavina, Irina and Klein, Eric J and Klimsa, Zdenek and Klonoff, David and Klug, Eric and Kobalava, Zhanna and Kodera, Satoshi and Koga, Tokushi and Kokkinos, Alexander and Koleckar, Pavel and K{\"o}nyves, L{\'a}szl{\'o} and Koren, Michael J and Kormann, Adrian P and Kostner, Karam and Kreutzmann, Kristin and Krishinan, Saravanan and Krishnasamy, Sathya S and Krivosheeva, Inga and Kruljac, Ivan and Kubicki, Ted and Kuchar, Ladislav and Kujawiak, Monika and Kunishige, Hideyuki and Kurtinecz, Melinda and Kurtz Lisboa, Hugo R and Kushnir, Mykola and Kyyak, Yulian and Lace, Arija and Lakka, Timo and Lalic, Nebojsa and Lalic, Katarina and Lambadiari, Vaia and Lanaras, Leonidas and Lang, Chim and Langlois, Marie-France and Lash, Joseph and Latkovskis, Gustavs and Lau, David and Lazcano Soto, Jos{\'e} Roberto and Le Roux, Carel and Ledesma, Gilbert N and Lee, Li Yuan and Lee, Thung-Lip and Lee, Kelvin and Lehrke, Michael and Leite, Silmara O and Leksycka, Agata and Lenzmeier, Thomas and Leonetti, Frida and Leonidova, Viktoriia and Lepor, Norman and Leung, Melissa and Levchenko, Olena and Levins, Peter and Levy, Louis J and Lewis, Matthew and Liberopoulos, Evangelos and Liberty, Idit and Lindholm, Carl-Johan and Lingvay, Ildiko and Linhart, Ales and Liu, Ming-En and Liu, Jenny and Lofton, Holly and Logemann, Timothy and Lombaard, Johannes J and Lombard, Landman and Lorraine, Richard and Lovell, Charles F and Ludvik, Bernhard and Lukaszewicz, Monika and Lupkovics, G{\'e}za and Lupovitch, Steven and Lupu, Sirona and Lynch, Mary and Lysak, Zoreslava and Lysenko, Tatyana A and Maeda, Hajime and Maeda, Itaru and M{\ae}ng, Michael and Mahajan, Ajay U and Maher, Vincent and Maia, Lilia N and Makotoko, Ellen M and Malavazos, Alexis and Malecha, Jan and Malicherova, Emilia and Manita, Mamoru and Mannucci, Edoardo and Mareev, Viacheslav and Marin, Liliana and Markova, Tatiana and Marso, Steven P and Martens, F.M.A.C. and Martinez, Cuper and Martinez Cano, Carlos A and Martins, Cristina and Masmiquel Comas, Luis and Matsumoto, Takashi and Mcdonald, Kenneth and Mcgowan, Barbara and Mcgrew, Frank and Mclean, Barry K and Mcpherson, David D and Merino Torres, Juan Francisco and Meyers, Peter and Meyh{\"o}fer, Sebastian and Mezquita Raya, Pedro and Milanova, Maria and Milicic, Davor and Miller, Gary and Mills, Richard E and M{\^i}ndrescu, Nicoleta M and Mingrone, Geltrude and Minkova, Dotska A and Mirani, Marco and Miras, Alexander and Mistodie, Cristina V and Mitomo, Satoru and Mittal, Sanjay and Miyake, Taiji and Miyamoto, Naomasa and Molony, David and Monteiro, Pedro and Mooe, Thomas and Moosa, Naeem and Morales Portillo, Cristobal and Morales Villegas, Enrique C and Morawski, Emily J and Morbey, Claire and Morin, Robert P and Morisaki, Kuniaki and Morosanu, Magdalena and Mosenzon, Ofri and Mostovoy, Yuriy and Munir, Iqbal and Muratori, Fabrizio and Murray, Ryan and Murthy, Avinash and Myint, Min and Myshanych, Galyna and Nafornita, Valerica and Nagano, Takuya and Nair, Sunil and Nakhle, Samer N and Natsuaki, Masahiro and Nayak, Bindu M and Nibouche, Djamel Eddine and Nicholls, Stephen and Nicolau, Jos{\'e} C and Nicolescu, Georgiana and Nierop, Peter and Niskanen, Leo and Ntaios, George and Nyg{\aa}rd, Ottar Kjell and Oaks, Joshua B and Obrezan, Andrey and O'donnell, Philip and Oguri, Mitsutoshi and Oguzhan, Abdurrahman and Oh, Fumiki and Ohsugi, Mitsuru and Okada, Yoshio and Okayama, Hideki and Onaca, Adriana and Onaka, Haruhiko and Oneil, Patrick and Ong, Tiong Kiam and Ong, Stephen and Ono, Yasuhiro and Opsahl, Paul J and Ostrowska, Lucyna and Oviedo, Alejandra and Ozdogan, Oner and Ozpelit, Ebru and Pagkalos, Emmanouil and Pagotto, Uberto and P{\'a}ll, D{\'e}nes and Pandey, Amritanshu- Shekhar and Parkhomenko, Oleksandr and Parvathareddy, Krishna Malakondareddy and Patel, Minesh B and Patsilinakos, Sotirios and Paul, Neil and Pedersen, Sue and Pereira, Isabel and Pereira, Edward Scott and Perez Terns, Paula and {Perez-Vargas}, Elba A and Pergaeva, Yulia and Perkelvald, Alexander and Peskov, Andrey B and Peter, Jonathan and Peters, Karina and Petit, Catherine and Petrov, Ivo and {Philis-Tsimikas}, Athena and Pietil{\"a}, Mikko and Pinto, Fausto and Piros, Annam{\'a}ria and Piyayotai, Dilok and Platonov, Dmitriy and Poirier, Paul and Pop, Lavinia and Popa, Bogdan and {Pop-Busui}, Rodica and Poremba, John and Porto, Alejandro and Postadzhiyan, Arman and Pothineni, Ramesh B and Potu, Ranganatha P and Powell, Talessa and Prafulla, Kerkar G and Prager, Rudolf and {Prakova-Teneva}, Zhulieta R and Pratley, Richard E and Price, Hermione and Pulka, Grazyna and Pullman, John and Punt, Zelda E and Purighalla, Raman S and Purnell, Peter and Qureshi, Mansoor and {Rabasa-Lhoret}, Remi and Raikhel, Marina A and Rancane, Gita and Randeva, Harpal and Rasouli, Neda and Reurean Pintilei, Delia V and Reyes, Ciro R and Rezgale, Inga and Rice, Eva and Riley, Thaddeus H and Risser, Joseph A and Ristic, Arsen and Rivas Fern{\'a}ndez, Margarita and Robbins, David and Robitaille, Yves and Rodbard, Helena W and Rodriguez Plazas, Jaime A and R{\"o}mer, T.J. and Rosen, Glenn and Rosman, Dr Azhari and Rossi, Paulo and Rudenko, Leonid and Ruffin, Omari and Ruhani, Anwar Irawan and Runev, Nikolay and Ruyatkin, Dmitriy and Ruzic, Alen and Ryabov, Vyacheslav V and Ryd{\'e}n, Lars and Saggar, Suraj and Sakamoto, Tomohiro and Salter, Tim and Samal, Aditya K and Samoilova, Yulia and Sanabria, Hugo D and Sancak, Seda and Sangrigoli, Renee and Sansanayudh, Nakarin and Santini, Ferruccio and Saraiva, Jos{\'e} F and Sardinov, Ruslan and Sargeant, William and Sari, Ramazan and Sathananthan, Airani and Sathyapalan, Thozhukat and Sato, Atsushi and Sauter, Joachim and Sbraccia, Paolo and Schaap, J. and Schaum, Thomas and Schiele, Fran{\c c}ois and Scott, John and Segal Lieberman, Gabriella and Segner, Alexander and Senior, Roxy and {Sergeeva-Kondrachenko}, Marina Y and Serota, Harvey and Serusclat, Pierre and Sethi, Rishi and Shah, Manoj K and Shah, Neerav and Shalaev, Sergey and Sharma, Raj and Sharma, Sumeet and Shaydyuk, Oksana and Shea, Heidi C and Shechter, Michael and Shehadeh, Naim and Shirazi, Mitra and Shlesinger, Yshay and Shneker, Ayham and Shutemova, Elena and Siasos, Gerasimos and Siddiqui, Imran A and Sidey, Jennifer and Sigal, Felix and Sime, Iveta and Singh, Narendra and Siraj, Elias and Sivalingam, Kanagaratnam and Skoczylas, Grzegorz and Smith, Stephen K and Smolenskaya, Olga and Snyder, Brian and Sofer, Yael and Sofley, C.W. and Solano, Royce and Sonmez, Yusuf A and Sorokin, Maxim and Soto Gonz{\'a}lez, Alfonso and Sotolongo, Carlos and Soufer, Joseph and Soyluk Selcukbiricik, Ozlem and Spaic, Tamara and Spriggs, Douglas and Sreenan, Seamus and Stahl, Hans-Detlev and Stamatelopoulos, Kimon and Stanislavchuk, Mykola and Stankovic, Goran and Stasek, Josef and Steg, Gabriel and Steindorf, Joerg and Stephan, Dominique and Stewart, John and Still, Christopher and {St-Maurice}, Francois and {Stogowska-Nikiciuk}, Barbara and Stoker, Jeff and Stokic, Edita and Strzelecka, Anna and Sturm, Kerstin and Sueyoshi, Atsushi and Sugiura, Toshiyuki and Sultan, Senan and Suplotova, Lyudmila A and Suwanagool, Arisara and Suwanwalaikorn, Sompongse and Sveklina, Tatiana and Swanson, Neil and Swart, Henk and Swenson, Bradley P and Szyprowska, Ewa and Tait, Graeme and Tak{\'a}cs, R{\'o}bert and Takeuchi, Yuzo and Tamirisa, Aparna and Tanaka, Hideki and Tatovic, Danijela and Tellier, Guy and Teragawa, Hiroki and Teterovska, Dace and Thomas, Nihal and Thuan, Jean-Francois and Tinahones, Francisco and {Tisheva-Gospodinova}, Snezhanka and Toarba, Cristina and Todoriuk, Liudmyla and Tokmakova, Mariya and Tonstad, Serena and Toplak, Hermann and Tran, Henry and Tripathy, Devjit and Trusau, Aliaksandr and Tsabedze, Nqoba and Tsougos, Elias and Tsoukas, George M and Tuccinardi, Dario and Tuna, Mazhar M and Turatti, Luiz A and Tziomalos, Konstantinos and Udommongkol, Chesda and Ueda, Osamu and Ukkola, Olavi and Unubol, Mustafa and Urbach, Dorothea and Urina Triana, Miguel A and Usdan, Lisa and Vaidya, Bijay and Vale, Noah and Vallieres, Gerald and Van Beek, Andre P and Van De Borne, Philippe and Van Der Walt, Eugene and Van Der Zwaan, C. and Van Nieuwenhuizen, Elane and Van Zyl, Louis and Vanduynhoven, Philippe and Varghese, Kiron and Vasileva, Svetla P and Vassilev, Dobrin and Vathesatogkit, Prin and Velychko, Valentyna and Vercammen, Chris and Verges, Bruno and Verma, Subodh and Verwerft, Jan and Vesela, Alica and Veselovskaya, Nadezhda G and Vettor, Roberto and Veze, Irina and Vijan, Vinod and Vijayaraghavan, Ram and Villarino, Adriana and Vincent, Royce and Vinogradova, Oksana and Vishlitzky, Victor and Vlad, Adrian and Vladu, Ionela Mihaela and Vo, Anthony and Von Engelhardt, Charlotte and Von M{\"u}nchhausen, Candy and Vorobyeva, Olga and Vossenberg, T. and Vrolix, Mathias and Vukicevic, Marjana and Vyshnyvetskyy, Ivan and Wadvalla, Shahid and Wagner, Jan and Wakeling, John and Wallace, James and Wan Mohamed, Wan Mohd Izani and Wander, Gurpreet S and Ward, Kathleen and Warren, Mark L and Watanabe, Atsuyuki and Weber, Bruce and Weintraub, Howard and Weisnagel, John and Welker, James and Wendisch, Ulrich and Wenocur, Howard S and Wierum, Craig and Wilding, John and William, Maged and Wilson, Pete and Wilson, Jonathan P and Wong, Yuk-Ki and Wongcharoen, Wanwarang and Wozniak, Iwona and Wu, Chau-Chung and Wyatt, Nell and Wynne, Alan and Yamaguchi, Hiroshi and Yamasaki, Masahiro and Yazici, Dilek and Yeh, Hung-I and Yotov, Yoto and Yuan, Qingyang and Zacher, Jeffrey and Zagrebelnaya, Olga and Zaidman, Cesar J and Zalevskaya, Alsu and Zarich, Stuart and Zatelli, Maria Chiara and Zeller, Helga and Zhdanova, Elena A and Zornitzki, Taiba and Zrazhevskiy, Konstantin and Zykov, Mikhail and Lincoff, A Michael and Ryan, Donna H and Colhoun, Helen M and Deanfield, John E and Emerson, Scott S and Kahn, Steven E and Kushner, Robert F and Plutzky, Jorge and {Brown-Frandsen}, Kirstine and Hovingh, G Kees and {Hardt-Lindberg}, Soren and Torn{\o}e, Christoffer W},
  year = {2024},
  month = aug,
  journal = {The Lancet},
  volume = {404},
  number = {10454},
  pages = {773--786},
  issn = {01406736},
  doi = {10.1016/S0140-6736(24)01498-3},
  urldate = {2025-03-17},
  abstract = {Background Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2{$\cdot$}4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure.},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/IBU5T7UU/mmc1.pdf;/Users/xx20081/Zotero/storage/XCWH8YYH/Deanfield et al. - 2024 - Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure a pres.pdf}
}

@article{dedenusGeneticAssociationStudy2020,
  title = {A Genetic Association Study of Heart Failure: More Evidence for the Role of {{BAG3}} in Idiopathic Dilated Cardiomyopathy},
  shorttitle = {A Genetic Association Study of Heart Failure},
  author = {{de Denus}, Simon and Mottet, Fannie and Korol, Sandra and Feroz Zada, Yassamin and Provost, Sylvie and Mongrain, Ian and Asselin, G{\'e}raldine and Oussa{\"i}d, Essa{\"i}d and Busseuil, David and Lettre, Guillaume and Rioux, John and Racine, Normand and O'Meara, Eileen and White, Michel and Rouleau, Jean and Tardif, Jean Claude and Dub{\'e}, Marie-Pierre},
  year = {2020},
  month = dec,
  journal = {ESC heart failure},
  volume = {7},
  number = {6},
  pages = {4384--4389},
  issn = {2055-5822},
  doi = {10.1002/ehf2.12934},
  abstract = {AIMS: Few investigations have been conducted to identify genetic determinants of common, polygenetic forms of heart failure (HF), and only a limited number of these genetic associations have been validated by multiple groups. METHODS AND RESULTS: We performed a case-control study to further investigate the potential impact of 14 previously reported candidate genes on the risk of HF and specific HF sub-types. We also performed an exploratory genome-wide study. We included 799 patients with HF and 1529 controls. After adjusting for age, sex, and genetic ancestry, we found that the C allele of rs2234962 in BAG3 was associated with a decreased risk of idiopathic dilated cardiomyopathy (odds ratio 0.42, 95\% confidence interval 0.25-0.68, P~=~0.0005), consistent with a previous report. No association for the other primary variants or exploratory genome-wide study was found. CONCLUSIONS: Our findings provide independent replication for the association between a common coding variant (rs2234962) in BAG3 and the risk of idiopathic dilated cardiomyopathy.},
  langid = {english},
  pmcid = {PMC7754954},
  pmid = {32869539},
  keywords = {B-cell lymphoma 2-associated anthanogene protein,Genetics,Heart failure},
  file = {/Users/xx20081/Zotero/storage/Q95ZUCZ7/de Denus et al. - 2020 - A genetic association study of heart failure more.pdf}
}

@article{digitaleKeyConceptsClinical2023,
  title = {Key Concepts in Clinical Epidemiology: Collider-Conditioning Bias},
  shorttitle = {Key Concepts in Clinical Epidemiology},
  author = {Digitale, Jean C. and Martin, Jeffrey N. and Glidden, David V. and Glymour, M. Maria},
  year = {2023},
  month = sep,
  journal = {Journal of Clinical Epidemiology},
  volume = {161},
  pages = {152--156},
  publisher = {Elsevier},
  issn = {0895-4356, 1878-5921},
  doi = {10.1016/j.jclinepi.2023.07.004},
  urldate = {2024-08-15},
  langid = {english},
  pmid = {37506950},
  file = {/Users/xx20081/Zotero/storage/TWY8YDNM/Digitale et al. - 2023 - Key concepts in clinical epidemiology collider-co.pdf}
}

@article{dudbridgeAdjustmentIndexEvent2019,
  title = {Adjustment for Index Event Bias in Genome-Wide Association Studies of Subsequent Events},
  author = {Dudbridge, Frank and Allen, Richard J. and Sheehan, Nuala A. and Schmidt, A. Floriaan and Lee, James C. and Jenkins, R. Gisli and Wain, Louise V. and Hingorani, Aroon D. and Patel, Riyaz S.},
  year = {2019},
  month = apr,
  journal = {Nature Communications},
  volume = {10},
  number = {1},
  pages = {1561},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-019-09381-w},
  urldate = {2024-03-08},
  abstract = {Following numerous genome-wide association studies of disease susceptibility, there is increasing interest in genetic associations with prognosis, survival or other subsequent events. Such associations are vulnerable to index event bias, by which selection of subjects according to disease status creates biased associations if common causes of incidence and prognosis are not accounted for. We propose an adjustment for index event bias using the residuals from the regression of genetic effects on prognosis on genetic effects on incidence. Our approach eliminates this bias when direct genetic effects on incidence and prognosis are independent, and otherwise reduces bias in realistic situations. In a study of idiopathic pulmonary fibrosis, we reverse a paradoxical association of the strong susceptibility gene MUC5B with increased survival, suggesting instead a significant association with decreased survival. In re-analysis of a study of Crohn's disease prognosis, four regions remain associated at genome-wide significance but with increased standard errors.},
  copyright = {2019 The Author(s)},
  langid = {english},
  keywords = {Epidemiology,Genetics research,Genome-wide association studies,Statistical methods},
  file = {/Users/xx20081/Zotero/storage/Y2QIZD3E/Dudbridge et al. - 2019 - Adjustment for index event bias in genome-wide ass.pdf}
}

@article{esslingerExomewideAssociationStudy2017,
  title = {Exome-Wide Association Study Reveals Novel Susceptibility Genes to Sporadic Dilated Cardiomyopathy},
  author = {Esslinger, Ulrike and Garnier, Sophie and Korniat, Agathe and Proust, Carole and Kararigas, Georgios and {M{\"u}ller-Nurasyid}, Martina and Empana, Jean-Philippe and Morley, Michael P. and Perret, Claire and Stark, Klaus and Bick, Alexander G. and Prasad, Sanjay K. and Kriebel, Jennifer and Li, Jin and Tiret, Laurence and Strauch, Konstantin and O'Regan, Declan P. and Marguiles, Kenneth B. and Seidman, Jonathan G. and Boutouyrie, Pierre and Lacolley, Patrick and Jouven, Xavier and Hengstenberg, Christian and Komajda, Michel and Hakonarson, Hakon and Isnard, Richard and Arbustini, Eloisa and Grallert, Harald and Cook, Stuart A. and Seidman, Christine E. and {Regitz-Zagrosek}, Vera and Cappola, Thomas P. and Charron, Philippe and Cambien, Fran{\c c}ois and Villard, Eric},
  year = {2017},
  journal = {PloS One},
  volume = {12},
  number = {3},
  pages = {e0172995},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0172995},
  abstract = {AIMS: Dilated cardiomyopathy (DCM) is an important cause of heart failure with a strong familial component. We performed an exome-wide array-based association study (EWAS) to assess the contribution of missense variants to sporadic DCM. METHODS AND RESULTS: 116,855 single nucleotide variants (SNVs) were analyzed in 2796 DCM patients and 6877 control subjects from 6 populations of European ancestry. We confirmed two previously identified associations with SNVs in BAG3 and ZBTB17 and discovered six novel DCM-associated loci (Q-value{$<$}0.01). The lead-SNVs at novel loci are common and located in TTN, SLC39A8, MLIP, FLNC, ALPK3 and FHOD3. In silico fine mapping identified HSPB7 as the most likely candidate at the ZBTB17 locus. Rare variant analysis (MAF{$<$}0.01) demonstrated significant association for TTN variants only (P = 0.0085). All candidate genes but one (SLC39A8) exhibit preferential expression in striated muscle tissues and mutations in TTN, BAG3, FLNC and FHOD3 are known to cause familial cardiomyopathy. We also investigated a panel of 48 known cardiomyopathy genes. Collectively, rare (n = 228, P = 0.0033) or common (n = 36, P = 0.019) variants with elevated in silico severity scores were associated with DCM, indicating that the spectrum of genes contributing to sporadic DCM extends beyond those identified here. CONCLUSION: We identified eight loci independently associated with sporadic DCM. The functions of the best candidate genes at these loci suggest that proteostasis regulation might play a role in DCM pathophysiology.},
  langid = {english},
  pmcid = {PMC5351854},
  pmid = {28296976},
  keywords = {Cardiomyopathy Dilated,Exome,Genetic Predisposition to Disease,Humans,Mutation Missense,Polymorphism Single Nucleotide},
  file = {/Users/xx20081/Zotero/storage/8KPM83X6/Esslinger et al. - 2017 - Exome-wide association study reveals novel suscept.pdf}
}

@article{evangelouPublisherCorrectionGenetic2018,
  title = {Publisher {{Correction}}: {{Genetic}} Analysis of over 1 Million People Identifies 535 New Loci Associated with Blood Pressure Traits},
  shorttitle = {Publisher {{Correction}}},
  author = {Evangelou, Evangelos and Warren, Helen R. and {Mosen-Ansorena}, David and Mifsud, Borbala and Pazoki, Raha and Gao, He and Ntritsos, Georgios and Dimou, Niki and Cabrera, Claudia P. and Karaman, Ibrahim and Ng, Fu Liang and Evangelou, Marina and Witkowska, Katarzyna and Tzanis, Evan and Hellwege, Jacklyn N. and Giri, Ayush and Velez Edwards, Digna R. and Sun, Yan V. and Cho, Kelly and Gaziano, J. Michael and Wilson, Peter W. F. and Tsao, Philip S. and Kovesdy, Csaba P. and Esko, Tonu and M{\"a}gi, Reedik and Milani, Lili and Almgren, Peter and Boutin, Thibaud and Debette, St{\'e}phanie and Ding, Jun and Giulianini, Franco and Holliday, Elizabeth G. and Jackson, Anne U. and {Li-Gao}, Ruifang and Lin, Wei-Yu and Luan, Jian'an and Mangino, Massimo and Oldmeadow, Christopher and Prins, Bram Peter and Qian, Yong and Sargurupremraj, Muralidharan and Shah, Nabi and Surendran, Praveen and Th{\'e}riault, S{\'e}bastien and Verweij, Niek and Willems, Sara M. and Zhao, Jing-Hua and Amouyel, Philippe and Connell, John and {de Mutsert}, Ren{\'e}e and Doney, Alex S. F. and Farrall, Martin and Menni, Cristina and Morris, Andrew D. and Noordam, Raymond and Par{\'e}, Guillaume and Poulter, Neil R. and Shields, Denis C. and Stanton, Alice and Thom, Simon and Abecasis, Gon{\c c}alo and Amin, Najaf and Arking, Dan E. and Ayers, Kristin L. and Barbieri, Caterina M. and Batini, Chiara and Bis, Joshua C. and Blake, Tineka and Bochud, Murielle and Boehnke, Michael and Boerwinkle, Eric and Boomsma, Dorret I. and Bottinger, Erwin P. and Braund, Peter S. and Brumat, Marco and Campbell, Archie and Campbell, Harry and Chakravarti, Aravinda and Chambers, John C. and Chauhan, Ganesh and Ciullo, Marina and Cocca, Massimiliano and Collins, Francis and Cordell, Heather J. and Davies, Gail and {de Borst}, Martin H. and {de Geus}, Eco J. and Deary, Ian J. and Deelen, Joris and Del Greco M, Fabiola and Demirkale, Cumhur Yusuf and D{\"o}rr, Marcus and Ehret, Georg B. and Elosua, Roberto and Enroth, Stefan and Erzurumluoglu, A. Mesut and Ferreira, Teresa and Fr{\aa}nberg, Mattias and Franco, Oscar H. and Gandin, Ilaria and Gasparini, Paolo and Giedraitis, Vilmantas and Gieger, Christian and Girotto, Giorgia and Goel, Anuj and Gow, Alan J. and Gudnason, Vilmundur and Guo, Xiuqing and Gyllensten, Ulf and Hamsten, Anders and Harris, Tamara B. and Harris, Sarah E. and Hartman, Catharina A. and Havulinna, Aki S. and Hicks, Andrew A. and Hofer, Edith and Hofman, Albert and Hottenga, Jouke-Jan and Huffman, Jennifer E. and Hwang, Shih-Jen and Ingelsson, Erik and James, Alan and Jansen, Rick and Jarvelin, Marjo-Riitta and Joehanes, Roby and Johansson, {\AA}sa and Johnson, Andrew D. and Joshi, Peter K. and Jousilahti, Pekka and Jukema, J. Wouter and Jula, Antti and K{\"a}h{\"o}nen, Mika and Kathiresan, Sekar and Keavney, Bernard D. and Khaw, Kay-Tee and Knekt, Paul and Knight, Joanne and Kolcic, Ivana and Kooner, Jaspal S. and Koskinen, Seppo and Kristiansson, Kati and Kutalik, Zoltan and Laan, Maris and Larson, Marty and Launer, Lenore J. and Lehne, Benjamin and Lehtim{\"a}ki, Terho and Liewald, David C. M. and Lin, Li and Lind, Lars and Lindgren, Cecilia M. and Liu, YongMei and Loos, Ruth J. F. and Lopez, Lorna M. and Lu, Yingchang and Lyytik{\"a}inen, Leo-Pekka and Mahajan, Anubha and Mamasoula, Chrysovalanto and Marrugat, Jaume and Marten, Jonathan and Milaneschi, Yuri and Morgan, Anna and Morris, Andrew P. and Morrison, Alanna C. and Munson, Peter J. and Nalls, Mike A. and Nandakumar, Priyanka and Nelson, Christopher P. and Niiranen, Teemu and Nolte, Ilja M. and Nutile, Teresa and Oldehinkel, Albertine J. and Oostra, Ben A. and O'Reilly, Paul F. and Org, Elin and Padmanabhan, Sandosh and Palmas, Walter and Palotie, Aarno and Pattie, Alison and Penninx, Brenda W. J. H. and Perola, Markus and Peters, Annette and Polasek, Ozren and Pramstaller, Peter P. and Nguyen, Quang Tri and Raitakari, Olli T. and Ren, Meixia and Rettig, Rainer and Rice, Kenneth and Ridker, Paul M. and Ried, Janina S. and Riese, Harri{\"e}tte and Ripatti, Samuli and Robino, Antonietta and Rose, Lynda M. and Rotter, Jerome I. and Rudan, Igor and Ruggiero, Daniela and Saba, Yasaman and Sala, Cinzia F. and Salomaa, Veikko and Samani, Nilesh J. and Sarin, Antti-Pekka and Schmidt, Reinhold and Schmidt, Helena and Shrine, Nick and Siscovick, David and Smith, Albert V. and Snieder, Harold and S{\~o}ber, Siim and Sorice, Rossella and Starr, John M. and Stott, David J. and Strachan, David P. and Strawbridge, Rona J. and Sundstr{\"o}m, Johan and Swertz, Morris A. and Taylor, Kent D. and Teumer, Alexander and Tobin, Martin D. and Tomaszewski, Maciej and Toniolo, Daniela and Traglia, Michela and Trompet, Stella and Tuomilehto, Jaakko and Tzourio, Christophe and Uitterlinden, Andr{\'e} G. and Vaez, Ahmad and {van der Most}, Peter J. and {van Duijn}, Cornelia M. and Vergnaud, Anne-Claire and Verwoert, Germaine C. and Vitart, Veronique and V{\"o}lker, Uwe and Vollenweider, Peter and Vuckovic, Dragana and Watkins, Hugh and Wild, Sarah H. and Willemsen, Gonneke and Wilson, James F. and Wright, Alan F. and Yao, Jie and Zemunik, Tatijana and Zhang, Weihua and Attia, John R. and Butterworth, Adam S. and Chasman, Daniel I. and Conen, David and Cucca, Francesco and Danesh, John and Hayward, Caroline and Howson, Joanna M. M. and Laakso, Markku and Lakatta, Edward G. and Langenberg, Claudia and Melander, Olle and {Mook-Kanamori}, Dennis O. and Palmer, Colin N. A. and Risch, Lorenz and Scott, Robert A. and Scott, Rodney J. and Sever, Peter and Spector, Tim D. and {van der Harst}, Pim and Wareham, Nicholas J. and Zeggini, Eleftheria and Levy, Daniel and Munroe, Patricia B. and {Newton-Cheh}, Christopher and Brown, Morris J. and Metspalu, Andres and Hung, Adriana M. and O'Donnell, Christopher J. and Edwards, Todd L. and {Million Veteran Program} and Psaty, Bruce M. and Tzoulaki, Ioanna and Barnes, Michael R. and Wain, Louise V. and Elliott, Paul and Caulfield, Mark J.},
  year = {2018},
  month = dec,
  journal = {Nature Genetics},
  volume = {50},
  number = {12},
  pages = {1755},
  issn = {1546-1718},
  doi = {10.1038/s41588-018-0297-3},
  abstract = {In the version of this article originally published, the name of author Martin H. de Borst was coded incorrectly in the XML. The error has now been corrected in the HTML version of the paper.},
  langid = {english},
  pmid = {30429575},
  file = {/Users/xx20081/Zotero/storage/4CRH3UP6/Evangelou et al. - 2018 - Publisher Correction Genetic analysis of over 1 m.pdf}
}

@article{everettAntiInflammatoryTherapyCanakinumab2019,
  title = {Anti-{{Inflammatory Therapy With Canakinumab}} for the {{Prevention}} of {{Hospitalization}} for {{Heart Failure}}},
  author = {Everett, Brendan M. and Cornel, Jan H. and Lainscak, Mitja and Anker, Stefan D. and Abbate, Antonio and Thuren, Tom and Libby, Peter and Glynn, Robert J. and Ridker, Paul M.},
  year = {2019},
  month = mar,
  journal = {Circulation},
  volume = {139},
  number = {10},
  pages = {1289--1299},
  issn = {1524-4539},
  doi = {10.1161/CIRCULATIONAHA.118.038010},
  abstract = {BACKGROUND: Subclinical inflammation is associated with an increased risk of heart failure and with adverse prognosis in patients with established heart failure. Yet, treatments specifically directed at reducing inflammation in patients with heart failure have not yet shown improved clinical outcomes. We tested the hypothesis that the interleukin-1{$\beta$} inhibitor canakinumab would prevent hospitalization for heart failure (HHF) and the composite of HHF or heart failure-related mortality. METHODS: We randomized 10\,061 patients with prior myocardial infarction and high-sensitivity C-reactive protein {$\geq$}2 mg/L to canakinumab 50, 150, or 300 mg or placebo, given subcutaneously once every 3 months. In total, 2173 (22\%) reported a history of heart failure at baseline. We tested the hypothesis that canakinumab prevents prospectively collected HHF events and the composite of HHF or heart failure-related mortality. RESULTS: A total of 385 patients had an HHF event during a median follow-up of 3.7 years. Patients who had HHF were older, had higher body mass index, and were more likely to have diabetes mellitus, hypertension, and prior coronary bypass surgery. As anticipated, median (quartile 1, 3) baseline concentrations of high-sensitivity C-reactive protein were higher among those who had HHF during follow-up than those who did not (5.7 [3.5, 9.9] mg/L versus 4.2 [2.8, 6.9] mg/L, respectively; P{$<$}0.0001). The unadjusted hazard ratios for HHF with each dose of canakinumab compared with placebo were 1.04 (95\% CI, 0.79-1.36) for 50 mg, 0.86 (95\% CI, 0.65-1.13) for 150 mg, and 0.76 (95\% CI, 0.57-1.01) for 300 mg ( P for trend=0.025). The composite of HHF or heart failure-related mortality was also reduced by canakinumab, with unadjusted hazard ratios of 1.00 (95\% CI, 0.78-1.29) for 50 mg, 0.88 (95\% CI, 0.68-1.13) for 150 mg, and 0.78 (95\% CI, 0.60-1.02) for 300 mg ( P for trend=0.042). CONCLUSIONS: These randomized double-blind placebo-controlled data suggest that therapy with canakinumab, an interleukin-1{$\beta$} inhibitor, is related to a dose-dependent reduction in HHF and the composite of HHF or heart failure-related mortality in a population of patients with prior myocardial infarction and elevations in high-sensitivity C-reactive protein. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01327846.},
  langid = {english},
  pmid = {30586730},
  keywords = {Aged,Anti-Inflammatory Agents,Antibodies Monoclonal Humanized,Biomarkers,C-Reactive Protein,clinical trial [publication type],Disease Progression,Dose-Response Relationship Drug,Double-Blind Method,Female,heart failure,Heart Failure,Humans,inflammation,Inflammation Mediators,Male,Middle Aged,Patient Admission,Prospective Studies,Protective Factors,Risk Factors,Time Factors,Treatment Outcome}
}

@article{fanNovelRecombinationProtein2023,
  title = {A Novel Recombination Protein {{C12ORF40}}/{{REDIC1}} Is Required for Meiotic Crossover Formation},
  author = {Fan, Suixing and Wang, Yuewen and Jiang, Hanwei and Jiang, Xiaohua and Zhou, Jianteng and Jiao, Yuying and Ye, Jingwei and Xu, Zishuo and Wang, Yue and Xie, Xuefeng and Zhang, Huan and Li, Yang and Liu, Wei and Zhang, Xiangjun and Ma, Hui and Shi, Baolu and Zhang, Yuanwei and Zubair, Muhammad and Shah, Wasim and Xu, Zhipeng and Xu, Bo and Shi, Qinghua},
  year = {2023},
  month = aug,
  journal = {Cell Discovery},
  volume = {9},
  number = {1},
  pages = {1--20},
  publisher = {Nature Publishing Group},
  issn = {2056-5968},
  doi = {10.1038/s41421-023-00577-5},
  urldate = {2024-04-12},
  abstract = {During meiosis, at least one crossover must occur per homologous chromosome pair to ensure normal progression of meiotic division and accurate chromosome segregation. However, the mechanism of crossover formation is not fully understood. Here, we report a novel recombination protein, C12ORF40/REDIC1, essential for meiotic crossover formation in mammals. A homozygous frameshift mutation in C12orf40 (c.232\_233insTT, p.Met78Ilefs*2) was identified in two infertile men with meiotic arrest. Spread mouse spermatocyte fluorescence immunostaining showed that REDIC1 forms discrete foci between the paired regions of homologous chromosomes depending on strand invasion and colocalizes with MSH4 and later with MLH1 at the crossover sites. Redic1 knock-in (KI) mice homozygous for mutation c.232\_233insTT are infertile in both sexes due to insufficient crossovers and consequent meiotic arrest, which is also observed in our patients. The foci of MSH4 and TEX11, markers of recombination intermediates, are significantly reduced numerically in the spermatocytes of Redic1 KI mice. More importantly, our biochemical results show that the N-terminus of REDIC1 binds branched DNAs present in recombination intermediates, while the identified mutation impairs this interaction. Thus, our findings reveal a crucial role for C12ORF40/REDIC1 in meiotic crossover formation by stabilizing the recombination intermediates, providing prospective molecular targets for the clinical diagnosis and therapy of infertility.},
  copyright = {2023 The Author(s)},
  langid = {english},
  keywords = {Homologous recombination,Meiosis},
  file = {/Users/xx20081/Zotero/storage/M2G6A3PB/Fan et al. - 2023 - A novel recombination protein C12ORF40REDIC1 is r.pdf}
}

@article{fryComparisonSociodemographicHealthRelated2017,
  title = {Comparison of {{Sociodemographic}} and {{Health-Related Characteristics}} of {{UK Biobank Participants With Those}} of the {{General Population}}},
  author = {Fry, Anna and Littlejohns, Thomas J. and Sudlow, Cathie and Doherty, Nicola and Adamska, Ligia and Sprosen, Tim and Collins, Rory and Allen, Naomi E.},
  year = {2017},
  month = nov,
  journal = {American Journal of Epidemiology},
  volume = {186},
  number = {9},
  pages = {1026--1034},
  issn = {1476-6256},
  doi = {10.1093/aje/kwx246},
  abstract = {The UK Biobank cohort is a population-based cohort of 500,000 participants recruited in the United Kingdom (UK) between 2006 and 2010. Approximately 9.2 million individuals aged 40-69 years who lived within 25 miles (40 km) of one of 22 assessment centers in England, Wales, and Scotland were invited to enter the cohort, and 5.5\% participated in the baseline assessment. The representativeness of the UK Biobank cohort was investigated by comparing demographic characteristics between nonresponders and responders. Sociodemographic, physical, lifestyle, and health-related characteristics of the cohort were compared with nationally representative data sources. UK Biobank participants were more likely to be older, to be female, and to live in less socioeconomically deprived areas than nonparticipants. Compared with the general population, participants were less likely to be obese, to smoke, and to drink alcohol on a daily basis and had fewer self-reported health conditions. At age 70-74 years, rates of all-cause mortality and total cancer incidence were 46.2\% and 11.8\% lower, respectively, in men and 55.5\% and 18.1\% lower, respectively, in women than in the general population of the same age. UK Biobank is not representative of the sampling population; there is evidence of a "healthy volunteer" selection bias. Nonetheless, valid assessment of exposure-disease relationships may be widely generalizable and does not require participants to be representative of the population at large.},
  langid = {english},
  pmcid = {PMC5860371},
  pmid = {28641372},
  keywords = {Adult,Aged,Biological Specimen Banks,cancer,Cause of Death,Female,Healthy Volunteers,Humans,Incidence,Life Style,lifestyle,Male,Middle Aged,mortality,Neoplasms,Prospective Studies,representativeness,Selection Bias,Self Report,Social Class,sociodemographic characteristics,UK Biobank,United Kingdom},
  file = {/Users/xx20081/Zotero/storage/8JIBKIVE/Fry et al. - 2017 - Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Th.pdf}
}

@article{galperLRRK2LipidPathways2022,
  title = {{{LRRK2}} and {{Lipid Pathways}}: {{Implications}} for {{Parkinson}}'s {{Disease}}},
  shorttitle = {{{LRRK2}} and {{Lipid Pathways}}},
  author = {Galper, Jasmin and Kim, Woojin S. and Dzamko, Nicolas},
  year = {2022},
  month = oct,
  journal = {Biomolecules},
  volume = {12},
  number = {11},
  pages = {1597},
  issn = {2218-273X},
  doi = {10.3390/biom12111597},
  urldate = {2024-04-12},
  abstract = {Genetic alterations in the LRRK2 gene, encoding leucine-rich repeat kinase 2, are a common risk factor for Parkinson's disease. How LRRK2 alterations lead to cell pathology is an area of ongoing investigation, however, multiple lines of evidence suggest a role for LRRK2 in lipid pathways. It is increasingly recognized that in addition to being energy reservoirs and structural entities, some lipids, including neural lipids, participate in signaling cascades. Early investigations revealed that LRRK2 localized to membranous and vesicular structures, suggesting an interaction of LRRK2 and lipids or lipid-associated proteins. LRRK2 substrates from the Rab GTPase family play a critical role in vesicle trafficking, lipid metabolism and lipid storage, all processes which rely on lipid dynamics. In addition, LRRK2 is associated with the phosphorylation and activity of enzymes that catabolize plasma membrane and lysosomal lipids. Furthermore, LRRK2 knockout studies have revealed that blood, brain and urine exhibit lipid level changes, including alterations to sterols, sphingolipids and phospholipids, respectively. In human LRRK2 mutation carriers, changes to sterols, sphingolipids, phospholipids, fatty acyls and glycerolipids are reported in multiple tissues. This review summarizes the evidence regarding associations between LRRK2 and lipids, and the functional consequences of LRRK2-associated lipid changes are discussed.},
  pmcid = {PMC9687231},
  pmid = {36358947},
  file = {/Users/xx20081/Zotero/storage/ALA3PKFQ/Galper et al. - 2022 - LRRK2 and Lipid Pathways Implications for Parkins.pdf}
}

@article{garnierGenomewideAssociationAnalysis2021,
  title = {Genome-Wide Association Analysis in Dilated Cardiomyopathy Reveals Two New Players in Systolic Heart Failure on Chromosomes 3p25.1 and 22q11.23},
  author = {Garnier, Sophie and Harakalova, Magdalena and Weiss, Stefan and Mokry, Michal and {Regitz-Zagrosek}, Vera and Hengstenberg, Christian and Cappola, Thomas P. and Isnard, Richard and Arbustini, Eloisa and Cook, Stuart A. and {van Setten}, Jessica and Calis, Jorg J. A. and Hakonarson, Hakon and Morley, Michael P. and Stark, Klaus and Prasad, Sanjay K. and Li, Jin and O'Regan, Declan P. and Grasso, Maurizia and {M{\"u}ller-Nurasyid}, Martina and Meitinger, Thomas and Empana, Jean-Philippe and Strauch, Konstantin and Waldenberger, Melanie and Marguiles, Kenneth B. and Seidman, Christine E. and Kararigas, Georgios and Meder, Benjamin and Haas, Jan and Boutouyrie, Pierre and Lacolley, Patrick and Jouven, Xavier and Erdmann, Jeanette and Blankenberg, Stefan and Wichter, Thomas and Ruppert, Volker and Tavazzi, Luigi and Dubourg, Olivier and Roizes, G{\'e}rard and Dorent, Richard and {de Groote}, Pascal and Fauchier, Laurent and Trochu, Jean-No{\"e}l and Aupetit, Jean-Fran{\c c}ois and Bilinska, Zofia T. and Germain, Marine and V{\"o}lker, Uwe and Hemerich, Daiane and Raji, Ibticem and {Bacq-Daian}, Delphine and Proust, Carole and Remior, Paloma and {Gomez-Bueno}, Manuel and Lehnert, Kristin and Maas, Renee and Olaso, Robert and Saripella, Ganapathi Varma and Felix, Stephan B. and McGinn, Steven and {Duboscq-Bidot}, La{\"e}titia and {van Mil}, Alain and Besse, C{\'e}line and Fontaine, Vincent and Blanch{\'e}, H{\'e}l{\`e}ne and Ader, Flavie and Keating, Brendan and Curjol, Ang{\'e}lique and Boland, Anne and Komajda, Michel and Cambien, Fran{\c c}ois and Deleuze, Jean-Fran{\c c}ois and D{\"o}rr, Marcus and Asselbergs, Folkert W. and Villard, Eric and Tr{\'e}gou{\"e}t, David-Alexandre and Charron, Philippe},
  year = {2021},
  month = may,
  journal = {European Heart Journal},
  volume = {42},
  number = {20},
  pages = {2000--2011},
  issn = {1522-9645},
  doi = {10.1093/eurheartj/ehab030},
  abstract = {AIMS: Our objective was to better understand the genetic bases of dilated cardiomyopathy (DCM), a leading cause of systolic heart failure. METHODS AND RESULTS: We conducted the largest genome-wide association study performed so far in DCM, with 2719 cases and 4440 controls in the discovery population. We identified and replicated two new DCM-associated loci on chromosome 3p25.1 [lead single-nucleotide polymorphism (SNP) rs62232870, P\,=\,8.7 {\texttimes} 10-11 and 7.7 {\texttimes} 10-4 in the discovery and replication steps, respectively] and chromosome 22q11.23 (lead SNP rs7284877, P\,=\,3.3 {\texttimes} 10-8 and 1.4 {\texttimes} 10-3 in the discovery and replication steps, respectively), while confirming two previously identified DCM loci on chromosomes 10 and 1, BAG3 and HSPB7. A genetic risk score constructed from the number of risk alleles at these four DCM loci revealed a 3-fold increased risk of DCM for individuals with 8 risk alleles compared to individuals with 5 risk alleles (median of the referral population). In silico annotation and functional 4C-sequencing analyses on iPSC-derived cardiomyocytes identify SLC6A6 as the most likely DCM gene at the 3p25.1 locus. This gene encodes a taurine transporter whose involvement in myocardial dysfunction and DCM is supported by numerous observations in humans and animals. At the 22q11.23 locus, in silico and data mining annotations, and to a lesser extent functional analysis, strongly suggest SMARCB1 as the candidate culprit gene. CONCLUSION: This study provides a better understanding of the genetic architecture of DCM and sheds light on novel biological pathways underlying heart failure.},
  langid = {english},
  pmcid = {PMC8139853},
  pmid = {33677556},
  keywords = {4C-sequencing,Adaptor Proteins Signal Transducing,Animals,Apoptosis Regulatory Proteins,Cardiomyopathy Dilated,Chromosomes,Dilated cardiomyopathy,Genetic Predisposition to Disease,Genetic risk score,Genome-Wide Association Study,GWAS,Heart failure,Heart Failure Systolic,Humans,Imputation,Polymorphism Single Nucleotide},
  file = {/Users/xx20081/Zotero/storage/9MULTWU8/Garnier et al. - 2021 - Genome-wide association analysis in dilated cardio.pdf}
}

@article{gkatzionisContextualizingSelectionBias2019,
  title = {Contextualizing Selection Bias in {{Mendelian}} Randomization: How Bad Is It Likely to Be?},
  shorttitle = {Contextualizing Selection Bias in {{Mendelian}} Randomization},
  author = {Gkatzionis, Apostolos and Burgess, Stephen},
  year = {2019},
  month = jun,
  journal = {International Journal of Epidemiology},
  volume = {48},
  number = {3},
  pages = {691--701},
  issn = {0300-5771},
  doi = {10.1093/ije/dyy202},
  urldate = {2025-01-22},
  abstract = {Selection bias affects Mendelian randomization investigations when selection into the study sample depends on a collider between the genetic variant and confounders of the risk factor--outcome association. However, the relative importance of selection bias for Mendelian randomization compared with other potential biases is unclear.We performed an extensive simulation study to assess the impact of selection bias on a typical Mendelian randomization investigation. We considered inverse probability weighting as a potential method for reducing selection bias. Finally, we investigated whether selection bias may explain a recently reported finding that lipoprotein(a) is not a causal risk factor for cardiovascular mortality in individuals with previous coronary heart disease.Selection bias had a severe impact on bias and Type 1 error rates in our simulation study, but only when selection effects were large. For moderate effects of the risk factor on selection, bias was generally small and Type 1 error rate inflation was not considerable. Inverse probability weighting ameliorated bias when the selection model was correctly specified, but increased bias when selection bias was moderate and the model was misspecified. In the example of lipoprotein(a), strong genetic associations and strong confounder effects on selection mean the reported null effect on cardiovascular mortality could plausibly be explained by selection bias.Selection bias can adversely affect Mendelian randomization investigations, but its impact is likely to be less than other biases. Selection bias is substantial when the effects of the risk factor and confounders on selection are particularly large.},
  file = {/Users/xx20081/Zotero/storage/XAT9PGEB/Gkatzionis and Burgess - 2019 - Contextualizing selection bias in Mendelian randomization how bad is it likely to be.pdf;/Users/xx20081/Zotero/storage/SIRLCT29/5132989.html}
}

@article{gomesGeneticArchitectureCardiac2023,
  title = {Genetic Architecture of Cardiac Dynamic Flow Volumes},
  author = {Gomes, Bruna and Singh, Aditya and O'Sullivan, Jack W. and Schnurr, Theresia M. and Goddard, Pag{\'e} C. and Loong, Shaun and Amar, David and Hughes, J. Weston and Kostur, Mykhailo and Haddad, Francois and Salerno, Michael and Foo, Roger and Montgomery, Stephen B. and Parikh, Victoria N. and Meder, Benjamin and Ashley, Euan A.},
  year = {2023},
  month = dec,
  journal = {Nature Genetics},
  pages = {1--13},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-023-01587-5},
  urldate = {2024-01-18},
  abstract = {Cardiac blood flow is a critical determinant of human health. However, the definition of its genetic architecture is limited by the technical challenge of capturing dynamic flow volumes from cardiac imaging at scale. We present DeepFlow, a deep-learning system to extract cardiac flow and volumes from phase-contrast cardiac magnetic resonance imaging. A mixed-linear model applied to 37,653 individuals from the UK Biobank reveals genome-wide significant associations across cardiac dynamic flow volumes spanning from aortic forward velocity to aortic regurgitation fraction. Mendelian randomization reveals a causal role for aortic root size in aortic valve regurgitation. Among the most significant contributing variants, localizing genes (near ELN, PRDM6 and ADAMTS7) are implicated in connective tissue and blood pressure pathways. Here we show that DeepFlow cardiac flow phenotyping at scale, combined with genotyping data, reinforces the contribution of connective tissue genes, blood pressure and root size to aortic valve function.},
  copyright = {2023 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  keywords = {Cardiovascular diseases,Genetics research,Population genetics},
  file = {/Users/xx20081/Zotero/storage/JVHX4EWU/Gomes et al. - 2023 - Genetic architecture of cardiac dynamic flow volum.pdf}
}

@article{gorskiGeneticLociPrioritization2022,
  title = {Genetic Loci and Prioritization of Genes for Kidney Function Decline Derived from a Meta-Analysis of 62 Longitudinal Genome-Wide Association Studies},
  author = {Gorski, Mathias and Rasheed, Humaira and Teumer, Alexander and Thomas, Laurent F. and Graham, Sarah E. and Sveinbjornsson, Gardar and Winkler, Thomas W. and G{\"u}nther, Felix and Stark, Klaus J. and Chai, Jin-Fang and Tayo, Bamidele O. and Wuttke, Matthias and Li, Yong and Tin, Adrienne and Ahluwalia, Tarunveer S. and {\"A}rnl{\"o}v, Johan and {\AA}svold, Bj{\o}rn Olav and Bakker, Stephan J. L. and Banas, Bernhard and Bansal, Nisha and Biggs, Mary L. and Biino, Ginevra and B{\"o}hnke, Michael and Boerwinkle, Eric and Bottinger, Erwin P. and Brenner, Hermann and Brumpton, Ben and Carroll, Robert J. and Chaker, Layal and Chalmers, John and Chee, Miao-Li and Chee, Miao-Ling and Cheng, Ching-Yu and Chu, Audrey Y. and Ciullo, Marina and Cocca, Massimiliano and Cook, James P. and Coresh, Josef and Cusi, Daniele and {de Borst}, Martin H. and Degenhardt, Frauke and Eckardt, Kai-Uwe and Endlich, Karlhans and Evans, Michele K. and Feitosa, Mary F. and Franke, Andre and {Freitag-Wolf}, Sandra and Fuchsberger, Christian and Gampawar, Piyush and Gansevoort, Ron T. and Ghanbari, Mohsen and Ghasemi, Sahar and Giedraitis, Vilmantas and Gieger, Christian and Gudbjartsson, Daniel F. and Hallan, Stein and Hamet, Pavel and Hishida, Asahi and Ho, Kevin and Hofer, Edith and Holleczek, Bernd and Holm, Hilma and Hoppmann, Anselm and Horn, Katrin and {Hutri-K{\"a}h{\"o}nen}, Nina and Hveem, Kristian and Hwang, Shih-Jen and Ikram, M. Arfan and Josyula, Navya Shilpa and Jung, Bettina and K{\"a}h{\"o}nen, Mika and Karabegovi{\'c}, Irma and Khor, Chiea-Chuen and Koenig, Wolfgang and Kramer, Holly and Kr{\"a}mer, Bernhard K. and K{\"u}hnel, Brigitte and Kuusisto, Johanna and Laakso, Markku and Lange, Leslie A. and Lehtim{\"a}ki, Terho and Li, Man and Lieb, Wolfgang and Lind, Lars and Lindgren, Cecilia M. and Loos, Ruth J. F. and Lukas, Mary Ann and Lyytik{\"a}inen, Leo-Pekka and Mahajan, Anubha and {Matias-Garcia}, Pamela R. and Meisinger, Christa and Meitinger, Thomas and Melander, Olle and Milaneschi, Yuri and Mishra, Pashupati P. and Mononen, Nina and Morris, Andrew P. and Mychaleckyj, Josyf C. and Nadkarni, Girish N. and Naito, Mariko and Nakatochi, Masahiro and Nalls, Mike A. and Nauck, Matthias and Nikus, Kjell and Ning, Boting and Nolte, Ilja M. and Nutile, Teresa and O'Donoghue, Michelle L. and O'Connell, Jeffrey and Olafsson, Isleifur and {Orho-Melander}, Marju and Parsa, Afshin and Pendergrass, Sarah A. and Penninx, Brenda W. J. H. and Pirastu, Mario and Preuss, Michael H. and Psaty, Bruce M. and Raffield, Laura M. and Raitakari, Olli T. and Rheinberger, Myriam and Rice, Kenneth M. and Rizzi, Federica and Rosenkranz, Alexander R. and Rossing, Peter and Rotter, Jerome I. and Ruggiero, Daniela and Ryan, Kathleen A. and Sabanayagam, Charumathi and Salvi, Erika and Schmidt, Helena and Schmidt, Reinhold and Scholz, Markus and Sch{\"o}ttker, Ben and Schulz, Christina-Alexandra and Sedaghat, Sanaz and Shaffer, Christian M. and Sieber, Karsten B. and Sim, Xueling and Sims, Mario and Snieder, Harold and Stanzick, Kira J. and Thorsteinsdottir, Unnur and Stocker, Hannah and Strauch, Konstantin and Stringham, Heather M. and Sulem, Patrick and Szymczak, Silke and Taylor, Kent D. and Thio, Chris H. L. and Tremblay, Johanne and Vaccargiu, Simona and {van der Harst}, Pim and {van der Most}, Peter J. and Verweij, Niek and V{\"o}lker, Uwe and Wakai, Kenji and Waldenberger, Melanie and Wallentin, Lars and Wallner, Stefan and Wang, Judy and Waterworth, Dawn M. and White, Harvey D. and Willer, Cristen J. and Wong, Tien-Yin and Woodward, Mark and Yang, Qiong and {Yerges-Armstrong}, Laura M. and Zimmermann, Martina and Zonderman, Alan B. and Bergler, Tobias and Stefansson, Kari and B{\"o}ger, Carsten A. and Pattaro, Cristian and K{\"o}ttgen, Anna and Kronenberg, Florian and Heid, Iris M.},
  year = {2022},
  month = sep,
  journal = {Kidney International},
  volume = {102},
  number = {3},
  pages = {624--639},
  issn = {0085-2538},
  doi = {10.1016/j.kint.2022.05.021},
  urldate = {2024-08-14},
  abstract = {Estimated glomerular filtration rate (eGFR) reflects kidney function. Progressive eGFR-decline can lead to kidney failure, necessitating dialysis or transplantation. Hundreds of loci from genome-wide association studies (GWAS) for eGFR help explain population cross section variability. Since the contribution of these or other loci to eGFR-decline remains largely unknown, we derived GWAS for annual eGFR-decline and meta-analyzed 62 longitudinal studies with eGFR assessed twice over time in all 343,339 individuals and in high-risk groups. We also explored different covariate adjustment. Twelve genome-wide significant independent variants for eGFR-decline unadjusted or adjusted for eGFR-baseline (11 novel, one known for this phenotype), including nine variants robustly associated across models were identified. All loci for eGFR-decline were known for cross-sectional eGFR and thus distinguished a subgroup of eGFR loci. Seven of the nine variants showed variant-by-age interaction on eGFR cross section (further about 350,000 individuals), which linked genetic associations for eGFR-decline with age-dependency of genetic cross-section associations. Clinically important were two to four-fold greater genetic effects on eGFR-decline in high-risk subgroups. Five variants associated also with chronic kidney disease progression mapped to genes with functional in-silico evidence (UMOD, SPATA7, GALNTL5, TPPP). An unfavorable versus favorable nine-variant genetic profile showed increased risk odds ratios of 1.35 for kidney failure (95\% confidence intervals 1.03-1.77) and 1.27 for acute kidney injury (95\% confidence intervals 1.08-1.50) in over 2000 cases each, with matched controls). Thus, we provide a large data resource, genetic loci, and prioritized genes for kidney function decline, which help inform drug development pipelines revealing important insights into the age-dependency of kidney function genetics.},
  keywords = {acute kidney injury,chronic kidney disease,diabetes,gene expression},
  file = {/Users/xx20081/Zotero/storage/TRQVE9GF/Gorski et al. - 2022 - Genetic loci and prioritization of genes for kidne.pdf;/Users/xx20081/Zotero/storage/ZKTQLPVL/S0085253822004549.html}
}

@article{grangerEffectsCandesartanPatients2003,
  title = {Effects of Candesartan in Patients with Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The {{CHARM-Alternative}} Trial},
  shorttitle = {Effects of Candesartan in Patients with Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors},
  author = {Granger, Christopher B. and McMurray, John J. V. and Yusuf, Salim and Held, Peter and Michelson, Eric L. and Olofsson, Bertil and Ostergren, Jan and Pfeffer, Marc A. and Swedberg, Karl and {CHARM Investigators and Committees}},
  year = {2003},
  month = sep,
  journal = {Lancet (London, England)},
  volume = {362},
  number = {9386},
  pages = {772--776},
  issn = {1474-547X},
  doi = {10.1016/S0140-6736(03)14284-5},
  abstract = {BACKGROUND: Angiotensin-converting-enzyme (ACE) inhibitors improve outcome of patients with chronic heart failure (CHF). A substantial proportion of patients, however, experience no benefit from ACE inhibitors because of previous intolerance. We aimed to find out whether candesartan, an angiotensin-receptor blocker, could improve outcome in such patients not taking an ACE inhibitor. METHODS: Between March, 1999, and March, 2001, we enrolled 2028 patients with symptomatic heart failure and left-ventricular ejection fraction 40\% or less who were not receiving ACE inhibitors because of previous intolerance. Patients were randomly assigned candesartan (target dose 32 mg once daily) or matching placebo. The primary outcome of the study was the composite of cardiovascular death or hospital admission for CHF. Analysis was by intention to treat. FINDINGS: The most common manifestation of ACE-inhibitor intolerance was cough (72\%), followed by symptomatic hypotension (13\%) and renal dysfunction (12\%). During a median follow-up of 33.7 months, 334 (33\%) of 1013 patients in the candesartan group and 406 (40\%) of 1015 in the placebo group had cardiovascular death or hospital admission for CHF (unadjusted hazard ratio 0.77 [95\% CI 0.67-0.89], p=0.0004; covariate adjusted 0.70 [0.60-0.81], p{$<$}0.0001). Each component of the primary outcome was reduced, as was the total number of hospital admissions for CHF. Study-drug discontinuation rates were similar in the candesartan (30\%) and placebo (29\%) groups. INTERPRETATION: Candesartan was generally well tolerated and reduced cardiovascular mortality and morbidity in patients with symptomatic chronic heart failure and intolerance to ACE inhibitors.},
  langid = {english},
  pmid = {13678870},
  keywords = {Aged,Angiotensin Receptor Antagonists,Angiotensin-Converting Enzyme Inhibitors,Antihypertensive Agents,Benzimidazoles,Biphenyl Compounds,Cardiac Output Low,Comorbidity,Cough,Female,Follow-Up Studies,Heart Failure,Humans,Hypotension,Kidney Diseases,Male,Tetrazoles,Treatment Outcome,Ventricular Dysfunction Left},
  file = {/Users/xx20081/Zotero/storage/35X6S867/Granger et al. - 2003 - Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic.pdf}
}

@article{hakanssonGeneticAssociationsRegulation2019,
  title = {Genetic Associations and Regulation of Expression Indicate an Independent Role for 14q32 {{snoRNAs}} in Human Cardiovascular Disease},
  author = {H{\aa}kansson, Kjell E J and Goossens, Eveline A C and Trompet, Stella and {van Ingen}, Eva and {de Vries}, Margreet R and {van der Kwast}, Reginald V C T and Ripa, Rasmus S and Kastrup, Jens and Hohensinner, Philipp J and Kaun, Christoph and Wojta, Johann and B{\"o}hringer, Stefan and Le Cessie, Saskia and Jukema, J Wouter and Quax, Paul H A and Nossent, A Ya{\"e}l},
  year = {2019},
  month = aug,
  journal = {Cardiovascular Research},
  volume = {115},
  number = {10},
  pages = {1519--1532},
  issn = {0008-6363},
  doi = {10.1093/cvr/cvy309},
  urldate = {2024-04-12},
  abstract = {We have shown that 14q32 microRNAs are highly involved in vascular remodelling and cardiovascular disease. However, the 14q32 locus also encodes 41 `orphan' small nucleolar RNAs (snoRNAs). We aimed to gather evidence for an independent role for 14q32 snoRNAs in human cardiovascular disease.We performed a lookup of the 14q32 region within the dataset of a genome wide association scan in 5244 participants of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Single nucleotide polymorphisms (SNPs) in the snoRNA-cluster were significantly associated with heart failure. These snoRNA-cluster SNPs were not linked to SNPs in the microRNA-cluster or in MEG3, indicating that snoRNAs modify the risk of cardiovascular disease independently. We looked at expression of 14q32 snoRNAs throughout the human cardio-vasculature. Expression profiles of the 14q32 snoRNAs appeared highly vessel specific. When we compared expression levels of 14q32 snoRNAs in human vena saphena magna (VSM) with those in failed VSM-coronary bypasses, we found that 14q32 snoRNAs were up-regulated. SNORD113.2, which showed a 17-fold up-regulation in failed bypasses, was also up-regulated two-fold in plasma samples drawn from patients with ST-elevation myocardial infarction directly after hospitalization compared with 30\,days after start of treatment. However, fitting with the genomic associations, 14q32 snoRNA expression was highest in failing human hearts. In vitro studies show that the 14q32 snoRNAs bind predominantly to methyl-transferase Fibrillarin, indicating that they act through canonical mechanisms, but on non-canonical RNA targets. The canonical C/D-box snoRNA seed sequences were highly conserved between humans and mice.14q32 snoRNAs appear to play an independent role in cardiovascular pathology. 14q32 snoRNAs are specifically regulated throughout the human vasculature and their expression is up-regulated during cardiovascular disease. Our data demonstrate that snoRNAs merit increased effort and attention in future basic and clinical cardiovascular research.},
  file = {/Users/xx20081/Zotero/storage/NWHKB7JU/Hkansson et al. - 2019 - Genetic associations and regulation of expression .pdf;/Users/xx20081/Zotero/storage/5ATHD9L7/5244092.html}
}

@article{hannaInflammatoryCytokinesChemokines2020,
  title = {Inflammatory {{Cytokines}} and {{Chemokines}} as {{Therapeutic Targets}} in {{Heart Failure}}},
  author = {Hanna, Anis and Frangogiannis, Nikolaos G.},
  year = {2020},
  month = dec,
  journal = {Cardiovascular Drugs and Therapy},
  volume = {34},
  number = {6},
  pages = {849--863},
  issn = {1573-7241},
  doi = {10.1007/s10557-020-07071-0},
  abstract = {Heart failure exhibits remarkable pathophysiologic heterogeneity. A large body of evidence suggests that regardless of the underlying etiology, heart failure is associated with induction of cytokines and chemokines that may contribute to the pathogenesis of adverse remodeling, and systolic and diastolic dysfunction. The pro-inflammatory cytokines tumor necrosis factor (TNF)-{$\alpha$}, interleukin (IL)-1, and IL-6 have been extensively implicated in the pathogenesis of heart failure. Inflammatory cytokines modulate phenotype and function of all myocardial cells, suppressing contractile function in cardiomyocytes, inducing inflammatory activation in macrophages, stimulating microvascular inflammation and dysfunction, and promoting a matrix-degrading phenotype in fibroblasts. Moreover, cytokine-induced growth factor synthesis may exert chronic fibrogenic actions contributing to the pathogenesis of heart failure with preserved ejection fraction (HFpEF). In addition to their role in adverse cardiac remodeling, some inflammatory cytokines may also exert protective actions on cardiomyocytes under conditions of stress. Chemokines, such as CCL2, are also upregulated in failing hearts and may stimulate recruitment of pro-inflammatory leukocytes, promoting myocardial injury, fibrotic remodeling, and dysfunction. Although experimental evidence suggests that cytokine and chemokine targeting may hold therapeutic promise in heart failure, clinical translation remains challenging. This review manuscript summarizes our knowledge on the role of TNF-{$\alpha$}, IL-1, IL-6, and CCL2 in the pathogenesis of heart failure, and discusses the promises and challenges of targeted anti-cytokine therapy. Dissection of protective and maladaptive cellular actions of cytokines in the failing heart, and identification of patient subsets with overactive or dysregulated myocardial inflammatory responses are required for design of successful therapeutic approaches.},
  langid = {english},
  pmcid = {PMC7479403},
  pmid = {32902739},
  keywords = {Animals,Anti-Inflammatory Agents,Chemokine,Chemokines,Cytokine,Cytokines,Heart failure,Heart Failure,Humans,Inflammation,Interleukin-1,Molecular Targeted Therapy,Myocytes Cardiac,Signal Transduction,TNF-,Translational Research Biomedical,Ventricular Function Left,Ventricular Remodeling},
  file = {/Users/xx20081/Zotero/storage/28STXRXN/Hanna and Frangogiannis - 2020 - Inflammatory Cytokines and Chemokines as Therapeut.pdf}
}

@article{hazewinkelMendelianRandomizationAnalysis2022,
  title = {Mendelian Randomization Analysis of the Causal Impact of Body Mass Index and Waist-Hip Ratio on Rates of Hospital Admission},
  author = {Hazewinkel, Audinga-Dea and Richmond, Rebecca C. and Wade, Kaitlin H. and Dixon, Padraig},
  year = {2022},
  month = jan,
  journal = {Economics \& Human Biology},
  volume = {44},
  pages = {101088},
  issn = {1570-677X},
  doi = {10.1016/j.ehb.2021.101088},
  urldate = {2024-03-08},
  abstract = {We analyze how measures of adiposity -- body mass index (BMI) and waist~hip ratio (WHR) -- causally influence rates of hospital admission. Conventional analyses of this relationship are susceptible to omitted variable bias from variables that jointly influence both hospital admission and adipose status. We implement a novel quasi-Poisson instrumental variable model in a Mendelian randomization framework, identifying causal effects from random perturbations to germline genetic variation. We estimate the individual and joint effects of BMI, WHR, and WHR adjusted for BMI. We also implement multivariable instrumental variable methods in which the causal effect of one exposure is estimated conditionally on the causal effect of another exposure. Data on 310,471 participants and over 550,000 inpatient admissions in the UK Biobank were used to perform one-sample and two-sample Mendelian randomization analyses. The results supported a causal role of adiposity on hospital admissions, with consistency across all estimates and sensitivity analyses. Point estimates were generally larger than estimates from comparable observational specifications. We observed an attenuation of the BMI effect when adjusting for WHR in the multivariable Mendelian randomization analyses, suggesting that an adverse fat distribution, rather than a higher BMI itself, may drive the relationship between adiposity and risk of hospital admission.},
  keywords = {BMI,Body mass index,Hospital admissions,Instrumental variables,Mendelian randomization,Poisson models,Waist hip ratio,WHR},
  file = {/Users/xx20081/Zotero/storage/5CAH4DXY/Hazewinkel et al. - 2022 - Mendelian randomization analysis of the causal imp.pdf;/Users/xx20081/Zotero/storage/8DZW63A6/S1570677X21001131.html}
}

@article{heGenomeWideAssociationStudy2013,
  title = {Genome-{{Wide Association Study Identifies}} 8 {{Novel Loci Associated With Blood Pressure Responses}} to {{Interventions}} in {{Han Chinese}}},
  author = {He, Jiang and Kelly, Tanika N. and Zhao, Qi and Li, Hongfan and Huang, Jianfeng and Wang, Laiyuan and Jaquish, Cashell E. and Sung, Yun Ju and Shimmin, Lawrence C. and Lu, Fanghong and Mu, Jianjun and Hu, Dongsheng and Ji, Xu and Shen, Chong and Guo, Dongshuang and Ma, Jixiang and Wang, Renping and Shen, Jinjin and Li, Shengxu and Chen, Jing and Mei, Hao and Chen, Chung-Shiuan and Chen, Shufeng and Chen, Jichun and Li, Jianxin and Cao, Jie and Lu, Xiangfeng and Wu, Xigui and Rice, Treva K. and Gu, C. Charles and Schwander, Karen and Hamm, L. Lee and Liu, Depei and Rao, Dabeeru C. and Hixson, James E. and Gu, Dongfeng},
  year = {2013},
  month = dec,
  journal = {Circulation: Cardiovascular Genetics},
  volume = {6},
  number = {6},
  pages = {598--607},
  publisher = {American Heart Association},
  doi = {10.1161/CIRCGENETICS.113.000307},
  urldate = {2024-04-12},
  abstract = {Background--- Blood pressure (BP) responses to dietary sodium and potassium intervention and cold pressor test vary considerably among individuals. We aimed to identify novel genetic variants influencing individuals' BP responses to dietary intervention and cold pressor test. Methods and Results--- We conducted a genome-wide association study of BP responses in 1881 Han Chinese and de novo genotyped top findings in 698 Han Chinese. Diet-feeding study included a 7-day low-sodium (51.3 mmol/d), a 7-day high-sodium (307.8 mmol/d), and a 7-day high-sodium plus potassium supplementation (60 mmol/d). Nine BP measurements were obtained during baseline observation and each intervention period. The meta-analyses identified 8 novel loci for BP phenotypes, which physically mapped in or near PRMT6 (P=7.29{\texttimes}10--9), CDCA7 (P=3.57{\texttimes}10--8), PIBF1 (P=1.78{\texttimes}10--9), ARL4C (P=1.86{\texttimes}10--8), IRAK1BP1 (P=1.44{\texttimes}10-10), SALL1 (P=7.01{\texttimes}10--13), TRPM8 (P=2.68{\texttimes}10--8), and FBXL13 (P=3.74{\texttimes}10--9). There was a strong dose--response relationship between the number of risk alleles of these independent single-nucleotide polymorphisms and the risk of developing hypertension during the 7.5-year follow-up in the study participants. Compared with those in the lowest quartile of risk alleles, odds ratios (95\% confidence intervals) for those in the second, third, and fourth quartiles were 1.39 (0.97, 1.99), 1.72 (1.19, 2.47), and 1.84 (1.29, 2.62), respectively (P=0.0003 for trend). Conclusions--- Our study identified 8 novel loci for BP responses to dietary sodium and potassium intervention and cold pressor test. The effect size of these novel loci on BP phenotypes is much larger than those reported by the previously published studies. Furthermore, these variants predict the risk of developing hypertension among individuals with normal BP at baseline.},
  keywords = {blood pressure,genomics,potassium,sodium},
  file = {/Users/xx20081/Zotero/storage/CLXZY8Z8/He et al. - 2013 - Genome-Wide Association Study Identifies 8 Novel L.pdf}
}

@article{hemaniMRBasePlatformSupports2018,
  title = {The {{MR-Base}} Platform Supports Systematic Causal Inference across the Human Phenome},
  author = {Hemani, Gibran and Zheng, Jie and Elsworth, Benjamin and Wade, Kaitlin H. and Haberland, Valeriia and Baird, Denis and Laurin, Charles and Burgess, Stephen and Bowden, Jack and Langdon, Ryan and Tan, Vanessa Y. and Yarmolinsky, James and Shihab, Hashem A. and Timpson, Nicholas J. and Evans, David M. and Relton, Caroline and Martin, Richard M. and Davey Smith, George and Gaunt, Tom R. and Haycock, Philip C.},
  year = {2018},
  month = may,
  journal = {eLife},
  volume = {7},
  pages = {e34408},
  issn = {2050-084X},
  doi = {10.7554/eLife.34408},
  abstract = {Results from genome-wide association studies (GWAS) can be used to infer causal relationships between phenotypes, using a strategy known as 2-sample Mendelian randomization (2SMR) and bypassing the need for individual-level data. However, 2SMR methods are evolving rapidly and GWAS results are often insufficiently curated, undermining efficient implementation of the approach. We therefore developed MR-Base ({$<$}ext-link ext-link-type="uri" xlink:href="http://www.mrbase.org"{$>$}http://www.mrbase.org{$<$}/ext-link{$>$}): a platform that integrates a curated database of complete GWAS results (no restrictions according to statistical significance) with an application programming interface, web app and R packages that automate 2SMR. The software includes several sensitivity analyses for assessing the impact of horizontal pleiotropy and other violations of assumptions. The database currently comprises 11 billion single nucleotide polymorphism-trait associations from 1673 GWAS and is updated on a regular basis. Integrating data with software ensures more rigorous application of hypothesis-driven analyses and allows millions of potential causal relationships to be efficiently evaluated in phenome-wide association studies.},
  langid = {english},
  pmcid = {PMC5976434},
  pmid = {29846171},
  keywords = {causal inference,Cholesterol LDL,computational biology,Coronary Disease,Databases Genetic,Genetic Pleiotropy,Genome-Wide Association Study,GWAS,human,human biology,Humans,medicine,Mendelian randomization,Mendelian Randomization Analysis,Models Genetic,Phenotype,Polymorphism Single Nucleotide,systems biology},
  file = {/Users/xx20081/Zotero/storage/VV6LNZZL/Hemani et al. - 2018 - The MR-Base platform supports systematic causal in.pdf}
}

@article{hicks2014ACCAHA2015,
  title = {2014 {{ACC}}/{{AHA Key Data Elements}} and {{Definitions}} for {{Cardiovascular Endpoint Events}} in {{Clinical Trials}}},
  author = {Hicks, Karen A. and Tcheng, James E. and Bozkurt, Biykem and Chaitman, Bernard R. and Cutlip, Donald E. and Farb, Andrew and Fonarow, Gregg C. and Jacobs, Jeffrey P. and Jaff, Michael R. and Lichtman, Judith H. and Limacher, Marian C. and Mahaffey, Kenneth W. and Mehran, Roxana and Nissen, Steven E. and Smith, Eric E. and Targum, Shari L.},
  year = {2015},
  month = jul,
  journal = {Circulation},
  volume = {132},
  number = {4},
  pages = {302--361},
  publisher = {American Heart Association},
  doi = {10.1161/CIR.0000000000000156},
  urldate = {2025-01-26},
  file = {/Users/xx20081/Zotero/storage/YZ4XHX69/Hicks et al. - 2015 - 2014 ACCAHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials.pdf}
}

@article{hoffmannLargeElectronichealthrecordbasedGenomewide2018,
  title = {A Large Electronic-Health-Record-Based Genome-Wide Study of Serum Lipids},
  author = {Hoffmann, Thomas J. and Theusch, Elizabeth and Haldar, Tanushree and Ranatunga, Dilrini K. and Jorgenson, Eric and Medina, Marisa W. and Kvale, Mark N. and Kwok, Pui-Yan and Schaefer, Catherine and Krauss, Ronald M. and Iribarren, Carlos and Risch, Neil},
  year = {2018},
  month = mar,
  journal = {Nature Genetics},
  volume = {50},
  number = {3},
  pages = {401--413},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-018-0064-5},
  urldate = {2024-04-12},
  abstract = {A genome-wide association study~(GWAS) of 94,674 ancestrally diverse Kaiser Permanente members using 478,866 longitudinal electronic health record (EHR)-derived measurements for untreated serum lipid levels empowered multiple new findings: 121 new SNP associations (46 primary, 15 conditional, and 60 in meta-analysis with Global Lipids Genetic Consortium data); an increase of 33--42\% in variance explained with multiple measurements; sex differences in genetic impact (greater impact in females for LDL, HDL, and total cholesterol and the opposite for triglycerides); differences in variance explained among non-Hispanic whites, Latinos, African Americans, and East Asians; genetic dominance and epistatic interaction, with strong evidence for both at the ABO and FUT2 genes for LDL; and tissue-specific enrichment~of GWAS-associated SNPs among liver, adipose, and pancreas~eQTLs. Using EHR pharmacy data, both LDL and triglyceride genetic risk scores (477 SNPs) were strongly predictive of age at initiation of lipid-lowering treatment. These findings highlight the value of longitudinal EHRs for identifying new genetic features of cholesterol and lipoprotein metabolism with implications for lipid treatment and risk of coronary heart disease.},
  copyright = {2018 The Author(s)},
  langid = {english},
  keywords = {Dyslipidaemias,Genome-wide association studies},
  file = {/Users/xx20081/Zotero/storage/ZXCFD8QF/Hoffmann et al. - 2018 - A large electronic-health-record-based genome-wide.pdf}
}

@article{hoffmannLargeMultiethnicGenomeWide2018,
  title = {A {{Large Multiethnic Genome-Wide Association Study}} of {{Adult Body Mass Index Identifies Novel Loci}}},
  author = {Hoffmann, Thomas J. and Choquet, H{\'e}l{\`e}ne and Yin, Jie and Banda, Yambazi and Kvale, Mark N. and Glymour, Maria and Schaefer, Catherine and Risch, Neil and Jorgenson, Eric},
  year = {2018},
  month = oct,
  journal = {Genetics},
  volume = {210},
  number = {2},
  pages = {499--515},
  issn = {1943-2631},
  doi = {10.1534/genetics.118.301479},
  abstract = {Body mass index (BMI), a proxy measure for obesity, is determined by both environmental (including ethnicity, age, and sex) and genetic factors, with {$>$} 400 BMI-associated loci identified to date. However, the impact, interplay, and underlying biological mechanisms among BMI, environment, genetics, and ancestry are not completely understood. To further examine these relationships, we utilized 427,509 calendar year-averaged BMI measurements from 100,418 adults from the single large multiethnic Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort. We observed substantial independent ancestry and nationality differences, including ancestry principal component interactions and nonlinear effects. To increase the list of BMI-associated variants before assessing other differences, we conducted a genome-wide association study (GWAS) in GERA, with replication in the Genetic Investigation of Anthropomorphic Traits (GIANT) consortium combined with the UK Biobank (UKB), followed by GWAS in GERA combined with GIANT, with replication in the UKB. We discovered 30 novel independent BMI loci (P {$<$} 5.0 {\texttimes} 10-8) that replicated. We then assessed the proportion of BMI variance explained by sex in the UKB using previously identified loci compared to previously and newly identified loci and found slight increases: from 3.0 to 3.3\% for males and from 2.7 to 3.0\% for females. Further, the variance explained by previously and newly identified variants decreased with increasing age in the GERA and UKB cohorts, echoed in the variance explained by the entire genome, which also showed gene-age interaction effects. Finally, we conducted a tissue expression QTL enrichment analysis, which revealed that GWAS BMI-associated variants were enriched in the cerebellum, consistent with prior work in humans and mice.},
  langid = {english},
  pmcid = {PMC6216593},
  pmid = {30108127},
  keywords = {adult BMI,adult body mass index,Body Mass Index,Body Weight,Ethnicity,Female,Genetic Loci,genome-wide association study,Genome-Wide Association Study,Humans,Male,Middle Aged,Multifactorial Inheritance,obesity,Sex Factors},
  file = {/Users/xx20081/Zotero/storage/JQUJMASP/Hoffmann et al. - 2018 - A Large Multiethnic Genome-Wide Association Study of Adult Body Mass Index Identifies Novel Loci.pdf}
}

@article{huangGenomewideDiscoveryGenetic2021,
  title = {Genome-Wide Discovery of Genetic Loci That Uncouple Excess Adiposity from Its Comorbidities},
  author = {Huang, Lam O. and Rauch, Alexander and Mazzaferro, Eugenia and Preuss, Michael and Carobbio, Stefania and Bayrak, Cigdem S. and Chami, Nathalie and Wang, Zhe and Schick, Ursula M. and Yang, Nancy and Itan, Yuval and {Vidal-Puig}, Antonio and {den Hoed}, Marcel and Mandrup, Susanne and Kilpel{\"a}inen, Tuomas O. and Loos, Ruth J. F.},
  year = {2021},
  month = feb,
  journal = {Nature Metabolism},
  volume = {3},
  number = {2},
  pages = {228--243},
  publisher = {Nature Publishing Group},
  issn = {2522-5812},
  doi = {10.1038/s42255-021-00346-2},
  urldate = {2024-08-15},
  abstract = {Obesity is a major risk factor for cardiometabolic diseases. Nevertheless, a substantial proportion of individuals with obesity do not suffer cardiometabolic comorbidities. The mechanisms that uncouple adiposity from its cardiometabolic complications are not fully understood. Here, we identify 62 loci of which the same allele is significantly associated with both higher adiposity and lower cardiometabolic risk. Functional analyses show that the 62 loci are enriched for genes expressed in adipose tissue, and for regulatory variants that influence nearby genes that affect adipocyte differentiation. Genes prioritized in each locus support a key role of fat distribution (FAM13A, IRS1 and PPARG) and adipocyte function (ALDH2, CCDC92, DNAH10, ESR1, FAM13A, MTOR, PIK3R1 and VEGFB). Several additional mechanisms are involved as well, such as insulin--glucose signalling (ADCY5, ARAP1, CREBBP, FAM13A, MTOR, PEPD, RAC1 and SH2B3), energy expenditure and fatty acid oxidation (IGF2BP2), browning of white adipose tissue (CSK, VEGFA, VEGFB and SLC22A3) and inflammation (SH2B3, DAGLB and ADCY9). Some of these genes may represent therapeutic targets to reduce cardiometabolic risk linked to excess adiposity.},
  copyright = {2021 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  keywords = {Cardiovascular diseases,Genome-wide association studies,Metabolic diseases,Obesity}
}

@article{jcIntensiveLipidLowering2005,
  title = {Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease},
  author = {Jc, LaRosa and Sm, Grundy and Dd, Waters and C, Shear and P, Barter and Jc, Fruchart and Am, Gotto and H, Greten and Jj, Kastelein and J, Shepherd and Nk, Wenger},
  year = {2005},
  month = jul,
  journal = {The New England journal of medicine},
  volume = {352},
  number = {14},
  publisher = {N Engl J Med},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa050461},
  urldate = {2023-12-08},
  abstract = {Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg of atorvastatin per day. This occurred with a greater incidence of elevated aminotransferase levels.},
  langid = {english},
  pmid = {15755765},
  file = {/Users/xx20081/Zotero/storage/C68V7WTX/Jc et al. - 2005 - Intensive lipid lowering with atorvastatin in pati.pdf;/Users/xx20081/Zotero/storage/IDZJ62ED/15755765.html}
}

@article{jGenomewideAssociationStudy2013,
  title = {Genome-Wide Association Study Identifies 8 Novel Loci Associated with Blood Pressure Responses to Interventions in {{Han Chinese}}},
  author = {J, He and Tn, Kelly and Q, Zhao and H, Li and J, Huang and L, Wang and Ce, Jaquish and Yj, Sung and Lc, Shimmin and F, Lu and J, Mu and D, Hu and X, Ji and C, Shen and D, Guo and J, Ma and R, Wang and J, Shen and S, Li and J, Chen and H, Mei and Cs, Chen and S, Chen and J, Chen and J, Li and J, Cao and X, Lu and X, Wu and Tk, Rice and Cc, Gu and K, Schwander and Ll, Hamm and D, Liu and Dc, Rao and Je, Hixson and D, Gu},
  year = {2013},
  month = dec,
  journal = {Circulation. Cardiovascular genetics},
  volume = {6},
  number = {6},
  publisher = {Circ Cardiovasc Genet},
  issn = {1942-3268},
  doi = {10.1161/CIRCGENETICS.113.000307},
  urldate = {2024-04-12},
  abstract = {Our study identified 8 novel loci for BP responses to dietary sodium and potassium intervention and cold pressor test. The effect size of these novel loci on BP phenotypes is much larger than those reported by the previously published studies. Furthermore, these variants predict the risk of developi {\dots}},
  langid = {english},
  pmid = {24165912},
  file = {/Users/xx20081/Zotero/storage/KALAZY9Z/J et al. - 2013 - Genome-wide association study identifies 8 novel l.pdf}
}

@article{jinHeritabilityLeftVentricular2011,
  title = {Heritability of Left Ventricular Structure and Function in {{Caucasian}} Families},
  author = {Jin, Yu and Kuznetsova, Tatiana and Bochud, Murielle and Richart, Tom and Thijs, Lutgarde and Cusi, Daniele and Fagard, Robert and Staessen, Jan A.},
  year = {2011},
  month = apr,
  journal = {European Journal of Echocardiography: The Journal of the Working Group on Echocardiography of the European Society of Cardiology},
  volume = {12},
  number = {4},
  pages = {326--332},
  issn = {1532-2114},
  doi = {10.1093/ejechocard/jer019},
  abstract = {AIMS: The aim of this study was to investigate the heritability as well as genetic and environmental correlations of left ventricular (LV) structural and functional traits in complex pedigrees of a Caucasian population. METHODS AND RESULTS: We randomly recruited 459 white European subjects from 52 families (50\% women; mean age 45 years). LV structure was measured by M-mode and 2D echocardiography and LV function was measured by conventional Doppler and tissue Doppler imaging (TDI). Other measurements included blood pressure, anthropometric, and biochemical measurements. We estimated the heritability of LV traits while adjusting for covariables, including sex, age, body height and weight, systolic and diastolic blood pressures, and heart rate. With full adjustment, heritability of LV mass was 0.23 (P= 0.025). The TDI-derived mitral annular velocities Ea and Aa showed moderate heritability (h(2)= 0.36 and 0.53, respectively), whereas the mitral inflow A peak had weak heritability (h(2) = 0.25) and the E peak was not heritable (h(2) = 0.11). We partitioned the total phenotypic correlation when it reached significance, into a genetic and an environmental component. The genetic correlations were 0.61 between the E and Ea peaks and 0.90 between the A and Aa peaks. CONCLUSION: Our study demonstrated moderate heritability for LV mass as well as the mitral annular Ea and Aa peaks. We also found significant genetic correlations between the E and Ea peaks and between the A and Aa peaks. Our current findings support the ongoing research to map and detect genetic variants that contribute to the variation in LV mass and other LV structural and functional phenotypes.},
  langid = {english},
  pmcid = {PMC3106286},
  pmid = {21398654},
  keywords = {Adult,Anthropometry,Biomarkers,Blood Pressure,Echocardiography Doppler,Female,Genotype,Humans,Hypertrophy Left Ventricular,Male,Middle Aged,Phenotype,Regression Analysis,White People},
  file = {/Users/xx20081/Zotero/storage/W66AAGB3/Jin et al. - 2011 - Heritability of left ventricular structure and fun.pdf}
}

@article{katzourouGenomewideAssociationStudy2020,
  title = {Genome-Wide Association Study of Progression in {{Alzheimer}}'s Disease},
  author = {Katzourou, Ioanna and Leonenko, Ganna and Williams, Julie and Holmans, Peter and {Escott-Price}, Valentina},
  year = {2020},
  journal = {Alzheimer's \& Dementia},
  volume = {16},
  number = {S2},
  pages = {e040950},
  issn = {1552-5279},
  doi = {10.1002/alz.040950},
  urldate = {2024-08-14},
  abstract = {Background The rate of disease progression is an important factor to consider regarding Alzheimer's disease (AD), as people with a rapid decline are considerably more likely to require additional care resources. The rate of progression in AD has been found to vary widely between individuals, with numerous factors driving this heterogeneity. In this project, a genome-wide association study (GWAS) was performed to investigate the presence of a genetic liability to faster progression in patients with AD. Methods A subset of 543 individuals with AD from the Cardiff MRC centre cohorts that have been assessed at multiple timepoints was used in this analysis. A progression score for each individual was approximated by a random slope from a random effects regression model of Mini Mental State Examination (MMSE) using all available MMSE measurements. The score was subsequently used in a GWAS of progression. Quality control analysis was performed following standard GWAS protocols resulting in 304,448 variants to be included in the analysis. Results The sample was 67.37\% female, with mean age at recruitment being 80.2 years. Mean MMSE was 17.03 at first assessment and 11.54 at last assessment, and mean number of assessments was 3.16. After correcting for multiple testing, no variant was found to be significantly associated with progression in this GWAS. Furthermore, apolipoprotein E (ApoE) genotype was not associated with progression. Conclusion Preliminary results show that, after Bonferroni correction for multiple testing, no variant was significantly associated with progression in AD. Suggestive associated variants were found in chromosome 20:5843812 (p-value = 3.12 {\texttimes} 10-7), 1:62271962 (p-value = 6.30 {\texttimes} 10-7), 10:15452800 (p-value = 1.65 {\texttimes} 10-6) and 5:117646945 (p-value = 2.40 {\texttimes} 10-6). Moreover, ApoE genotype was not found to affect the rate progression, the lowest p-value in the ApoE region (19:44905791 - 19:44909393) being 0.23. This non-significant result might indicate that the genetic risk for accelerated cognitive decline within AD is separate from the genetic risk for developing AD. The sample size is one of the main limitations of this study. Replication in a larger dataset is necessary in order to validate these findings and uncover the presence of genetic variants that affect the rate of decline in AD.},
  copyright = {{\copyright} 2020 the Alzheimer's Association},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/GLJRUEDW/Katzourou et al. - 2020 - Genome-wide association study of progression in Al.pdf;/Users/xx20081/Zotero/storage/Q3I4NCIM/alz.html}
}

@article{kenchaiahBodyMassIndex2007,
  title = {Body Mass Index and Prognosis in Patients with Chronic Heart Failure: Insights from the {{Candesartan}} in {{Heart}} Failure: {{Assessment}} of {{Reduction}} in {{Mortality}} and Morbidity ({{CHARM}}) Program},
  shorttitle = {Body Mass Index and Prognosis in Patients with Chronic Heart Failure},
  author = {Kenchaiah, Satish and Pocock, Stuart J. and Wang, Duolao and Finn, Peter V. and Zornoff, Leonardo A. M. and Skali, Hicham and Pfeffer, Marc A. and Yusuf, Salim and Swedberg, Karl and Michelson, Eric L. and Granger, Christopher B. and McMurray, John J. V. and Solomon, Scott D. and {CHARM Investigators}},
  year = {2007},
  month = aug,
  journal = {Circulation},
  volume = {116},
  number = {6},
  pages = {627--636},
  issn = {1524-4539},
  doi = {10.1161/CIRCULATIONAHA.106.679779},
  abstract = {BACKGROUND: In individuals without known cardiovascular disease, elevated body mass index (BMI) (weight/height2) is associated with an increased risk of death. However, in patients with certain specific chronic diseases, including heart failure, low BMI has been associated with increased mortality. METHODS AND RESULTS: We examined the influence of BMI on prognosis using Cox proportional hazards models in 7599 patients (mean age, 65 years; 35\% women) with symptomatic heart failure (New York Heart Association class II to IV) and a broad spectrum of left ventricular ejection fractions (mean, 39\%) in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. During a median follow-up of 37.7 months, 1831 patients died. After adjustment for potential confounders, compared with patients with BMI between 30 and 34.9, patients in lower BMI categories had a graded increase in the risk of death. The hazard ratios (95\% confidence intervals) were 1.22 (1.06 to 1.41), 1.46 (1.24 to 1.71), and 1.69 (1.43 to 2.01) among those with BMI of 25 to 29.9, 22.5 to 24.9, and {$<$} 22.5, respectively. The increase in risk of death among patients with BMI {$>$} or = 35 was not statistically significant (hazard ratio, 1.17; 95\% confidence interval, 0.95 to 1.43). The association between BMI and mortality was not altered by age, smoking status, or left ventricular ejection fraction (P for interaction {$>$}0.20). However, lower BMI was associated with a greater risk of all-cause death in patients without edema but not in patients with edema (P for interaction {$<$}0.0001). Lower BMI was associated with a greater risk of cardiovascular death and noncardiovascular death. Baseline BMI did not influence the risk of hospitalization for worsening heart failure or due to all causes. CONCLUSIONS: In patients with symptomatic heart failure and either reduced or preserved left ventricular systolic function, underweight or low BMI was associated with increased mortality, primarily in patients without evidence of fluid overload (edema).},
  langid = {english},
  pmid = {17638930},
  keywords = {Aged,Aged 80 and over,Benzimidazoles,Biphenyl Compounds,Body Mass Index,Cohort Studies,Double-Blind Method,Female,Follow-Up Studies,Heart Failure,Humans,Internationality,Male,Middle Aged,Morbidity,Prognosis,Survival Rate,Tetrazoles}
}

@article{kenchaiahObesityRiskHeart2002,
  title = {Obesity and the Risk of Heart Failure},
  author = {Kenchaiah, Satish and Evans, Jane C. and Levy, Daniel and Wilson, Peter W. F. and Benjamin, Emelia J. and Larson, Martin G. and Kannel, William B. and Vasan, Ramachandran S.},
  year = {2002},
  month = aug,
  journal = {The New England Journal of Medicine},
  volume = {347},
  number = {5},
  pages = {305--313},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa020245},
  abstract = {BACKGROUND: Extreme obesity is recognized to be a risk factor for heart failure. It is unclear whether overweight and lesser degrees of obesity also pose a risk. METHODS: We investigated the relation between the body-mass index (the weight in kilograms divided by the square of the height in meters) and the incidence of heart failure among 5881 participants in the Framingham Heart Study (mean age, 55 years; 54 percent women). With the use of Cox proportional-hazards models, the body-mass index was evaluated both as a continuous variable and as a categorical variable (normal, 18.5 to 24.9; overweight, 25.0 to 29.9; and obese, 30.0 or more). RESULTS: During follow-up (mean, 14 years), heart failure developed in 496 subjects (258 women and 238 men). After adjustment for established risk factors, there was an increase in the risk of heart failure of 5 percent for men and 7 percent for women for each increment of 1 in body-mass index. As compared with subjects with a normal body-mass index, obese subjects had a doubling of the risk of heart failure. For women, the hazard ratio was 2.12 (95 percent confidence interval, 1.51 to 2.97); for men, the hazard ratio was 1.90 (95 percent confidence interval, 1.30 to 2.79). A graded increase in the risk of heart failure was observed across categories of body-mass index. The hazard ratios per increase in category were 1.46 in women (95 percent confidence interval, 1.23 to 1.72) and 1.37 in men (95 percent confidence interval, 1.13 to 1.67). CONCLUSIONS: In our large, community-based sample, increased body-mass index was associated with an increased risk of heart failure. Given the high prevalence of obesity in the United States, strategies to promote optimal body weight may reduce the population burden of heart failure.},
  langid = {english},
  pmid = {12151467},
  keywords = {Body Mass Index,Echocardiography,Female,Heart Failure,Humans,Incidence,Longitudinal Studies,Male,Middle Aged,Obesity,Proportional Hazards Models,Risk Factors,Thinness}
}

@article{khChallengesUndertakingNonlinear2023,
  title = {Challenges in Undertaking Nonlinear {{Mendelian}} Randomization},
  author = {Kh, Wade and Fw, Hamilton and D, Carslake and N, Sattar and G, Davey Smith and Nj, Timpson},
  year = {2023},
  month = dec,
  journal = {Obesity (Silver Spring, Md.)},
  volume = {31},
  number = {12},
  publisher = {Obesity (Silver Spring)},
  issn = {1930-739X},
  doi = {10.1002/oby.23927},
  urldate = {2025-01-22},
  abstract = {Mendelian randomization (MR) is a widely used method that exploits the unique properties of germline genetic variation to strengthen causal inference in relationships between exposures and outcomes. Nonlinear MR allows estimation of the shape of these relationships. In a previous paper, the authors {\dots}},
  langid = {english},
  pmid = {37845826},
  file = {/Users/xx20081/Zotero/storage/RZH8R4EJ/Kh et al. - 2023 - Challenges in undertaking nonlinear Mendelian randomization.pdf;/Users/xx20081/Zotero/storage/UU9ZZSWB/37845826.html}
}

@article{komajdaIncrementalBenefitDrug2018,
  title = {Incremental Benefit of Drug Therapies for Chronic Heart Failure with Reduced Ejection Fraction: A Network Meta-Analysis},
  shorttitle = {Incremental Benefit of Drug Therapies for Chronic Heart Failure with Reduced Ejection Fraction},
  author = {Komajda, Michel and B{\"o}hm, Michael and Borer, Jeffrey S. and Ford, Ian and Tavazzi, Luigi and Pannaux, Matthieu and Swedberg, Karl},
  year = {2018},
  month = sep,
  journal = {European Journal of Heart Failure},
  volume = {20},
  number = {9},
  pages = {1315--1322},
  issn = {1879-0844},
  doi = {10.1002/ejhf.1234},
  abstract = {AIMS: A network meta-analysis (NMA) of all recommended drug groups for the treatment of heart failure with reduced ejection fraction (HFrEF), including their combinations, was performed to assess the relative efficacy and incremental benefit. METHODS AND RESULTS: A search was made in biomedical databases for randomized controlled trials published between 1987 and 2017 on angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers (BBs), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), ivabradine (IVA), or angiotensin receptor-neprilysin inhibitors (ARNI). A total of 58 relevant trials were identified. The relative efficacy of each treatment group (or combination) in terms of all-cause mortality, cardiovascular mortality, all-cause hospitalizations and hospitalizations for heart failure, per patient-year of follow-up, were combined in a random-effects Bayesian NMA. The pairwise comparison between each regimen and for each outcome was estimated. The NMA was dominated by 15 large-scale trials with between 1984 and 18\,898 patient-years of follow-up. Combinations of drug groups showed incremental benefits on outcomes over single groups. The most effective combinations were ARNI+BB\,+\,MRA and ACEI+BB\,+\,MRA\,+\,IVA, showing reductions in all-cause mortality (vs. placebo) of 62\% and 59\%, respectively; hazard ratios were 0.38 [credible interval (CrI) 0.20-0.65] and 0.41 (CrI 0.21-0.70); and in all-cause hospitalizations with reductions of 42\% for both. These two combinations were also the most effective for the other outcomes studied. CONCLUSION: Our analysis shows that the incremental use of combinations of disease-modifying therapies has resulted in the progressive improvement in mortality and hospitalization outcomes in HFrEF. Our findings support the current guideline recommendations.},
  langid = {english},
  pmid = {29806165},
  keywords = {Cardiovascular Agents,Drug therapy,Heart failure,Heart Failure,Humans,Network meta-analysis,Network Meta-Analysis,Practice Guidelines as Topic,Randomized controlled trials,Randomized Controlled Trials as Topic,Stroke Volume,Treatment Outcome},
  file = {/Users/xx20081/Zotero/storage/XDMGGPJ2/Komajda et al. - 2018 - Incremental benefit of drug therapies for chronic .pdf}
}

@article{kosiborodSemaglutidePatientsHeart2023,
  title = {Semaglutide in {{Patients}} with {{Heart Failure}} with {{Preserved Ejection Fraction}} and {{Obesity}}},
  author = {Kosiborod, Mikhail N. and Abildstr{\o}m, Steen Z. and Borlaug, Barry A. and Butler, Javed and Rasmussen, S{\o}ren and Davies, Melanie and Hovingh, G. Kees and Kitzman, Dalane W. and Lindegaard, Marie L. and M{\o}ller, Dani{\'e}l V. and Shah, Sanjiv J. and Treppendahl, Marianne B. and Verma, Subodh and Abhayaratna, Walter and Ahmed, Fozia Z. and Chopra, Vijay and Ezekowitz, Justin and Fu, Michael and Ito, Hiroshi and Lelonek, Ma{\l}gorzata and Melenovsky, Vojtech and Merkely, Bela and N{\'u}{\~n}ez, Julio and Perna, Eduardo and Schou, Morten and Senni, Michele and Sharma, Kavita and der Meer, Peter Van and von Lewinski, Dirk and Wolf, Dennis and Petrie, Mark C.},
  year = {2023},
  month = sep,
  journal = {New England Journal of Medicine},
  volume = {389},
  number = {12},
  pages = {1069--1084},
  publisher = {Massachusetts Medical Society},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa2306963},
  urldate = {2025-01-20},
  abstract = {In patients with heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg) led to greater reductions in symptoms and physical limitations and greater improvements in exercise function than placebo.},
  file = {/Users/xx20081/Zotero/storage/MIC5YXYG/Kosiborod et al. - 2023 - Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.pdf}
}

@article{kristensenCardiovascularMortalityKidney2019a,
  title = {Cardiovascular, Mortality, and Kidney Outcomes with {{GLP-1}} Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials},
  shorttitle = {Cardiovascular, Mortality, and Kidney Outcomes with {{GLP-1}} Receptor Agonists in Patients with Type 2 Diabetes},
  author = {Kristensen, S{\o}ren L. and R{\o}rth, Rasmus and Jhund, Pardeep S. and Docherty, Kieran F. and Sattar, Naveed and Preiss, David and K{\o}ber, Lars and Petrie, Mark C. and McMurray, John J. V.},
  year = {2019},
  month = oct,
  journal = {The Lancet. Diabetes \& Endocrinology},
  volume = {7},
  number = {10},
  pages = {776--785},
  issn = {2213-8595},
  doi = {10.1016/S2213-8587(19)30249-9},
  abstract = {BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes reported. We aimed to synthesise the available evidence by doing a systematic review and meta-analysis of cardiovascular outcome trials of these drugs. METHODS: We searched MEDLINE (via PubMed) and the Cochrane Central Register of Controlled Trials for eligible placebo-controlled trials reporting major adverse cardiovascular events (MACE; ie, cardiovascular death, stroke, or myocardial infarction) up to June 15, 2019. We did a meta-analysis using a random-effects model to estimate overall hazard ratios (HRs) for MACE, its components, death from any cause, hospital admission for heart failure, kidney outcomes, and key safety outcomes (severe hypoglycaemia, pancreatitis, and pancreatic cancer). We also examined MACE in several subgroups based on patient characteristics (history of cardiovascular disease, BMI, age, baseline HbA1c, and baseline estimated glomerular filtration rate), trial duration, treatment dosing interval, and structural homology. FINDINGS: Of 27 publications screened, seven trials, with a combined total of 56\hphantom{,}004 participants, were included: ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (semaglutide), EXSCEL (exenatide), Harmony Outcomes (albiglutide), REWIND (dulaglutide), and PIONEER 6 (oral semaglutide). Overall, GLP-1 receptor agonist treatment reduced MACE by 12\% (HR 0{$\cdot$}88, 95\% CI 0{$\cdot$}82-0{$\cdot$}94; p{$<$}0{$\cdot$}0001). There was no statistically significant heterogeneity across the subgroups examined. HRs were 0{$\cdot$}88 (95\% CI 0{$\cdot$}81-0{$\cdot$}96; p=0{$\cdot$}003) for death from cardiovascular causes, 0{$\cdot$}84 (0{$\cdot$}76-0{$\cdot$}93; p{$<$}0{$\cdot$}0001) for fatal or non-fatal stroke, and 0{$\cdot$}91 (0{$\cdot$}84-1{$\cdot$}00; p=0{$\cdot$}043) for fatal or non-fatal myocardial infarction. GLP-1 receptor agonist treatment reduced all-cause mortality by 12\% (0{$\cdot$}88, 0{$\cdot$}83-0{$\cdot$}95; p=0{$\cdot$}001), hospital admission for heart failure by 9\% (0{$\cdot$}91, 0{$\cdot$}83-0{$\cdot$}99; p=0{$\cdot$}028), and a broad composite kidney outcome (development of new-onset macroalbuminuria, decline in estimated glomerular filtration rate [or increase in creatinine], progression to end-stage kidney disease, or death attributable to kidney causes) by 17\% (0{$\cdot$}83, 0{$\cdot$}78-0{$\cdot$}89; p{$<$}0{$\cdot$}0001), mainly due to a reduction in urinary albumin excretion. There was no increase in risk of severe hypoglycaemia, pancreatitis, or pancreatic cancer. INTERPRETATION: Treatment with GLP-1 receptor agonists has beneficial effects on cardiovascular, mortality, and kidney outcomes in patients with type 2 diabetes. FUNDING: None.},
  langid = {english},
  pmid = {31422062},
  keywords = {Diabetes Mellitus Type 2,Diabetic Angiopathies,Diabetic Nephropathies,Glucagon-Like Peptide-1 Receptor Agonists,Humans,Hypoglycemic Agents,Randomized Controlled Trials as Topic,Treatment Outcome},
  file = {/Users/xx20081/Zotero/storage/7KT6XUFZ/Kristensen et al. - 2019 - Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2.pdf}
}

@article{leeAssociationParentalHeart2006,
  title = {Association of Parental Heart Failure with Risk of Heart Failure in Offspring},
  author = {Lee, Douglas S. and Pencina, Michael J. and Benjamin, Emelia J. and Wang, Thomas J. and Levy, Daniel and O'Donnell, Christopher J. and Nam, Byung-Ho and Larson, Martin G. and D'Agostino, Ralph B. and Vasan, Ramachandran S.},
  year = {2006},
  month = jul,
  journal = {The New England Journal of Medicine},
  volume = {355},
  number = {2},
  pages = {138--147},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa052948},
  abstract = {BACKGROUND: The association between heart failure in parents and the prevalence of left ventricular systolic dysfunction and the risk of heart failure in their offspring has not been investigated in a community-based setting. METHODS: We examined the cross-sectional association of heart failure in parents with the prevalence of left ventricular systolic dysfunction, as well as left ventricular mass, internal dimensions, and wall thickness, in 1497 participants of the Framingham Offspring Study (mean age, 57 years; 819 women) who underwent routine echocardiography. We also investigated prospectively whether heart failure in parents increased the risk of heart failure in 2214 offspring (mean age, 44 years; 1150 women). RESULTS: As compared with the 1039 participants whose parents did not have heart failure, the 458 participants in the cross-sectional cohort who had at least one parent with heart failure were more likely to have increased left ventricular mass (17.0 percent vs. 26.9 percent), left ventricular internal dimensions (18.6 percent vs. 23.4 percent), and left ventricular systolic dysfunction (3.1 percent vs. 5.7 percent); the multivariable-adjusted odds ratios were 1.35 (95 percent confidence interval, 0.99 to 1.84), 1.29 (95 percent confidence interval, 0.96 to 1.72), and 2.37 (95 percent confidence interval, 1.22 to 4.61), respectively. In the longitudinal cohort, heart failure developed in 90 offspring during follow-up (mean length of follow-up, 20 years). The age- and sex-adjusted 10-year incidence rates of heart failure were 2.72 percent among offspring with a parent with heart failure, as compared with 1.62 percent among those without a parent with heart failure. This increase in risk persisted after multivariable adjustment (hazard ratio, 1.70; 95 percent confidence interval, 1.11 to 2.60). CONCLUSIONS: Heart failure in parents is associated with an increased prevalence of left ventricular systolic dysfunction cross-sectionally and an elevated risk of heart failure longitudinally. Our data emphasize the contribution of familial factors to the heart-failure burden in the community.},
  langid = {english},
  pmid = {16837677},
  keywords = {Adult Children,Aged,Cohort Studies,Cross-Sectional Studies,Echocardiography Doppler Color,Female,Heart Failure,Humans,Hypertrophy Left Ventricular,Incidence,Longitudinal Studies,Male,Middle Aged,Parents,Prevalence,Proportional Hazards Models,Risk,Ventricular Dysfunction Left},
  file = {/Users/xx20081/Zotero/storage/ZVUQ5HNB/Lee et al. - 2006 - Association of parental heart failure with risk of.pdf}
}

@article{levinGenomewideAssociationMultitrait2022,
  title = {Genome-Wide Association and Multi-Trait Analyses Characterize the Common Genetic Architecture of Heart Failure},
  author = {Levin, Michael G. and Tsao, Noah L. and Singhal, Pankhuri and Liu, Chang and Vy, Ha My T. and Paranjpe, Ishan and Backman, Joshua D. and Bellomo, Tiffany R. and Bone, William P. and Biddinger, Kiran J. and Hui, Qin and Dikilitas, Ozan and Satterfield, Benjamin A. and Yang, Yifan and Morley, Michael P. and Bradford, Yuki and Burke, Megan and Reza, Nosheen and Charest, Brian and Judy, Renae L. and Puckelwartz, Megan J. and Hakonarson, Hakon and Khan, Atlas and Kottyan, Leah C. and Kullo, Iftikhar and Luo, Yuan and McNally, Elizabeth M. and {Rasmussen-Torvik}, Laura J. and Day, Sharlene M. and Do, Ron and Phillips, Lawrence S. and Ellinor, Patrick T. and Nadkarni, Girish N. and Ritchie, Marylyn D. and Arany, Zoltan and Cappola, Thomas P. and Margulies, Kenneth B. and Aragam, Krishna G. and Haggerty, Christopher M. and Joseph, Jacob and Sun, Yan V. and Voight, Benjamin F. and Damrauer, Scott M.},
  year = {2022},
  month = nov,
  journal = {Nature Communications},
  volume = {13},
  number = {1},
  pages = {6914},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-022-34216-6},
  urldate = {2024-08-15},
  abstract = {Heart failure is a leading cause of cardiovascular morbidity and mortality. However, the contribution of common genetic variation to heart failure risk has not been fully elucidated, particularly in comparison to other common cardiometabolic traits. We report a multi-ancestry genome-wide association study meta-analysis of all-cause heart failure including up to 115,150 cases and 1,550,331 controls of diverse genetic ancestry, identifying 47 risk loci. We also perform multivariate genome-wide association studies that integrate heart failure with related cardiac magnetic resonance imaging endophenotypes, identifying 61 risk loci. Gene-prioritization analyses including colocalization and transcriptome-wide association studies identify known and previously unreported candidate cardiomyopathy genes and cellular processes, which we validate in gene-expression profiling of failing and healthy human hearts. Colocalization, gene expression profiling, and Mendelian randomization provide convergent evidence for the roles of BCKDHA and circulating branch-chain amino acids in heart failure and cardiac structure. Finally, proteome-wide Mendelian randomization identifies 9 circulating proteins associated with heart failure or quantitative imaging traits. These analyses highlight similarities and differences among heart failure and associated cardiovascular imaging endophenotypes, implicate common genetic variation in the pathogenesis of heart failure, and identify circulating proteins that may represent cardiomyopathy treatment targets.},
  copyright = {2022 This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply},
  langid = {english},
  keywords = {Cardiology,Cardiomyopathies,Genetic association study,Genomics,Heart failure},
  file = {/Users/xx20081/Zotero/storage/MCEKZDW5/Levin et al. - 2022 - Genome-wide association and multi-trait analyses c.pdf}
}

@article{lewisBiologicalPhenotypesHeart2017,
  title = {Biological {{Phenotypes}} of {{Heart Failure With Preserved Ejection Fraction}}},
  author = {Lewis, Gavin A. and Schelbert, Erik B. and Williams, Simon G. and Cunnington, Colin and Ahmed, Fozia and McDonagh, Theresa A. and Miller, Christopher A.},
  year = {2017},
  month = oct,
  journal = {Journal of the American College of Cardiology},
  volume = {70},
  number = {17},
  pages = {2186--2200},
  issn = {1558-3597},
  doi = {10.1016/j.jacc.2017.09.006},
  abstract = {Heart failure with preserved ejection fraction (HFpEF) involves multiple pathophysiological mechanisms, which result in the heterogeneous phenotypes that are evident clinically, and which have potentially confounded previous HFpEF trials. A greater understanding of the in~vivo human processes involved, and in particular, which are the causes and which are the downstream effects, may allow the syndrome of HFpEF to be distilled into distinct diagnoses based on the underlying biology. From this, specific interventions can follow, targeting individuals identified on the basis of their biological phenotype. This review describes the biological phenotypes of HFpEF and therapeutic interventions aimed at targeting these phenotypes.},
  langid = {english},
  pmid = {29050567},
  keywords = {Blood Vessels,diastolic dysfunction,ejection fraction,Extracellular Matrix,heart failure,Heart Failure,heart failure with preserved ejection fraction,Humans,Kidney Diseases,Lung Diseases,myocardial fibrosis,Obesity,Phenotype,Pulmonary Artery,Stroke Volume,titin}
}

@article{lewisEffectOralIron2017,
  title = {Effect of {{Oral Iron Repletion}} on {{Exercise Capacity}} in {{Patients With Heart Failure With Reduced Ejection Fraction}} and {{Iron Deficiency}}: {{The IRONOUT HF Randomized Clinical Trial}}},
  shorttitle = {Effect of {{Oral Iron Repletion}} on {{Exercise Capacity}} in {{Patients With Heart Failure With Reduced Ejection Fraction}} and {{Iron Deficiency}}},
  author = {Lewis, Gregory D. and Malhotra, Rajeev and Hernandez, Adrian F. and McNulty, Steven E. and Smith, Andrew and Felker, G. Michael and Tang, W. H. Wilson and LaRue, Shane J. and Redfield, Margaret M. and Semigran, Marc J. and Givertz, Michael M. and Van Buren, Peter and Whellan, David and Anstrom, Kevin J. and Shah, Monica R. and {Desvigne-Nickens}, Patrice and Butler, Javed and Braunwald, Eugene and {NHLBI Heart Failure Clinical Research Network}},
  year = {2017},
  month = may,
  journal = {JAMA},
  volume = {317},
  number = {19},
  pages = {1958--1966},
  issn = {1538-3598},
  doi = {10.1001/jama.2017.5427},
  abstract = {IMPORTANCE: Iron deficiency is present in approximately 50\% of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) and is an independent predictor of reduced functional capacity and mortality. However, the efficacy of inexpensive readily available oral iron supplementation in heart failure is unknown. OBJECTIVE: To test whether therapy with oral iron improves peak exercise capacity in patients with HFrEF and iron deficiency. DESIGN, SETTING, AND PARTICIPANTS: Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with HFrEF ({$<$}40\%) and iron deficiency, defined as a serum ferritin level of 15 to 100 ng/mL or a serum ferritin level of 101 to 299 ng/mL with transferrin saturation of less than 20\%. Participants were enrolled between September 2014 and November 2015 at 23 US sites. INTERVENTIONS: Oral iron polysaccharide (n\,=\,111) or placebo (n\,=\,114), 150 mg twice daily for 16 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was a change in peak oxygen uptake ({\.V}o2) from baseline to 16 weeks. Secondary end points were change in 6-minute walk distance, plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and health status as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ, range 0-100, higher scores reflect better quality of life). RESULTS: Among 225 randomized participants (median age, 63 years; 36\% women) 203 completed the study. The median baseline peak {\.V}o2 was 1196 mL/min (interquartile range [IQR], 887-1448 mL/min) in the oral iron group and 1167 mL/min (IQR, 887-1449 mL/min) in the placebo group. The primary end point, change in peak {\.V}o2 at 16 weeks, did not significantly differ between the oral iron and placebo groups (+23 mL/min vs -2 mL/min; difference, 21 mL/min [95\% CI, -34 to +76 mL/min]; P\,=\,.46). Similarly, at 16 weeks, there were no significant differences between treatment groups in changes in 6-minute walk distance (-13 m; 95\% CI, -32 to 6 m), NT-proBNP levels (159; 95\% CI, -280 to 599 pg/mL), or KCCQ score (1; 95\% CI, -2.4 to 4.4), all P\,{$>$}\,.05. CONCLUSIONS AND RELEVANCE: Among participants with HFrEF with iron deficiency, high-dose oral iron did not improve exercise capacity over 16 weeks. These results do not support use of oral iron supplementation in patients with HFrEF. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02188784.},
  langid = {english},
  pmcid = {PMC5703044},
  pmid = {28510680},
  keywords = {Administration Oral,Aged,Double-Blind Method,Exercise Tolerance,Female,Ferritins,Health Status,Heart Failure,Humans,Iron Compounds,Iron Deficiencies,Male,Middle Aged,Natriuretic Peptide Brain,Oxygen Consumption,Peptide Fragments,Quality of Life,Stroke Volume,Time Factors,Transferrin,Treatment Outcome,Walk Test},
  file = {/Users/xx20081/Zotero/storage/UPD8UTVF/Lewis et al. - 2017 - Effect of Oral Iron Repletion on Exercise Capacity.pdf}
}

@article{lincoffSemaglutideCardiovascularOutcomes2023,
  title = {Semaglutide and {{Cardiovascular Outcomes}} in {{Obesity}} without {{Diabetes}}},
  author = {Lincoff, A. Michael and {Brown-Frandsen}, Kirstine and Colhoun, Helen M. and Deanfield, John and Emerson, Scott S. and Esbjerg, Sille and {Hardt-Lindberg}, S{\o}ren and Hovingh, G. Kees and Kahn, Steven E. and Kushner, Robert F. and Lingvay, Ildiko and Oral, Tugce K. and Michelsen, Marie M. and Plutzky, Jorge and Torn{\o}e, Christoffer W. and Ryan, Donna H.},
  year = {2023},
  month = dec,
  journal = {New England Journal of Medicine},
  volume = {389},
  number = {24},
  pages = {2221--2232},
  publisher = {Massachusetts Medical Society},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa2307563},
  urldate = {2024-08-15},
  abstract = {In a trial in patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8 months.},
  file = {/Users/xx20081/Zotero/storage/ZTRC5SVJ/Lincoff et al. - 2023 - Semaglutide and Cardiovascular Outcomes in Obesity.pdf}
}

@article{liuGenomewideSurvivalStudy2021a,
  title = {Genome-Wide Survival Study Identifies a Novel Synaptic Locus and Polygenic Score for Cognitive Progression in {{Parkinson}}'s Disease},
  author = {Liu, Ganqiang and Peng, Jiajie and Liao, Zhixiang and Locascio, Joseph J. and Corvol, Jean-Christophe and Zhu, Frank and Dong, Xianjun and {Maple-Gr{\o}dem}, Jodi and Campbell, Meghan C. and Elbaz, Alexis and Lesage, Suzanne and Brice, Alexis and Mangone, Graziella and Growdon, John H. and Hung, Albert Y. and Schwarzschild, Michael A. and Hayes, Michael T. and Wills, Anne-Marie and Herrington, Todd M. and Ravina, Bernard and Shoulson, Ira and Taba, Pille and K{\~o}ks, Sulev and Beach, Thomas G. and {Cormier-Dequaire}, Florence and Alves, Guido and Tysnes, Ole-Bj{\o}rn and Perlmutter, Joel S. and Heutink, Peter and Amr, Sami S. and {van Hilten}, Jacobus J. and Kasten, Meike and Mollenhauer, Brit and Trenkwalder, Claudia and Klein, Christine and Barker, Roger A. and {Williams-Gray}, Caroline H. and Marinus, Johan and {van Hilten}, Jacobus J. and Scherzer, Clemens R.},
  year = {2021},
  month = jun,
  journal = {Nature Genetics},
  volume = {53},
  number = {6},
  pages = {787--793},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-021-00847-6},
  urldate = {2024-08-14},
  abstract = {A key driver of patients' well-being and clinical trials for Parkinson's disease (PD) is the course that the disease takes over time (progression and prognosis). To assess how genetic variation influences the progression of PD over time to dementia, a major determinant for quality of life, we performed a longitudinal genome-wide survival study of 11.2 million variants in 3,821 patients with PD over 31,053 visits. We discover RIMS2 as a progression locus and confirm this in a replicate population (hazard ratio (HR)\,=\,4.77, P\,=\,2.78\,{\texttimes}\,10-11), identify suggestive evidence for TMEM108 (HR\,=\,2.86, P\,=\,2.09\,{\texttimes}\,10-8) and WWOX (HR\,=\,2.12, P\,=\,2.37\,{\texttimes}\,10-8) as progression loci, and confirm associations for GBA (HR\,=\,1.93, P\,=\,0.0002) and APOE (HR\,=\,1.48, P\,=\,0.001). Polygenic progression scores exhibit a substantial aggregate association with dementia risk, while polygenic susceptibility scores are not predictive. This study identifies a novel synaptic locus and polygenic score for cognitive disease progression in PD and proposes diverging genetic architectures of progression and susceptibility.},
  copyright = {2021 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  keywords = {Genome-wide association studies,Parkinson's disease},
  file = {/Users/xx20081/Zotero/storage/LVW9RZAX/Liu et al. - 2021 - Genome-wide survival study identifies a novel syna.pdf}
}

@article{ljContinuedTreatmentTirzepatide2024,
  title = {Continued {{Treatment With Tirzepatide}} for {{Maintenance}} of {{Weight Reduction}} in {{Adults With Obesity}}: {{The SURMOUNT-4 Randomized Clinical Trial}}},
  shorttitle = {Continued {{Treatment With Tirzepatide}} for {{Maintenance}} of {{Weight Reduction}} in {{Adults With Obesity}}},
  author = {Lj, Aronne and N, Sattar and Db, Horn and He, Bays and S, Wharton and Wy, Lin and Nn, Ahmad and S, Zhang and R, Liao and Mc, Bunck and I, Jouravskaya and Ma, Murphy},
  year = {2024},
  month = feb,
  journal = {JAMA},
  volume = {331},
  number = {1},
  publisher = {JAMA},
  issn = {1538-3598},
  doi = {10.1001/jama.2023.24945},
  urldate = {2025-03-17},
  abstract = {ClinicalTrials.gov Identifier: NCT04660643.},
  langid = {english},
  pmid = {38078870},
  file = {/Users/xx20081/Zotero/storage/8UH549HY/38078870.html}
}

@article{lockeGeneticStudiesBody2015,
  title = {Genetic Studies of Body Mass Index Yield New Insights for Obesity Biology},
  author = {Locke, Adam E. and Kahali, Bratati and Berndt, Sonja I. and Justice, Anne E. and Pers, Tune H. and Day, Felix R. and Powell, Corey and Vedantam, Sailaja and Buchkovich, Martin L. and Yang, Jian and {Croteau-Chonka}, Damien C. and Esko, Tonu and Fall, Tove and Ferreira, Teresa and Gustafsson, Stefan and Kutalik, Zolt{\'a}n and Luan, Jian'an and M{\"a}gi, Reedik and Randall, Joshua C. and Winkler, Thomas W. and Wood, Andrew R. and Workalemahu, Tsegaselassie and Faul, Jessica D. and Smith, Jennifer A. and Zhao, Jing Hua and Zhao, Wei and Chen, Jin and Fehrmann, Rudolf and Hedman, {\AA}sa K. and Karjalainen, Juha and Schmidt, Ellen M. and Absher, Devin and Amin, Najaf and Anderson, Denise and Beekman, Marian and Bolton, Jennifer L. and {Bragg-Gresham}, Jennifer L. and Buyske, Steven and Demirkan, Ayse and Deng, Guohong and Ehret, Georg B. and Feenstra, Bjarke and Feitosa, Mary F. and Fischer, Krista and Goel, Anuj and Gong, Jian and Jackson, Anne U. and Kanoni, Stavroula and Kleber, Marcus E. and Kristiansson, Kati and Lim, Unhee and Lotay, Vaneet and Mangino, Massimo and Leach, Irene Mateo and {Medina-Gomez}, Carolina and Medland, Sarah E. and Nalls, Michael A. and Palmer, Cameron D. and Pasko, Dorota and Pechlivanis, Sonali and Peters, Marjolein J. and Prokopenko, Inga and Shungin, Dmitry and Stan{\v c}{\'a}kov{\'a}, Alena and Strawbridge, Rona J. and Sung, Yun Ju and Tanaka, Toshiko and Teumer, Alexander and Trompet, Stella and {van der Laan}, Sander W. and {van Setten}, Jessica and {Van Vliet-Ostaptchouk}, Jana V. and Wang, Zhaoming and Yengo, Lo{\"i}c and Zhang, Weihua and Isaacs, Aaron and Albrecht, Eva and {\"A}rnl{\"o}v, Johan and Arscott, Gillian M. and Attwood, Antony P. and Bandinelli, Stefania and Barrett, Amy and Bas, Isabelita N. and Bellis, Claire and Bennett, Amanda J. and Berne, Christian and Blagieva, Roza and Bl{\"u}her, Matthias and B{\"o}hringer, Stefan and Bonnycastle, Lori L. and B{\"o}ttcher, Yvonne and Boyd, Heather A. and Bruinenberg, Marcel and Caspersen, Ida H. and Chen, Yii-Der Ida and Clarke, Robert and Daw, E. Warwick and {de Craen}, Anton J. M. and Delgado, Graciela and Dimitriou, Maria and Doney, Alex S. F. and Eklund, Niina and Estrada, Karol and Eury, Elodie and Folkersen, Lasse and Fraser, Ross M. and Garcia, Melissa E. and Geller, Frank and Giedraitis, Vilmantas and Gigante, Bruna and Go, Alan S. and Golay, Alain and Goodall, Alison H. and Gordon, Scott D. and Gorski, Mathias and Grabe, Hans-J{\"o}rgen and Grallert, Harald and Grammer, Tanja B. and Gr{\"a}{\ss}ler, J{\"u}rgen and Gr{\"o}nberg, Henrik and Groves, Christopher J. and Gusto, Ga{\"e}lle and Haessler, Jeffrey and Hall, Per and Haller, Toomas and Hallmans, Goran and Hartman, Catharina A. and Hassinen, Maija and Hayward, Caroline and {Heard-Costa}, Nancy L. and Helmer, Quinta and Hengstenberg, Christian and Holmen, Oddgeir and Hottenga, Jouke-Jan and James, Alan L. and Jeff, Janina M. and Johansson, {\AA}sa and Jolley, Jennifer and Juliusdottir, Thorhildur and Kinnunen, Leena and Koenig, Wolfgang and Koskenvuo, Markku and Kratzer, Wolfgang and Laitinen, Jaana and Lamina, Claudia and Leander, Karin and Lee, Nanette R. and Lichtner, Peter and Lind, Lars and Lindstr{\"o}m, Jaana and Lo, Ken Sin and Lobbens, St{\'e}phane and Lorbeer, Roberto and Lu, Yingchang and Mach, Fran{\c c}ois and Magnusson, Patrik K. E. and Mahajan, Anubha and McArdle, Wendy L. and McLachlan, Stela and Menni, Cristina and Merger, Sigrun and Mihailov, Evelin and Milani, Lili and Moayyeri, Alireza and Monda, Keri L. and Morken, Mario A. and Mulas, Antonella and M{\"u}ller, Gabriele and {M{\"u}ller-Nurasyid}, Martina and Musk, Arthur W. and Nagaraja, Ramaiah and N{\"o}then, Markus M. and Nolte, Ilja M. and Pilz, Stefan and Rayner, Nigel W. and Renstrom, Frida and Rettig, Rainer and Ried, Janina S. and Ripke, Stephan and Robertson, Neil R. and Rose, Lynda M. and Sanna, Serena and Scharnagl, Hubert and Scholtens, Salome and Schumacher, Fredrick R. and Scott, William R. and Seufferlein, Thomas and Shi, Jianxin and Smith, Albert Vernon and Smolonska, Joanna and Stanton, Alice V. and Steinthorsdottir, Valgerdur and Stirrups, Kathleen and Stringham, Heather M. and Sundstr{\"o}m, Johan and Swertz, Morris A. and Swift, Amy J. and Syv{\"a}nen, Ann-Christine and Tan, Sian-Tsung and Tayo, Bamidele O. and Thorand, Barbara and Thorleifsson, Gudmar and Tyrer, Jonathan P. and Uh, Hae-Won and Vandenput, Liesbeth and Verhulst, Frank C. and Vermeulen, Sita H. and Verweij, Niek and Vonk, Judith M. and Waite, Lindsay L. and Warren, Helen R. and Waterworth, Dawn and Weedon, Michael N. and Wilkens, Lynne R. and Willenborg, Christina and Wilsgaard, Tom and Wojczynski, Mary K. and Wong, Andrew and Wright, Alan F. and Zhang, Qunyuan and Brennan, Eoin P. and Choi, Murim and Dastani, Zari and Drong, Alexander W. and Eriksson, Per and {Franco-Cereceda}, Anders and G{\aa}din, Jesper R. and Gharavi, Ali G. and Goddard, Michael E. and Handsaker, Robert E. and Huang, Jinyan and Karpe, Fredrik and Kathiresan, Sekar and Keildson, Sarah and Kiryluk, Krzysztof and Kubo, Michiaki and Lee, Jong-Young and Liang, Liming and Lifton, Richard P. and Ma, Baoshan and McCarroll, Steven A. and McKnight, Amy J. and Min, Josine L. and Moffatt, Miriam F. and Montgomery, Grant W. and Murabito, Joanne M. and Nicholson, George and Nyholt, Dale R. and Okada, Yukinori and Perry, John R. B. and Dorajoo, Rajkumar and Reinmaa, Eva and Salem, Rany M. and Sandholm, Niina and Scott, Robert A. and Stolk, Lisette and Takahashi, Atsushi and Tanaka, Toshihiro and {van 't Hooft}, Ferdinand M. and Vinkhuyzen, Anna A. E. and Westra, Harm-Jan and Zheng, Wei and Zondervan, Krina T. and Heath, Andrew C. and Arveiler, Dominique and Bakker, Stephan J. L. and Beilby, John and Bergman, Richard N. and Blangero, John and Bovet, Pascal and Campbell, Harry and Caulfield, Mark J. and Cesana, Giancarlo and Chakravarti, Aravinda and Chasman, Daniel I. and Chines, Peter S. and Collins, Francis S. and Crawford, Dana C. and Cupples, L. Adrienne and Cusi, Daniele and Danesh, John and {de Faire}, Ulf and {den Ruijter}, Hester M. and Dominiczak, Anna F. and Erbel, Raimund and Erdmann, Jeanette and Eriksson, Johan G. and Farrall, Martin and Felix, Stephan B. and Ferrannini, Ele and Ferri{\`e}res, Jean and Ford, Ian and Forouhi, Nita G. and Forrester, Terrence and Franco, Oscar H. and Gansevoort, Ron T. and Gejman, Pablo V. and Gieger, Christian and Gottesman, Omri and Gudnason, Vilmundur and Gyllensten, Ulf and Hall, Alistair S. and Harris, Tamara B. and Hattersley, Andrew T. and Hicks, Andrew A. and Hindorff, Lucia A. and Hingorani, Aroon D. and Hofman, Albert and Homuth, Georg and Hovingh, G. Kees and Humphries, Steve E. and Hunt, Steven C. and Hypp{\"o}nen, Elina and Illig, Thomas and Jacobs, Kevin B. and Jarvelin, Marjo-Riitta and J{\"o}ckel, Karl-Heinz and Johansen, Berit and Jousilahti, Pekka and Jukema, J. Wouter and Jula, Antti M. and Kaprio, Jaakko and Kastelein, John J. P. and {Keinanen-Kiukaanniemi}, Sirkka M. and Kiemeney, Lambertus A. and Knekt, Paul and Kooner, Jaspal S. and Kooperberg, Charles and Kovacs, Peter and Kraja, Aldi T. and Kumari, Meena and Kuusisto, Johanna and Lakka, Timo A. and Langenberg, Claudia and Marchand, Loic Le and Lehtim{\"a}ki, Terho and Lyssenko, Valeriya and M{\"a}nnist{\"o}, Satu and Marette, Andr{\'e} and Matise, Tara C. and McKenzie, Colin A. and McKnight, Barbara and Moll, Frans L. and Morris, Andrew D. and Morris, Andrew P. and Murray, Jeffrey C. and Nelis, Mari and Ohlsson, Claes and Oldehinkel, Albertine J. and Ong, Ken K. and Madden, Pamela A. F. and Pasterkamp, Gerard and Peden, John F. and Peters, Annette and Postma, Dirkje S. and Pramstaller, Peter P. and Price, Jackie F. and Qi, Lu and Raitakari, Olli T. and Rankinen, Tuomo and Rao, D. C. and Rice, Treva K. and Ridker, Paul M. and Rioux, John D. and Ritchie, Marylyn D. and Rudan, Igor and Salomaa, Veikko and Samani, Nilesh J. and Saramies, Jouko and Sarzynski, Mark A. and Schunkert, Heribert and Schwarz, Peter E. H. and Sever, Peter and Shuldiner, Alan R. and Sinisalo, Juha and Stolk, Ronald P. and Strauch, Konstantin and T{\"o}njes, Anke and Tr{\'e}gou{\"e}t, David-Alexandre and Tremblay, Angelo and Tremoli, Elena and Virtamo, Jarmo and Vohl, Marie-Claude and V{\"o}lker, Uwe and Waeber, G{\'e}rard and Willemsen, Gonneke and Witteman, Jacqueline C. and Zillikens, M. Carola and Adair, Linda S. and Amouyel, Philippe and Asselbergs, Folkert W. and Assimes, Themistocles L. and Bochud, Murielle and Boehm, Bernhard O. and Boerwinkle, Eric and Bornstein, Stefan R. and Bottinger, Erwin P. and Bouchard, Claude and Cauchi, St{\'e}phane and Chambers, John C. and Chanock, Stephen J. and Cooper, Richard S. and {de Bakker}, Paul I. W. and Dedoussis, George and Ferrucci, Luigi and Franks, Paul W. and Froguel, Philippe and Groop, Leif C. and Haiman, Christopher A. and Hamsten, Anders and Hui, Jennie and Hunter, David J. and Hveem, Kristian and Kaplan, Robert C. and Kivimaki, Mika and Kuh, Diana and Laakso, Markku and Liu, Yongmei and Martin, Nicholas G. and M{\"a}rz, Winfried and Melbye, Mads and Metspalu, Andres and Moebus, Susanne and Munroe, Patricia B. and Nj{\o}lstad, Inger and Oostra, Ben A. and Palmer, Colin N. A. and Pedersen, Nancy L. and Perola, Markus and P{\'e}russe, Louis and Peters, Ulrike and Power, Chris and Quertermous, Thomas and Rauramaa, Rainer and Rivadeneira, Fernando and Saaristo, Timo E. and Saleheen, Danish and Sattar, Naveed and Schadt, Eric E. and Schlessinger, David and Slagboom, P. Eline and Snieder, Harold and Spector, Tim D. and Thorsteinsdottir, Unnur and Stumvoll, Michael and Tuomilehto, Jaakko and Uitterlinden, Andr{\'e} G. and Uusitupa, Matti and {van der Harst}, Pim and Walker, Mark and Wallaschofski, Henri and Wareham, Nicholas J. and Watkins, Hugh and Weir, David R. and Wichmann, H-Erich and Wilson, James F. and Zanen, Pieter and Borecki, Ingrid B. and Deloukas, Panos and Fox, Caroline S. and Heid, Iris M. and O'Connell, Jeffrey R. and Strachan, David P. and Stefansson, Kari and {van Duijn}, Cornelia M. and Abecasis, Gon{\c c}alo R. and Franke, Lude and Frayling, Timothy M. and McCarthy, Mark I. and Visscher, Peter M. and Scherag, Andr{\'e} and Willer, Cristen J. and Boehnke, Michael and Mohlke, Karen L. and Lindgren, Cecilia M. and Beckmann, Jacques S. and Barroso, In{\^e}s and North, Kari E. and Ingelsson, Erik and Hirschhorn, Joel N. and Loos, Ruth J. F. and Speliotes, Elizabeth K.},
  year = {2015},
  month = feb,
  journal = {Nature},
  volume = {518},
  number = {7538},
  pages = {197--206},
  issn = {0028-0836},
  doi = {10.1038/nature14177},
  urldate = {2024-09-24},
  abstract = {Obesity is heritable and predisposes to many diseases. To understand the genetic basis of obesity better, here we conduct a genome-wide association study and Metabochip meta-analysis of body mass index (BMI), a measure commonly used to define obesity and assess adiposity, in up to 339,224 individuals. This analysis identifies 97 BMI-associated loci (P {$<$} 5 {\texttimes} 10-8), 56 of which are novel. Five loci demonstrate clear evidence of several independent association signals, and many loci have significant effects on other metabolic phenotypes. The 97 loci account for {\textasciitilde}2.7\% of BMI variation, and genome-wide estimates suggest that common variation accounts for {$>$}20\% of BMI variation. Pathway analyses provide strong support for a role of the central nervous system in obesity susceptibility and implicate new genes and pathways, including those related to synaptic function, glutamate signalling, insulin secretion/action, energy metabolism, lipid biology and adipogenesis.},
  pmcid = {PMC4382211},
  pmid = {25673413},
  file = {/Users/xx20081/Zotero/storage/7M6K4CW4/Locke et al. - 2015 - Genetic studies of body mass index yield new insights for obesity biology.pdf}
}

@misc{lumbersBodyMassIndex2020,
  title = {Body Mass Index and Heart Failure Risk: A Cohort Study in 1.5 Million Individuals and {{Mendelian}} Randomisation Analysis},
  shorttitle = {Body Mass Index and Heart Failure Risk},
  author = {Lumbers, R. Thomas and Katsoulis, Michail and Henry, Albert and Mordi, Ify and Lang, Chim and Hemingway, Harry and Langenberg, Claudia and Holmes, Michael V. and Sattar, Naveed and Consortium, on behalf of the HERMES},
  year = {2020},
  month = sep,
  pages = {2020.09.23.20200360},
  publisher = {medRxiv},
  doi = {10.1101/2020.09.23.20200360},
  urldate = {2025-01-06},
  abstract = {{$<$}img class="highwire-fragment fragment-image" alt="Figure" src="https://www.medrxiv.org/content/medrxiv/early/2020/09/25/2020.09.23.20200360.1/F1.medium.gif" width="440" height="228"/{$>$}Download figureOpen in new tab Aims Elevated body mass index (BMI) is a known risk factor for heart failure (HF), however, the underlying mechanisms are incompletely understood. The aim of this study was to investigate the role of common HF risk factors as potential mediators. Methods and Results Electronic health record data from primary care, hospital admissions and death registrations in England were used to perform an observational analysis. Data for 1.5 million individuals aged {$\geq$}18 years, with BMI measurements and free from heart failure at baseline, were included between 1998 and 2016. Cox models were used to estimate the association between BMI and HF with and without adjustment for atrial fibrillation (AF), diabetes mellitus (DM), coronary heart disease (CHD), and hypertension (HTN). Univariable and multivariable two-sample Mendelian randomisation was performed to estimate causal effects.Among non-underweight individuals, BMI was positively associated with HF with a 1-SD ({$\sim$} 4.8kg/m2) higher BMI associated with a hazard ratio (HR) of 1.31 (1.30, 1.32). Genetically predicted BMI yielded a causal odds ratio (OR) of 1.64 per 4.8 kg/m2 BMI (1.58, 1.70) which attenuated by 41\% (to OR of 1.38 (95\% CI 1.31-1.45), when simultaneously accounting for AF, DM, CHD and SBP. Conclusion About 40\% of the excess risk of HF due to adiposity is driven by SBP, AF, DM and CHD. These findings highlight the importance of the prevention and treatment of excess adiposity and downstream HF risk factors to prevent HF, even in people in whom the above risk factors are well managed. One-sentence summary This study of the role of excess adiposity as a risk factor for HF, including an observational analysis of measured BMI 1.5 million individuals and multivariable MR analysis of genetically elevated BMI, provides evidence that adiposity is causally associated with HF, with approximately 40\% of the effect being mediated by conventional risk pathways.},
  archiveprefix = {medRxiv},
  copyright = {{\copyright} 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/CBGAXGA2/Lumbers et al. - 2020 - Body mass index and heart failure risk a cohort study in 1.5 million individuals and Mendelian rand.pdf}
}

@article{magiGWAMASoftwareGenomewide2010,
  title = {{{GWAMA}}: Software for Genome-Wide Association Meta-Analysis},
  shorttitle = {{{GWAMA}}},
  author = {M{\"a}gi, Reedik and Morris, Andrew P.},
  year = {2010},
  month = may,
  journal = {BMC Bioinformatics},
  volume = {11},
  number = {1},
  pages = {288},
  issn = {1471-2105},
  doi = {10.1186/1471-2105-11-288},
  urldate = {2024-04-08},
  abstract = {Despite the recent success of genome-wide association studies in identifying novel loci contributing effects to complex human traits, such as type 2 diabetes and obesity, much of the genetic component of variation in these phenotypes remains unexplained. One way to improving power to detect further novel loci is through meta-analysis of studies from the same population, increasing the sample size over any individual study. Although statistical software analysis packages incorporate routines for meta-analysis, they are ill equipped to meet the challenges of the scale and complexity of data generated in genome-wide association studies.},
  keywords = {Allelic Effect,Manhattan Plot,Reference Allele,Reference Panel,Wellcome Trust Case Control Consortium},
  file = {/Users/xx20081/Zotero/storage/3LHFHWHQ/Mgi and Morris - 2010 - GWAMA software for genome-wide association meta-a.pdf;/Users/xx20081/Zotero/storage/LXPM56IZ/1471-2105-11-288.html}
}

@article{mahmoudRobustMethodCollider2022,
  title = {A Robust Method for Collider Bias Correction in Conditional Genome-Wide Association Studies},
  author = {Mahmoud, Osama and Dudbridge, Frank and Davey Smith, George and Munafo, Marcus and Tilling, Kate},
  year = {2022},
  month = feb,
  journal = {Nature Communications},
  volume = {13},
  number = {1},
  pages = {619},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-022-28119-9},
  urldate = {2024-03-08},
  abstract = {Estimated genetic associations with prognosis, or conditional on a phenotype (e.g. disease incidence), may be affected by collider bias, whereby conditioning on the phenotype induces associations between causes of the phenotype and prognosis. We propose a method, `Slope-Hunter', that uses model-based clustering to identify and utilise the class of variants only affecting the phenotype to estimate the adjustment factor, assuming this class explains more variation in the phenotype than any other variant classes. Simulation studies show that our approach eliminates the bias and outperforms alternatives even in the presence of genetic correlation. In a study of fasting blood insulin levels (FI) conditional on body mass index, we eliminate paradoxical associations of the underweight loci: COBLLI; PPARG with increased FI, and reveal an association for the locus rs1421085 (FTO). In an analysis of a case-only study for breast cancer mortality, a single region remains associated with more pronounced results.},
  copyright = {2022 The Author(s)},
  langid = {english},
  keywords = {Computational models,Epidemiology,Genetics research,Machine learning,Risk factors},
  file = {/Users/xx20081/Zotero/storage/WBHRXICU/Mahmoud et al. - 2022 - A robust method for collider bias correction in co.pdf}
}

@article{marcksReappraisalObesityParadox2021,
  title = {Re-Appraisal of the Obesity Paradox in Heart Failure: A Meta-Analysis of Individual Data},
  shorttitle = {Re-Appraisal of the Obesity Paradox in Heart Failure},
  author = {Marcks, Nick and Aimo, Alberto and Januzzi, James L. and Vergaro, Giuseppe and Clerico, Aldo and Latini, Roberto and Meessen, Jennifer and Anand, Inder S. and Cohn, Jay N. and Gravning, J{\o}rgen and Ueland, Thor and {Bayes-Genis}, Antoni and Lup{\'o}n, Josep and {de Boer}, Rudolf A. and Yoshihisa, Akiomi and Takeishi, Yasuchika and Egstrup, Michael and Gustafsson, Ida and Gaggin, Hanna K. and Eggers, Kai M. and Huber, Kurt and Tentzeris, Ioannis and Ripoli, Andrea and Passino, Claudio and {Sanders-van Wijk}, Sandra and Emdin, Michele and {Brunner-La Rocca}, Hans-Peter},
  year = {2021},
  month = aug,
  journal = {Clinical Research in Cardiology},
  volume = {110},
  number = {8},
  pages = {1280--1291},
  issn = {1861-0692},
  doi = {10.1007/s00392-021-01822-1},
  urldate = {2025-01-31},
  abstract = {Higher body mass index (BMI) is associated with better outcome compared with normal weight in patients with HF and other chronic diseases. It remains uncertain whether the apparent protective role of obesity relates to the absence of comorbidities. Therefore, we investigated the effect of BMI on outcome in younger patients without co-morbidities as compared to older patients with co-morbidities in a large heart failure (HF) population.},
  langid = {english},
  keywords = {Biomarkers,Body mass index,Co-morbidities,Disease severity,Heart failure,Obesity},
  file = {/Users/xx20081/Zotero/storage/XGL7W2RM/Marcks et al. - 2021 - Re-appraisal of the obesity paradox in heart failure a meta-analysis of individual data.pdf}
}

@article{marguliesEffectsLiraglutideClinical2016a,
  title = {Effects of {{Liraglutide}} on {{Clinical Stability Among Patients With Advanced Heart Failure}} and {{Reduced Ejection Fraction}}: {{A Randomized Clinical Trial}}},
  shorttitle = {Effects of {{Liraglutide}} on {{Clinical Stability Among Patients With Advanced Heart Failure}} and {{Reduced Ejection Fraction}}},
  author = {Margulies, Kenneth B. and Hernandez, Adrian F. and Redfield, Margaret M. and Givertz, Michael M. and Oliveira, Guilherme H. and Cole, Robert and Mann, Douglas L. and Whellan, David J. and Kiernan, Michael S. and Felker, G. Michael and McNulty, Steven E. and Anstrom, Kevin J. and Shah, Monica R. and Braunwald, Eugene and Cappola, Thomas P. and {for the NHLBI Heart Failure Clinical Research Network}},
  year = {2016},
  month = aug,
  journal = {JAMA},
  volume = {316},
  number = {5},
  pages = {500--508},
  issn = {0098-7484},
  doi = {10.1001/jama.2016.10260},
  urldate = {2025-01-22},
  abstract = {Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status.To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure.Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized. Patients were enrolled between August 2013 and March 2015 at 24 US sites.The GLP-1 agonist liraglutide (n\,=\,154) or placebo (n\,=\,146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days.The primary end point was a global rank score in which all patients, regardless of treatment assignment, were ranked across 3 hierarchical tiers: time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 days. Higher values indicate better health (stability). Exploratory secondary outcomes included primary end point components, cardiac structure and function, 6-minute walk distance, quality of life, and combined events.Among the 300 patients who were randomized (median age, 61 years [interquartile range \{IQR\}, 52-68 years]; 64 [21\%] women; 178 [59\%] with type 2 diabetes; median LVEF of 25\% [IQR, 19\%-33\%]; median N-terminal pro-B-type natriuretic peptide level of 2049 pg/mL [IQR, 1054-4235 pg/mL]), 271 completed the study. Compared with placebo, liraglutide had no significant effect on the primary end point (mean rank of 146 for the liraglutide group vs 156 for the placebo group, P\,=\,.31). There were no significant between-group differences in the number of deaths (19 [12\%] in the liraglutide group vs 16 [11\%] in the placebo group; hazard ratio, 1.10 [95\% CI, 0.57-2.14]; P\,=\,.78) or rehospitalizations for heart failure (63 [41\%] vs 50 [34\%], respectively; hazard ratio, 1.30 [95\% CI, 0.89-1.88]; P\,=\,.17) or for the exploratory secondary end points. Prespecified subgroup analyses in patients with diabetes did not reveal any significant between-group differences. The number of investigator-reported hyperglycemic events was 16 (10\%) in the liraglutide group vs 27 (18\%) in the placebo group and hypoglycemic events were infrequent (2 [1\%] vs 4 [3\%], respectively). Among patients recently hospitalized with heart failure and reduced LVEF, the use of liraglutide did not lead to greater posthospitalization clinical stability. These findings do not support the use of liraglutide in this clinical situation.clinicaltrials.gov Identifier: NCT01800968},
  file = {/Users/xx20081/Zotero/storage/B63USX7L/Margulies et al. - 2016 - Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced.pdf;/Users/xx20081/Zotero/storage/8AW6P97A/2540402.html}
}

@article{martinezcarrascoGenomewideAnalysisMotor2023,
  title = {Genome-Wide {{Analysis}} of {{Motor Progression}} in {{Parkinson Disease}}},
  author = {Mart{\'i}nez Carrasco, Alejandro and Real, Raquel and Lawton, Michael and Hertfelder Reynolds, Regina and Tan, Manuela and Wu, Lesley and Williams, Nigel and Carroll, Camille and Corvol, Jean-Christophe and Hu, Michele and Grosset, Donald and Hardy, John and Ryten, Mina and {Ben-Shlomo}, Yoav and Shoai, Maryam and Morris, Huw R.},
  year = {2023},
  month = aug,
  journal = {Neurology: Genetics},
  volume = {9},
  number = {5},
  pages = {e200092},
  issn = {2376-7839},
  doi = {10.1212/NXG.0000000000200092},
  urldate = {2023-12-05},
  abstract = {Background and Objectives The genetic basis of Parkinson disease (PD) motor progression is largely unknown. Previous studies of the genetics of PD progression have included small cohorts and shown a limited overlap with genetic PD risk factors from case-control studies. Here, we have studied genomic variation associated with PD motor severity and early-stage progression in large longitudinal cohorts to help to define the biology of PD progression and potential new drug targets. Methods We performed a GWAS meta-analysis of early PD motor severity and progression up to 3 years from study entry. We used linear mixed-effect models with additive effects, corrected for age at diagnosis, sex, and the first 5 genetic principal components to assess variability in axial, limb, and total Movement Disorder Society--Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III scores. Results We included 3,572 unrelated European ancestry patients with PD from 5 observational cohorts and 1 drug trial. The average AAO was 62.6 years (SD = 9.83), and 63\% of participants were male. We found an average increase in the total MDS-UPDRS III score of 2.3 points/year. We identified an association between PD axial motor progression and variation at the GJA5 locus at 1q12 ({$\beta$} = -0.25, SE = 0.04, p = 3.4e-10). Exploration of the regulation of gene expression in the region (cis-expression quantitative trait loci [eQTL] analysis) showed that the lead variant was associated with expression of ACP6, a lysophosphatidic acid phosphatase that regulates mitochondrial lipid biosynthesis (cis-eQTL p-values in blood and brain RNA expression data sets: {$<$}10-14 in eQTLGen and 10-7 in PsychEncode). Discussion Our study highlights the potential role of mitochondrial lipid homeostasis in the progression of PD, which may be important in establishing new drug targets that might modify disease progression.},
  pmcid = {PMC10409573},
  pmid = {37560120},
  file = {/Users/xx20081/Zotero/storage/MJD5HZZ7/Martnez Carrasco et al. - 2023 - Genome-wide Analysis of Motor Progression in Parki.pdf}
}

@article{mcmurrayEffectsCandesartanPatients2003a,
  title = {Effects of Candesartan in Patients with Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The {{CHARM-Added}} Trial},
  shorttitle = {Effects of Candesartan in Patients with Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors},
  author = {McMurray, John JV and {\"O}stergren, Jan and Swedberg, Karl and Granger, Christopher B. and Held, Peter and Michelson, Eric L. and Olofsson, Bertil and Yusuf, Salim and Pfeffer, Marc A.},
  year = {2003},
  month = sep,
  journal = {The Lancet},
  volume = {362},
  number = {9386},
  pages = {767--771},
  publisher = {Elsevier},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(03)14283-3},
  urldate = {2025-02-26},
  langid = {english},
  pmid = {13678869},
  file = {/Users/xx20081/Zotero/storage/H5RIM2TY/McMurray et al. - 2003 - Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic.pdf}
}

@article{mitchellStrategiesInvestigateMitigate2023,
  title = {Strategies to Investigate and Mitigate Collider Bias in Genetic and {{Mendelian}} Randomisation Studies of Disease Progression},
  author = {Mitchell, Ruth E. and Hartley, April E. and Walker, Venexia M. and Gkatzionis, Apostolos and Yarmolinsky, James and Bell, Joshua A. and Chong, Amanda H. W. and Paternoster, Lavinia and Tilling, Kate and Smith, George Davey},
  year = {2023},
  month = feb,
  journal = {PLoS genetics},
  volume = {19},
  number = {2},
  pages = {e1010596},
  issn = {1553-7404},
  doi = {10.1371/journal.pgen.1010596},
  abstract = {Genetic studies of disease progression can be used to identify factors that may influence survival or prognosis, which may differ from factors that influence on disease susceptibility. Studies of disease progression feed directly into therapeutics for disease, whereas studies of incidence inform prevention strategies. However, studies of disease progression are known to be affected by collider (also known as "index event") bias since the disease progression phenotype can only be observed for individuals who have the disease. This applies equally to observational and genetic studies, including genome-wide association studies and Mendelian randomisation (MR) analyses. In this paper, our aim is to review several statistical methods that can be used to detect and adjust for index event bias in studies of disease progression, and how they apply to genetic and MR studies using both individual- and summary-level data. Methods to detect the presence of index event bias include the use of negative controls, a comparison of associations between risk factors for incidence in individuals with and without the disease, and an inspection of Miami plots. Methods to adjust for the bias include inverse probability weighting (with individual-level data), or Slope-Hunter and Dudbridge et al.'s index event bias adjustment (when only summary-level data are available). We also outline two approaches for sensitivity analysis. We then illustrate how three methods to minimise bias can be used in practice with two applied examples. Our first example investigates the effects of blood lipid traits on mortality from coronary heart disease, while our second example investigates genetic associations with breast cancer mortality.},
  langid = {english},
  pmcid = {PMC9949638},
  pmid = {36821633},
  keywords = {Bias,Disease Progression,Genome-Wide Association Study,Humans,Mendelian Randomization Analysis,Phenotype,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/S24F8W7I/Mitchell et al. - 2023 - Strategies to investigate and mitigate collider bi.pdf}
}

@article{mitchellStrategiesInvestigateMitigate2023a,
  title = {Strategies to Investigate and Mitigate Collider Bias in Genetic and {{Mendelian}} Randomisation Studies of Disease Progression},
  author = {Mitchell, Ruth E. and Hartley, April E. and Walker, Venexia M. and Gkatzionis, Apostolos and Yarmolinsky, James and Bell, Joshua A. and Chong, Amanda H. W. and Paternoster, Lavinia and Tilling, Kate and Smith, George Davey},
  year = {2023},
  month = feb,
  journal = {PLOS Genetics},
  volume = {19},
  number = {2},
  pages = {e1010596},
  publisher = {Public Library of Science},
  issn = {1553-7404},
  doi = {10.1371/journal.pgen.1010596},
  urldate = {2024-03-08},
  abstract = {Genetic studies of disease progression can be used to identify factors that may influence survival or prognosis, which may differ from factors that influence on disease susceptibility. Studies of disease progression feed directly into therapeutics for disease, whereas studies of incidence inform prevention strategies. However, studies of disease progression are known to be affected by collider (also known as ``index event'') bias since the disease progression phenotype can only be observed for individuals who have the disease. This applies equally to observational and genetic studies, including genome-wide association studies and Mendelian randomisation (MR) analyses. In this paper, our aim is to review several statistical methods that can be used to detect and adjust for index event bias in studies of disease progression, and how they apply to genetic and MR studies using both individual- and summary-level data. Methods to detect the presence of index event bias include the use of negative controls, a comparison of associations between risk factors for incidence in individuals with and without the disease, and an inspection of Miami plots. Methods to adjust for the bias include inverse probability weighting (with individual-level data), or Slope-Hunter and Dudbridge et al.'s index event bias adjustment (when only summary-level data are available). We also outline two approaches for sensitivity analysis. We then illustrate how three methods to minimise bias can be used in practice with two applied examples. Our first example investigates the effects of blood lipid traits on mortality from coronary heart disease, while our second example investigates genetic associations with breast cancer mortality.},
  langid = {english},
  keywords = {Breast cancer,Cancer risk factors,Colliders,Epidemiology,Genetics of disease,Genome-wide association studies,Medical risk factors,Prognosis},
  file = {/Users/xx20081/Zotero/storage/FI8TWL7Y/Mitchell et al. - 2023 - Strategies to investigate and mitigate collider bi.pdf}
}

@article{molderSustainableDataAnalysis2021,
  title = {Sustainable Data Analysis with {{Snakemake}}},
  author = {M{\"o}lder, Felix and Jablonski, Kim Philipp and Letcher, Brice and Hall, Michael B. and {Tomkins-Tinch}, Christopher H. and Sochat, Vanessa and Forster, Jan and Lee, Soohyun and Twardziok, Sven O. and Kanitz, Alexander and Wilm, Andreas and Holtgrewe, Manuel and Rahmann, Sven and Nahnsen, Sven and K{\"o}ster, Johannes},
  year = {2021},
  journal = {F1000Research},
  volume = {10},
  pages = {33},
  issn = {2046-1402},
  doi = {10.12688/f1000research.29032.2},
  abstract = {Data analysis often entails a multitude of heterogeneous steps, from the application of various command line tools to the usage of scripting languages like R or Python for the generation of plots and tables. It is widely recognized that data analyses should ideally be conducted in a reproducible way.~Reproducibility enables technical validation and regeneration of results on the original or even new data. However, reproducibility alone is by no means sufficient to deliver an analysis that is of lasting impact (i.e., sustainable) for the field, or even just one research group. We postulate that it is equally important to ensure adaptability and transparency. The former describes the ability to modify the analysis to answer extended or slightly different research questions. The latter describes the ability to understand the analysis in order to judge whether it is not only technically, but methodologically valid. Here, we analyze the properties needed for a data analysis to become reproducible, adaptable, and transparent. We show how the popular workflow management system Snakemake can be used to guarantee this, and how it enables an ergonomic, combined, unified representation of all steps involved in data analysis, ranging from raw data processing, to quality control and fine-grained, interactive exploration and plotting of final results.},
  langid = {english},
  pmcid = {PMC8114187},
  pmid = {34035898},
  keywords = {adaptability,data analysis,Data Analysis,reproducibility,Reproducibility of Results,scalability,Software,sustainability,transparency,Workflow,workflow management},
  file = {/Users/xx20081/Zotero/storage/TTC3QQTE/Mlder et al. - 2021 - Sustainable data analysis with Snakemake.pdf}
}

@article{mottetPharmacogenomicsHeartFailure2016,
  title = {Pharmacogenomics of Heart Failure: A Systematic Review},
  shorttitle = {Pharmacogenomics of Heart Failure},
  author = {Mottet, Fannie and Vardeny, Orly and {de Denus}, Simon},
  year = {2016},
  month = nov,
  journal = {Pharmacogenomics},
  volume = {17},
  number = {16},
  pages = {1817--1858},
  issn = {1744-8042},
  doi = {10.2217/pgs-2016-0118},
  abstract = {BACKGROUND: Heart failure (HF) and multiple HF-related phenotypes are heritable. Genes implicated in the HF pathophysiology would be expected to influence the response to treatment. METHODS: We conducted a series of systematic literature searches on the pharmacogenetics of HF therapy to assess the current knowledge on this field. RESULTS: Existing data related to HF pharmacogenomics are still limited. The ADRB1 gene is a likely candidate to predict response to {$\beta$}-blockers. Moreover, the cytochrome P450 2D6 coding gene (CYP2D6) clearly affects the pharmacokinetics of metoprolol, although the clinical impact of this association remains to be established. CONCLUSION: Given the rising prevalence of HF and related costs, a more personalized use of HF drugs could have a remarkable benefit for patients, caregivers and healthcare systems.},
  langid = {english},
  pmid = {27813451},
  keywords = {Adrenergic beta-Antagonists,Angiotensin-Converting Enzyme Inhibitors,Cytochrome P-450 CYP2D6,Heart Failure,Humans,Pharmacogenetics,Polymorphism Genetic,Receptors Adrenergic beta-1}
}

@article{musunuruGeneticTestingInherited2020,
  title = {Genetic {{Testing}} for {{Inherited Cardiovascular Diseases}}: {{A Scientific Statement From}} the {{American Heart Association}}},
  shorttitle = {Genetic {{Testing}} for {{Inherited Cardiovascular Diseases}}},
  author = {Musunuru, Kiran and Hershberger, Ray E. and Day, Sharlene M. and Klinedinst, N. Jennifer and Landstrom, Andrew P. and Parikh, Victoria N. and Prakash, Siddharth and Semsarian, Christopher and Sturm, Amy C. and {American Heart Association Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology}},
  year = {2020},
  month = aug,
  journal = {Circulation. Genomic and Precision Medicine},
  volume = {13},
  number = {4},
  pages = {e000067},
  issn = {2574-8300},
  doi = {10.1161/HCG.0000000000000067},
  abstract = {Advances in human genetics are improving the understanding of a variety of inherited cardiovascular diseases, including cardiomyopathies, arrhythmic disorders, vascular disorders, and lipid disorders such as familial hypercholesterolemia. However, not all cardiovascular practitioners are fully aware of the utility and potential pitfalls of incorporating genetic test results into the care of patients and their families. This statement summarizes current best practices with respect to genetic testing and its implications for the management of inherited cardiovascular diseases.},
  langid = {english},
  pmid = {32698598},
  keywords = {AHA Scientific Statements,American Heart Association,aneurysm,arrhythmia,Arrhythmias Cardiac,Cardiomyopathies,cardiomyopathy,cardiovascular diseases,Cardiovascular Diseases,channelopathy,genetic testing,Genetic Testing,genetics,Humans,Hyperlipoproteinemia Type II,Risk Factors,United States,Vascular Diseases}
}

@article{nealCanagliflozinCardiovascularRenal2017,
  title = {Canagliflozin and {{Cardiovascular}} and {{Renal Events}} in {{Type}} 2 {{Diabetes}}},
  author = {Neal, Bruce and Perkovic, Vlado and Mahaffey, Kenneth W. and {de Zeeuw}, Dick and Fulcher, Greg and Erondu, Ngozi and Shaw, Wayne and Law, Gordon and Desai, Mehul and Matthews, David R. and {CANVAS Program Collaborative Group}},
  year = {2017},
  month = aug,
  journal = {The New England Journal of Medicine},
  volume = {377},
  number = {7},
  pages = {644--657},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1611925},
  abstract = {Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. Methods The CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks. The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Results The mean age of the participants was 63.3 years, 35.8\% were women, the mean duration of diabetes was 13.5 years, and 65.6\% had a history of cardiovascular disease. The rate of the primary outcome was lower with canagliflozin than with placebo (occurring in 26.9 vs. 31.5 participants per 1000 patient-years; hazard ratio, 0.86; 95\% confidence interval [CI], 0.75 to 0.97; P{$<$}0.001 for noninferiority; P=0.02 for superiority). Although on the basis of the prespecified hypothesis testing sequence the renal outcomes are not viewed as statistically significant, the results showed a possible benefit of canagliflozin with respect to the progression of albuminuria (hazard ratio, 0.73; 95\% CI, 0.67 to 0.79) and the composite outcome of a sustained 40\% reduction in the estimated glomerular filtration rate, the need for renal-replacement therapy, or death from renal causes (hazard ratio, 0.60; 95\% CI, 0.47 to 0.77). Adverse reactions were consistent with the previously reported risks associated with canagliflozin except for an increased risk of amputation (6.3 vs. 3.4 participants per 1000 patient-years; hazard ratio, 1.97; 95\% CI, 1.41 to 2.75); amputations were primarily at the level of the toe or metatarsal. Conclusions In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal. (Funded by Janssen Research and Development; CANVAS and CANVAS-R ClinicalTrials.gov numbers, NCT01032629 and NCT01989754 , respectively.).},
  langid = {english},
  pmid = {28605608},
  keywords = {Aged,Albuminuria,Amputation Surgical,Canagliflozin,Cardiovascular Diseases,Diabetes Mellitus Type 2,Disease Progression,Female,Foot,Glomerular Filtration Rate,Hospitalization,Humans,Hypoglycemic Agents,Kidney Diseases,Male,Middle Aged},
  file = {/Users/xx20081/Zotero/storage/JPKX5ED5/Neal et al. - 2017 - Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.pdf}
}

@article{nelsonAssociationAnalysesBased2017,
  title = {Association Analyses Based on False Discovery Rate Implicate New Loci for Coronary Artery Disease},
  author = {Nelson, Christopher P. and Goel, Anuj and Butterworth, Adam S. and Kanoni, Stavroula and Webb, Tom R. and Marouli, Eirini and Zeng, Lingyao and Ntalla, Ioanna and Lai, Florence Y. and Hopewell, Jemma C. and Giannakopoulou, Olga and Jiang, Tao and Hamby, Stephen E. and Di Angelantonio, Emanuele and Assimes, Themistocles L. and Bottinger, Erwin P. and Chambers, John C. and Clarke, Robert and Palmer, Colin N. A. and Cubbon, Richard M. and Ellinor, Patrick and Ermel, Raili and Evangelou, Evangelos and Franks, Paul W. and Grace, Christopher and Gu, Dongfeng and Hingorani, Aroon D. and Howson, Joanna M. M. and Ingelsson, Erik and Kastrati, Adnan and Kessler, Thorsten and Kyriakou, Theodosios and Lehtim{\"a}ki, Terho and Lu, Xiangfeng and Lu, Yingchang and M{\"a}rz, Winfried and McPherson, Ruth and Metspalu, Andres and {Pujades-Rodriguez}, Mar and Ruusalepp, Arno and Schadt, Eric E. and Schmidt, Amand F. and Sweeting, Michael J. and Zalloua, Pierre A. and AlGhalayini, Kamal and Keavney, Bernard D. and Kooner, Jaspal S. and Loos, Ruth J. F. and Patel, Riyaz S. and Rutter, Martin K. and Tomaszewski, Maciej and Tzoulaki, Ioanna and Zeggini, Eleftheria and Erdmann, Jeanette and Dedoussis, George and Bj{\"o}rkegren, Johan L. M. and {EPIC-CVD Consortium} and {CARDIoGRAMplusC4D} and {UK Biobank CardioMetabolic Consortium CHD working group} and Schunkert, Heribert and Farrall, Martin and Danesh, John and Samani, Nilesh J. and Watkins, Hugh and Deloukas, Panos},
  year = {2017},
  month = sep,
  journal = {Nature Genetics},
  volume = {49},
  number = {9},
  pages = {1385--1391},
  issn = {1546-1718},
  doi = {10.1038/ng.3913},
  abstract = {Genome-wide association studies (GWAS) in coronary artery disease (CAD) had identified 66 loci at 'genome-wide significance' (P {$<$} 5 {\texttimes} 10-8) at the time of this analysis, but a much larger number of putative loci at a false discovery rate (FDR) of 5\% (refs. 1,2,3,4). Here we leverage an interim release of UK Biobank (UKBB) data to evaluate the validity of the FDR approach. We tested a CAD phenotype inclusive of angina (SOFT; ncases = 10,801) as well as a stricter definition without angina (HARD; ncases = 6,482) and selected cases with the former phenotype to conduct a meta-analysis using the two most recent CAD GWAS. This approach identified 13 new loci at genome-wide significance, 12 of which were on our previous list of loci meeting the 5\% FDR threshold, thus providing strong support that the remaining loci identified by FDR represent genuine signals. The 304 independent variants associated at 5\% FDR in this study explain 21.2\% of CAD heritability and identify 243 loci that implicate pathways in blood vessel morphogenesis as well as lipid metabolism, nitric oxide signaling and inflammation.},
  langid = {english},
  pmid = {28714975},
  keywords = {Coronary Artery Disease,Genetic Association Studies,Genetic Loci,Genetic Predisposition to Disease,Genome-Wide Association Study,Genotype,Health Information Systems,Humans,Meta-Analysis as Topic,Phenotype,Polymorphism Single Nucleotide,Reproducibility of Results,Risk Factors,United Kingdom},
  file = {/Users/xx20081/Zotero/storage/TIYBGUKS/Nelson et al. - 2017 - Association analyses based on false discovery rate.pdf}
}

@article{nossentPlasmaLevelsSnoRNAs2019,
  title = {Plasma {{Levels}} of {{snoRNAs}} Are {{Associated}} with {{Platelet Activation}} in {{Patients}} with {{Peripheral Artery Disease}}},
  author = {Nossent, Anne Ya{\"e}l and Ektefaie, Neda and Wojta, Johann and Eichelberger, Beate and Kopp, Christoph and Panzer, Simon and Gremmel, Thomas},
  year = {2019},
  month = dec,
  journal = {International Journal of Molecular Sciences},
  volume = {20},
  number = {23},
  publisher = {Multidisciplinary Digital Publishing Institute  (MDPI)},
  doi = {10.3390/ijms20235975},
  urldate = {2024-04-12},
  abstract = {In addition to supervised walking therapy, antithrombotic therapy and the management of risk factors, the treatment of peripheral artery disease (PAD) is limited to endovascular and surgical interventions, i.e., angioplasty with stent implantation and ...},
  langid = {english},
  pmid = {31783567},
  file = {/Users/xx20081/Zotero/storage/DNQZFYGK/Nossent et al. - 2019 - Plasma Levels of snoRNAs are Associated with Plate.pdf;/Users/xx20081/Zotero/storage/MVEYZTIT/PMC6929168.html}
}

@article{odonoghueEffectDarapladibMajor2014,
  title = {Effect of Darapladib on Major Coronary Events after an Acute Coronary Syndrome: The {{SOLID-TIMI}} 52 Randomized Clinical Trial},
  shorttitle = {Effect of Darapladib on Major Coronary Events after an Acute Coronary Syndrome},
  author = {O'Donoghue, Michelle L. and Braunwald, Eugene and White, Harvey D. and Lukas, Mary Ann and Tarka, Elizabeth and Steg, P. Gabriel and Hochman, Judith S. and Bode, Christoph and Maggioni, Aldo P. and Im, KyungAh and Shannon, Jennifer B. and Davies, Richard Y. and Murphy, Sabina A. and Crugnale, Sharon E. and Wiviott, Stephen D. and Bonaca, Marc P. and Watson, David F. and Weaver, W. Douglas and Serruys, Patrick W. and Cannon, Christopher P. and {SOLID-TIMI 52 Investigators} and Steen, Dylan L.},
  year = {2014},
  month = sep,
  journal = {JAMA},
  volume = {312},
  number = {10},
  pages = {1006--1015},
  issn = {1538-3598},
  doi = {10.1001/jama.2014.11061},
  abstract = {IMPORTANCE: Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherogenesis through pathways related to inflammation. Darapladib is an oral, selective inhibitor of the Lp-PLA2 enzyme. OBJECTIVE: To evaluate the efficacy and safety of darapladib in patients after an acute coronary syndrome (ACS) event. DESIGN, SETTING, AND PARTICIPANTS: SOLID-TIMI 52 was a multinational, double-blind, placebo-controlled trial that randomized 13,026 participants within 30 days of hospitalization with an ACS (non-ST-elevation or ST-elevation myocardial infarction [MI]) at 868 sites in 36 countries. INTERVENTIONS: Patients were randomized to either once-daily darapladib (160 mg) or placebo on a background of guideline-recommended therapy. Patients were followed up for a median of 2.5 years between December 7, 2009, and December 6, 2013. MAIN OUTCOMES AND MEASURES: The primary end point (major coronary events) was the composite of coronary heart disease (CHD) death, MI, or urgent coronary revascularization for myocardial ischemia. Kaplan-Meier event rates are reported at 3 years. RESULTS: During a median duration of 2.5 years, the primary end point occurred in 903 patients in the darapladib group and 910 in the placebo group (16.3\% vs 15.6\% at 3 years; hazard ratio [HR], 1.00 [95\% CI, 0.91-1.09]; P\,=\,.93). The composite of cardiovascular death, MI, or stroke occurred in 824 in the darapladib group and 838 in the placebo group (15.0\% vs 15.0\% at 3 years; HR, 0.99 [95\% CI, 0.90-1.09]; P\,=\,.78). There were no differences between the treatment groups for additional secondary end points, for individual components of the primary end point, or in all-cause mortality (371 events in the darapladib group and 395 in the placebo group [7.3\% vs 7.1\% at 3 years; HR, 0.94 [95\% CI, 0.82-1.08]; P\,=\,.40). Patients were more likely to report an odor-related concern in the darapladib group vs the placebo group (11.5\% vs 2.5\%) and also more likely to report diarrhea (10.6\% vs 5.6\%). CONCLUSIONS AND RELEVANCE: In patients who experienced an ACS event, direct inhibition of Lp-PLA2 with darapladib added to optimal medical therapy and initiated within 30 days of hospitalization did not reduce the risk of major coronary events. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01000727.},
  langid = {english},
  pmid = {25173516},
  keywords = {Acute Coronary Syndrome,Aged,Benzaldehydes,Blood Proteins,Cardiovascular Diseases,Double-Blind Method,Female,Follow-Up Studies,Humans,Incidence,Kaplan-Meier Estimate,Male,Middle Aged,Myocardial Infarction,Myocardial Ischemia,Oximes,Secondary Prevention}
}

@article{okbayGeneticVariantsAssociated2016,
  title = {Genetic Variants Associated with Subjective Well-Being, Depressive Symptoms, and Neuroticism Identified through Genome-Wide Analyses},
  author = {Okbay, Aysu and Baselmans, Bart M. L. and De Neve, Jan-Emmanuel and Turley, Patrick and Nivard, Michel G. and Fontana, Mark Alan and Meddens, S. Fleur W. and Linn{\'e}r, Richard Karlsson and Rietveld, Cornelius A. and Derringer, Jaime and Gratten, Jacob and Lee, James J. and Liu, Jimmy Z. and {de Vlaming}, Ronald and Ahluwalia, Tarunveer S. and Buchwald, Jadwiga and Cavadino, Alana and {Frazier-Wood}, Alexis C. and Furlotte, Nicholas A. and Garfield, Victoria and Geisel, Marie Henrike and Gonzalez, Juan R. and Haitjema, Saskia and Karlsson, Robert and {van der Laan}, Sander W. and Ladwig, Karl-Heinz and Lahti, Jari and {van der Lee}, Sven J. and Lind, Penelope A. and Liu, Tian and Matteson, Lindsay and Mihailov, Evelin and Miller, Michael B. and Minica, Camelia C. and Nolte, Ilja M. and {Mook-Kanamori}, Dennis and {van der Most}, Peter J. and Oldmeadow, Christopher and Qian, Yong and Raitakari, Olli and Rawal, Rajesh and Realo, Anu and Rueedi, Rico and Schmidt, B{\"o}rge and Smith, Albert V. and Stergiakouli, Evie and Tanaka, Toshiko and Taylor, Kent and Thorleifsson, Gudmar and Wedenoja, Juho and Wellmann, Juergen and Westra, Harm-Jan and Willems, Sara M. and Zhao, Wei and {LifeLines Cohort Study} and Amin, Najaf and Bakshi, Andrew and Bergmann, Sven and Bjornsdottir, Gyda and Boyle, Patricia A. and Cherney, Samantha and Cox, Simon R. and Davies, Gail and Davis, Oliver S. P. and Ding, Jun and Direk, Nese and Eibich, Peter and Emeny, Rebecca T. and Fatemifar, Ghazaleh and Faul, Jessica D. and Ferrucci, Luigi and Forstner, Andreas J. and Gieger, Christian and Gupta, Richa and Harris, Tamara B. and Harris, Juliette M. and Holliday, Elizabeth G. and Hottenga, Jouke-Jan and De Jager, Philip L. and Kaakinen, Marika A. and Kajantie, Eero and Karhunen, Ville and Kolcic, Ivana and Kumari, Meena and Launer, Lenore J. and Franke, Lude and {Li-Gao}, Ruifang and Liewald, David C. and Koini, Marisa and Loukola, Anu and {Marques-Vidal}, Pedro and Montgomery, Grant W. and Mosing, Miriam A. and Paternoster, Lavinia and Pattie, Alison and Petrovic, Katja E. and {Pulkki-R{\aa}back}, Laura and Quaye, Lydia and R{\"a}ikk{\"o}nen, Katri and Rudan, Igor and Scott, Rodney J. and Smith, Jennifer A. and Sutin, Angelina R. and Trzaskowski, Maciej and Vinkhuyzen, Anna E. and Yu, Lei and Zabaneh, Delilah and Attia, John R. and Bennett, David A. and Berger, Klaus and Bertram, Lars and Boomsma, Dorret I. and Snieder, Harold and Chang, Shun-Chiao and Cucca, Francesco and Deary, Ian J. and {van Duijn}, Cornelia M. and Eriksson, Johan G. and B{\"u}ltmann, Ute and {de Geus}, Eco J. C. and Groenen, Patrick J. F. and Gudnason, Vilmundur and Hansen, Torben and Hartman, Catharine A. and Haworth, Claire M. A. and Hayward, Caroline and Heath, Andrew C. and Hinds, David A. and Hypp{\"o}nen, Elina and Iacono, William G. and J{\"a}rvelin, Marjo-Riitta and J{\"o}ckel, Karl-Heinz and Kaprio, Jaakko and Kardia, Sharon L. R. and {Keltikangas-J{\"a}rvinen}, Liisa and Kraft, Peter and Kubzansky, Laura D. and Lehtim{\"a}ki, Terho and Magnusson, Patrik K. E. and Martin, Nicholas G. and McGue, Matt and Metspalu, Andres and Mills, Melinda and {de Mutsert}, Ren{\'e}e and Oldehinkel, Albertine J. and Pasterkamp, Gerard and Pedersen, Nancy L. and Plomin, Robert and Polasek, Ozren and Power, Christine and Rich, Stephen S. and Rosendaal, Frits R. and {den Ruijter}, Hester M. and Schlessinger, David and Schmidt, Helena and Svento, Rauli and Schmidt, Reinhold and Alizadeh, Behrooz Z. and S{\o}rensen, Thorkild I. A. and Spector, Tim D. and Starr, John M. and Stefansson, Kari and Steptoe, Andrew and Terracciano, Antonio and Thorsteinsdottir, Unnur and Thurik, A. Roy and Timpson, Nicholas J. and Tiemeier, Henning and Uitterlinden, Andr{\'e} G. and Vollenweider, Peter and Wagner, Gert G. and Weir, David R. and Yang, Jian and Conley, Dalton C. and Smith, George Davey and Hofman, Albert and Johannesson, Magnus and Laibson, David I. and Medland, Sarah E. and Meyer, Michelle N. and Pickrell, Joseph K. and Esko, T{\~o}nu and Krueger, Robert F. and Beauchamp, Jonathan P. and Koellinger, Philipp D. and Benjamin, Daniel J. and Bartels, Meike and Cesarini, David},
  year = {2016},
  month = jun,
  journal = {Nature Genetics},
  volume = {48},
  number = {6},
  pages = {624--633},
  issn = {1546-1718},
  doi = {10.1038/ng.3552},
  abstract = {Very few genetic variants have been associated with depression and neuroticism, likely because of limitations on sample size in previous studies. Subjective well-being, a phenotype that is genetically correlated with both of these traits, has not yet been studied with genome-wide data. We conducted genome-wide association studies of three phenotypes: subjective well-being (n = 298,420), depressive symptoms (n = 161,460), and neuroticism (n = 170,911). We identify 3 variants associated with subjective well-being, 2 variants associated with depressive symptoms, and 11 variants associated with neuroticism, including 2 inversion polymorphisms. The two loci associated with depressive symptoms replicate in an independent depression sample. Joint analyses that exploit the high genetic correlations between the phenotypes ({\textbar}{$\rho$}{\textasciicircum}{\textbar} {$\approx$} 0.8) strengthen the overall credibility of the findings and allow us to identify additional variants. Across our phenotypes, loci regulating expression in central nervous system and adrenal or pancreas tissues are strongly enriched for association.},
  langid = {english},
  pmcid = {PMC4884152},
  pmid = {27089181},
  keywords = {Anxiety Disorders,Bayes Theorem,Depression,Genome-Wide Association Study,Humans,Neuroticism,Phenotype,Polymorphism Single Nucleotide},
  file = {/Users/xx20081/Zotero/storage/SWUS87D6/Okbay et al. - 2016 - Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identif.pdf}
}

@article{olivierEffectEplerenonePatients2017,
  title = {Effect of Eplerenone in Patients with Heart Failure and Reduced Ejection Fraction: Potential Effect Modification by Abdominal Obesity. {{Insight}} from the {{EMPHASIS-HF}} Trial},
  shorttitle = {Effect of Eplerenone in Patients with Heart Failure and Reduced Ejection Fraction},
  author = {Olivier, Arnaud and Pitt, Bertram and Girerd, Nicolas and Lamiral, Zohra and Machu, Jean-Loup and McMurray, John J. V. and Swedberg, Karl and {van Veldhuisen}, Dirk J. and Collier, Timothy J. and Pocock, Stuart J. and Rossignol, Patrick and Zannad, Faiez and Pizard, Anne},
  year = {2017},
  month = sep,
  journal = {European Journal of Heart Failure},
  volume = {19},
  number = {9},
  pages = {1186--1197},
  issn = {1879-0844},
  doi = {10.1002/ejhf.792},
  abstract = {AIMS: An excessive production of aldosterone influences outcome in patients with heart failure (HF) and in obese patients. Findings from laboratory studies suggest that chronic aldosterone blockade maybe more beneficial in abdominally obese HF-prone rats. In the current study, we investigated if the clinical response to a mineralocorticoid receptor antagonist in mildly symptomatic HF patients varied by abdominal obesity. METHODS AND RESULTS: A total of 2587 NYHA class II, reduced ejection fraction HF (HFrEF) patients enrolled in the EMPHASIS-HF trial were randomly assigned to eplerenone and placebo. In this post hoc analysis, patients were categorized according to waist circumference (WC) (normal if WC {$<$} 102\,cm in men and\,{$<$}\,88\,cm in women; abdominal obesity if WC {$\geq$} 102\,cm in men and\,{$\geq$}\,88\,cm women). The potential statistical interaction between the treatment and WC was assessed on the primary endpoint of death from cardiovascular causes or hospitalization for HF and other secondary endpoints. Over a median follow-up of 21 months, a significant benefit of eplerenone for the primary outcome was noted in both normal [hazard ratio (HR) 0.77, 95\% confidence interval (CI) 0.61-0.98, P = 0.03] and increased (HR 0.48, 95\% CI 0.37-0.63, P {$<$} 0.0001) WC subgroups, but the latter patients appeared to receive greater benefit than patients with normal WC (P for interaction = 0.01). This suggests a significant quantitative (treatment effect varies in magnitude by subgroup, but is always in same direction) rather than a qualitative interaction (direction of the treatment effect varies by subgroup) between eplerenone and WC in the adjusted analysis. Mean doses of eplerenone, blood pressure and serum potassium changes and adverse events were similar between WC subgroups. CONCLUSION: In EMPHASIS-HF, eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although the benefit appeared to be more pronounced among those with abdominal obesity. The findings are potentially hypothesis generating and need to be replicated in other HFrEF populations.},
  langid = {english},
  pmid = {28303624},
  keywords = {Abdominal obesity,Aged,Aldosterone,Drug Monitoring,Eplerenone,Female,Heart Failure Systolic,Heart failure with reduced ejection fraction,Humans,Male,Middle Aged,Mineralocorticoid Receptor Antagonists,Obesity Abdominal,Spironolactone,Stroke Volume,Treatment Outcome,Ventricular Dysfunction Left},
  file = {/Users/xx20081/Zotero/storage/CWRUKSSZ/Olivier et al. - 2017 - Effect of eplerenone in patients with heart failur.pdf}
}

@article{packerTirzepatideHeartFailure2024,
  title = {Tirzepatide for {{Heart Failure}} with {{Preserved Ejection Fraction}} and {{Obesity}}},
  author = {Packer, Milton and Zile, Michael R. and Kramer, Christopher M. and Baum, Seth J. and Litwin, Sheldon E. and Menon, Venu and Ge, Junbo and Weerakkody, Govinda J. and Ou, Yang and Bunck, Mathijs C. and Hurt, Karla C. and Murakami, Masahiro and Borlaug, Barry A. and {SUMMIT Trial Study Group}},
  year = {2024},
  month = nov,
  journal = {The New England Journal of Medicine},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa2410027},
  abstract = {BACKGROUND: Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS: In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50\%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks. The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life). RESULTS: A total of 364 patients were assigned to the tirzepatide group and 367 to the placebo group; the median duration of follow-up was 104 weeks. Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9\%) in the tirzepatide group and in 56 patients (15.3\%) in the placebo group (hazard ratio, 0.62; 95\% confidence interval [CI], 0.41 to 0.95; P\,=\,0.026). Worsening heart-failure events occurred in 29 patients (8.0\%) in the tirzepatide group and in 52 patients (14.2\%) in the placebo group (hazard ratio, 0.54; 95\% CI, 0.34 to 0.85), and adjudicated death from cardiovascular causes occurred in 8 patients (2.2\%) and 5 patients (1.4\%), respectively (hazard ratio, 1.58; 95\% CI, 0.52 to 4.83). At 52 weeks, the mean ({\textpm}SD) change in the KCCQ-CSS was 19.5{\textpm}1.2 in the tirzepatide group as compared with 12.7{\textpm}1.3 in the placebo group (between-group difference, 6.9; 95\% CI, 3.3 to 10.6; P{$<$}0.001). Adverse events (mainly gastrointestinal) leading to discontinuation of the trial drug occurred in 23 patients (6.3\%) in the tirzepatide group and in 5 patients (1.4\%) in the placebo group. CONCLUSIONS: Treatment with tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure than placebo and improved health status in patients with heart failure with preserved ejection fraction and obesity. (Funded by Eli Lilly; SUMMIT ClinicalTrials.gov number, NCT04847557.).},
  langid = {english},
  pmid = {39555826},
  file = {/Users/xx20081/Zotero/storage/KYIA7H34/nejmoa2410027_appendix.pdf;/Users/xx20081/Zotero/storage/RR4R3BN4/Packer et al. - 2024 - Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.pdf}
}

@article{paternosterGeneticEpidemiologyMendelian2017,
  title = {Genetic Epidemiology and {{Mendelian}} Randomization for Informing Disease Therapeutics: {{Conceptual}} and Methodological Challenges},
  shorttitle = {Genetic Epidemiology and {{Mendelian}} Randomization for Informing Disease Therapeutics},
  author = {Paternoster, Lavinia and Tilling, Kate and Davey Smith, George},
  year = {2017},
  month = oct,
  journal = {PLoS genetics},
  volume = {13},
  number = {10},
  pages = {e1006944},
  issn = {1553-7404},
  doi = {10.1371/journal.pgen.1006944},
  abstract = {The past decade has been proclaimed as a hugely successful era of gene discovery through the high yields of many genome-wide association studies (GWAS). However, much of the perceived benefit of such discoveries lies in the promise that the identification of genes that influence disease would directly translate into the identification of potential therapeutic targets, but this has yet to be realized at a level reflecting expectation. One reason for this, we suggest, is that GWAS, to date, have generally not focused on phenotypes that directly relate to the progression of disease and thus speak to disease treatment.},
  langid = {english},
  pmcid = {PMC5628782},
  pmid = {28981501},
  keywords = {Coronary Disease,Disease Progression,Genetic Diseases Inborn,Genetic Predisposition to Disease,Genome-Wide Association Study,Humans,Mendelian Randomization Analysis,Phenotype,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/995GCGNL/Paternoster et al. - 2017 - Genetic epidemiology and Mendelian randomization f.pdf}
}

@article{postHeritabilityLeftVentricular1997,
  title = {Heritability of Left Ventricular Mass: The {{Framingham Heart Study}}},
  shorttitle = {Heritability of Left Ventricular Mass},
  author = {Post, W. S. and Larson, M. G. and Myers, R. H. and Galderisi, M. and Levy, D.},
  year = {1997},
  month = nov,
  journal = {Hypertension (Dallas, Tex.: 1979)},
  volume = {30},
  number = {5},
  pages = {1025--1028},
  issn = {0194-911X},
  doi = {10.1161/01.hyp.30.5.1025},
  abstract = {Left ventricular hypertrophy is associated with an increased risk for cardiovascular disease. The known determinants of left ventricular hypertrophy only partially explain its variability. The purpose of this study was to estimate heritability of left ventricular mass. The study sample included adults in the original Framingham Heart Study and the Framingham Offspring Study who were not receiving antihypertensive medications and who were free of coronary heart disease, congestive heart failure, diabetes mellitus, renal insufficiency, valvular heart disease, and severe left ventricular hypertrophy. Intraclass correlations for left ventricular mass among first-degree relatives, second-degree relatives, and unrelated spouse pairs were calculated to determine the contribution of heredity to the variability in left ventricular mass. After adjustments for age, height, weight, and systolic blood pressure, the intraclass correlations between first-degree relatives were .15 (parent-child, P{$<$}.001) to .16 (siblings, P{$<$}.001), between second-degree relatives the correlation was .06 (P=NS), and between spouses it was .05 (P=NS). The estimated heritability of adjusted left ventricular mass was between .24 and .32. The proportion of the variance in sex-specific left ventricular mass explained by age, height, weight, and systolic blood pressure was .26 in men and .34 in women. On the basis of intraclass correlations for left ventricular mass, incorporation of adjusted left ventricular mass of a parent or sibling would increase the explained variance by an additional .02 to .03. Heredity explains a small, but discernible proportion of the variance in left ventricular mass. Studies are currently under way to identify genetic markers that predict an individual's predisposition to left ventricular hypertrophy. This knowledge may lead to advances in the prevention of left ventricular hypertrophy, which is strongly associated with cardiovascular morbidity and mortality.},
  langid = {english},
  pmid = {9369250},
  keywords = {Adult,Aged,Cohort Studies,Echocardiography,Epidemiologic Methods,Female,Genetic Variation,Heart,Humans,Male,Middle Aged,Prospective Studies,Regression Analysis}
}

@article{pulitMetaanalysisGenomewideAssociation2019,
  title = {Meta-Analysis of Genome-Wide Association Studies for Body Fat Distribution in 694~649 Individuals of {{European}} Ancestry},
  author = {Pulit, Sara L and Stoneman, Charli and Morris, Andrew P and Wood, Andrew R and Glastonbury, Craig A and Tyrrell, Jessica and Yengo, Lo{\"i}c and Ferreira, Teresa and Marouli, Eirini and Ji, Yingjie and Yang, Jian and Jones, Samuel and Beaumont, Robin and {Croteau-Chonka}, Damien C and Winkler, Thomas W and {GIANT Consortium} and Hattersley, Andrew T and Loos, Ruth J F and Hirschhorn, Joel N and Visscher, Peter M and Frayling, Timothy M and Yaghootkar, Hanieh and Lindgren, Cecilia M},
  year = {2019},
  month = jan,
  journal = {Human Molecular Genetics},
  volume = {28},
  number = {1},
  pages = {166--174},
  issn = {0964-6906},
  doi = {10.1093/hmg/ddy327},
  urldate = {2024-04-08},
  abstract = {More than one in three adults worldwide is either overweight or obese. Epidemiological studies indicate that the location and distribution of excess fat, rather than general adiposity, are more informative for predicting risk of obesity sequelae, including cardiometabolic disease and cancer. We performed a genome-wide association study meta-analysis of body fat distribution, measured by waist-to-hip ratio (WHR) adjusted for body mass index (WHRadjBMI), and identified 463 signals in 346 loci. Heritability and variant effects were generally stronger in women than men, and we found approximately one-third of all signals to be sexually dimorphic. The 5\% of individuals carrying the most WHRadjBMI-increasing alleles were 1.62 times more likely than the bottom 5\% to have a WHR above the thresholds used for metabolic syndrome. These data, made publicly available, will inform the biology of body fat distribution and its relationship with disease.},
  file = {/Users/xx20081/Zotero/storage/7ZY59VCE/Pulit et al. - 2019 - Meta-analysis of genome-wide association studies f.pdf;/Users/xx20081/Zotero/storage/CAB8IPS8/5098227.html}
}

@article{reddyINDIEHFpEFInorganicNitrite2017,
  title = {{{INDIE-HFpEF}} ({{Inorganic Nitrite Delivery}} to {{Improve Exercise Capacity}} in {{Heart Failure With Preserved Ejection Fraction}}): {{Rationale}} and {{Design}}},
  shorttitle = {{{INDIE-HFpEF}} ({{Inorganic Nitrite Delivery}} to {{Improve Exercise Capacity}} in {{Heart Failure With Preserved Ejection Fraction}})},
  author = {Reddy, Yogesh N. V. and Lewis, Gregory D. and Shah, Sanjiv J. and LeWinter, Martin and Semigran, Marc and {Davila-Roman}, Victor G. and Anstrom, Kevin and Hernandez, Adrian and Braunwald, Eugene and Redfield, Margaret M. and Borlaug, Barry A.},
  year = {2017},
  month = may,
  journal = {Circulation. Heart Failure},
  volume = {10},
  number = {5},
  pages = {e003862},
  issn = {1941-3297},
  doi = {10.1161/CIRCHEARTFAILURE.117.003862},
  abstract = {Approximately half of patients with heart failure have preserved ejection fraction. There is no proven treatment that improves outcome. The pathophysiology of heart failure with preserved ejection fraction is complex and includes left ventricular systolic and diastolic dysfunction, pulmonary vascular disease, endothelial dysfunction, and peripheral abnormalities. Multiple lines of evidence point to impaired nitric oxide (NO)-cGMP bioavailability as playing a central role in each of these abnormalities. In contrast to traditional organic nitrate therapies, an alternative strategy to restore NO-cGMP signaling is via inorganic nitrite. Inorganic nitrite, previously considered to be an inert byproduct of NO metabolism, functions as an important in vivo reservoir for NO generation, particularly under hypoxic and acidosis conditions. As such, inorganic nitrite becomes most active at times of greater need for NO signaling, as during exercise when left ventricular filling pressures and pulmonary artery pressures increase. Herein, we present the rationale and design for the INDIE-HFpEF trial (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure with Preserved Ejection Fraction), which is a multicenter, randomized, double-blind, placebo-controlled cross-over study assessing the effect of inhaled inorganic nitrite on peak exercise capacity, conducted in the National Heart, Lung, and Blood Institute-sponsored Heart Failure Clinical Research Network. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02742129.},
  langid = {english},
  pmcid = {PMC5484533},
  pmid = {28476756},
  keywords = {clinical trial,exercise,Exercise Test,Exercise Tolerance,heart failure,Heart Failure,heart failure with preserved ejection fraction,Humans,metabolism,Nitrates,nitric oxide,Randomized Controlled Trials as Topic,Stroke Volume,Ventricular Function Left},
  file = {/Users/xx20081/Zotero/storage/DFKHWVIA/Reddy et al. - 2017 - INDIE-HFpEF (Inorganic Nitrite Delivery to Improve.pdf}
}

@article{redfieldEffectPhosphodiesterase5Inhibition2013,
  title = {Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction: A Randomized Clinical Trial},
  shorttitle = {Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction},
  author = {Redfield, Margaret M. and Chen, Horng H. and Borlaug, Barry A. and Semigran, Marc J. and Lee, Kerry L. and Lewis, Gregory and LeWinter, Martin M. and Rouleau, Jean L. and Bull, David A. and Mann, Douglas L. and Deswal, Anita and Stevenson, Lynne W. and Givertz, Michael M. and Ofili, Elizabeth O. and O'Connor, Christopher M. and Felker, G. Michael and Goldsmith, Steven R. and Bart, Bradley A. and McNulty, Steven E. and Ibarra, Jenny C. and Lin, Grace and Oh, Jae K. and Patel, Manesh R. and Kim, Raymond J. and Tracy, Russell P. and Velazquez, Eric J. and Anstrom, Kevin J. and Hernandez, Adrian F. and Mascette, Alice M. and Braunwald, Eugene and {RELAX Trial}},
  year = {2013},
  month = mar,
  journal = {JAMA},
  volume = {309},
  number = {12},
  pages = {1268--1277},
  issn = {1538-3598},
  doi = {10.1001/jama.2013.2024},
  abstract = {IMPORTANCE: Studies in experimental and human heart failure suggest that phosphodiesterase-5 inhibitors may enhance cardiovascular function and thus exercise capacity in heart failure with preserved ejection fraction (HFPEF). OBJECTIVE: To determine the effect of the phosphodiesterase-5 inhibitor sildenafil compared with placebo on exercise capacity and clinical status in HFPEF. DESIGN: Multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial of 216 stable outpatients with HF, ejection fraction {$\geq$}50\%, elevated N-terminal brain-type natriuretic peptide or elevated invasively measured filling pressures, and reduced exercise capacity. Participants were randomized from October 2008 through February 2012 at 26 centers in North America. Follow-up was through August 30, 2012. INTERVENTIONS: Sildenafil (n = 113) or placebo (n = 103) administered orally at 20 mg, 3 times daily for 12 weeks, followed by 60 mg, 3 times daily for 12 weeks. MAIN OUTCOME MEASURES: Primary end point was change in peak oxygen consumption after 24 weeks of therapy. Secondary end points included change in 6-minute walk distance and a hierarchical composite clinical status score (range, 1-n, a higher value indicates better status; expected value with no treatment effect, 95) based on time to death, time to cardiovascular or cardiorenal hospitalization, and change in quality of life for participants without cardiovascular or cardiorenal hospitalization at 24 weeks. RESULTS: Median age was 69 years, and 48\% of patients were women. At baseline, median peak oxygen consumption (11.7 mL/kg/min) and 6-minute walk distance (308 m) were reduced. The median E/e' (16), left atrial volume index (44 mL/m2), and pulmonary artery systolic pressure (41 mm Hg) were consistent with chronically elevated left ventricular filling pressures. At 24 weeks, median (IQR) changes in peak oxygen consumption (mL/kg/min) in patients who received placebo (-0.20 [IQR, -0.70 to 1.00]) or sildenafil (-0.20 [IQR, -1.70 to 1.11]) were not significantly different (P = .90) in analyses in which patients with missing week-24 data were excluded, and in sensitivity analysis based on intention to treat with multiple imputation for missing values (mean between-group difference, 0.01 mL/kg/min, [95\% CI, -0.60 to 0.61]). The mean clinical status rank score was not significantly different at 24 weeks between placebo (95.8) and sildenafil (94.2) (P = .85). Changes in 6-minute walk distance at 24 weeks in patients who received placebo (15.0 m [IQR, -26.0 to 45.0]) or sildenafil (5.0 m [IQR, -37.0 to 55.0]; P = .92) were also not significantly different. Adverse events occurred in 78 placebo patients (76\%) and 90 sildenafil patients (80\%). Serious adverse events occurred in 16 placebo patients (16\%) and 25 sildenafil patients (22\%). CONCLUSION AND RELEVANCE: Among patients with HFPEF, phosphodiesterase-5 inhibition with administration of sildenafil for 24 weeks, compared with placebo, did not result in significant improvement in exercise capacity or clinical status. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00763867.},
  langid = {english},
  pmcid = {PMC3835156},
  pmid = {23478662},
  keywords = {Aged,Blood Pressure,Double-Blind Method,Exercise Tolerance,Female,Health Status,Heart Failure,Humans,Male,Middle Aged,Outpatients,Oxygen Consumption,Phosphodiesterase 5 Inhibitors,Piperazines,Purines,Sildenafil Citrate,Stroke Volume,Sulfones,Treatment Outcome,Walking},
  file = {/Users/xx20081/Zotero/storage/WEYABUYB/Redfield et al. - 2013 - Effect of phosphodiesterase-5 inhibition on exerci.pdf}
}

@article{redfieldIsosorbideMononitrateHeart2015,
  title = {Isosorbide {{Mononitrate}} in {{Heart Failure}} with {{Preserved Ejection Fraction}}},
  author = {Redfield, Margaret M. and Anstrom, Kevin J. and Levine, James A. and Koepp, Gabe A. and Borlaug, Barry A. and Chen, Horng H. and LeWinter, Martin M. and Joseph, Susan M. and Shah, Sanjiv J. and Semigran, Marc J. and Felker, G. Michael and Cole, Robert T. and Reeves, Gordon R. and Tedford, Ryan J. and Tang, W. H. Wilson and McNulty, Steven E. and Velazquez, Eric J. and Shah, Monica R. and Braunwald, Eugene and {NHLBI Heart Failure Clinical Research Network}},
  year = {2015},
  month = dec,
  journal = {The New England Journal of Medicine},
  volume = {373},
  number = {24},
  pages = {2314--2324},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1510774},
  abstract = {BACKGROUND: Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily activity in such patients. METHODS: In this multicenter, double-blind, crossover study, 110 patients with heart failure and a preserved ejection fraction were randomly assigned to a 6-week dose-escalation regimen of isosorbide mononitrate (from 30 mg to 60 mg to 120 mg once daily) or placebo, with subsequent crossover to the other group for 6 weeks. The primary end point was the daily activity level, quantified as the average daily accelerometer units during the 120-mg phase, as assessed by patient-worn accelerometers. Secondary end points included hours of activity per day during the 120-mg phase, daily accelerometer units during all three dose regimens, quality-of-life scores, 6-minute walk distance, and levels of N-terminal pro-brain natriuretic peptide (NT-proBNP). RESULTS: In the group receiving the 120-mg dose of isosorbide mononitrate, as compared with the placebo group, there was a nonsignificant trend toward lower daily activity (-381 accelerometer units; 95\% confidence interval [CI], -780 to 17; P=0.06) and a significant decrease in hours of activity per day (-0.30 hours; 95\% CI, -0.55 to -0.05; P=0.02). During all dose regimens, activity in the isosorbide mononitrate group was lower than that in the placebo group (-439 accelerometer units; 95\% CI, -792 to -86; P=0.02). Activity levels decreased progressively and significantly with increased doses of isosorbide mononitrate (but not placebo). There were no significant between-group differences in the 6-minute walk distance, quality-of-life scores, or NT-proBNP levels. CONCLUSIONS: Patients with heart failure and a preserved ejection fraction who received isosorbide mononitrate were less active and did not have better quality of life or submaximal exercise capacity than did patients who received placebo. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT02053493.).},
  langid = {english},
  pmcid = {PMC4712067},
  pmid = {26549714},
  keywords = {Accelerometry,Aged,Cross-Over Studies,Double-Blind Method,Exercise Tolerance,Female,Heart Failure,Humans,Isosorbide Dinitrate,Male,Middle Aged,Motor Activity,Natriuretic Peptide Brain,Peptide Fragments,Quality of Life,Stroke Volume,Vasodilator Agents,Walking},
  file = {/Users/xx20081/Zotero/storage/Y2ZNIYUM/Redfield et al. - 2015 - Isosorbide Mononitrate in Heart Failure with Prese.pdf}
}

@article{reinhardtObesityParadoxHeart2024,
  title = {Obesity {{Paradox}} in {{Heart Failure}} with {{Mildly Reduced Ejection Fraction}}},
  author = {Reinhardt, Marielen and Schupp, Tobias and Abumayyaleh, Mohammad and Lau, Felix and Schmitt, Alexander and Abel, Noah and Akin, Muharrem and Rusnak, Jonas and Akin, Ibrahim and Behnes, Michael},
  year = {2024},
  journal = {Pragmatic and Observational Research},
  volume = {15},
  pages = {31--43},
  issn = {1179-7266},
  doi = {10.2147/POR.S444361},
  abstract = {OBJECTIVE: The study investigates the prognostic impact of body mass index (BMI) in patients hospitalized with heart failure with mildly reduced ejection fraction (HFmrEF). BACKGROUND: Limited data regarding the prognostic impact of BMI in patients with HFmrEF is available. METHODS: Consecutive patients with HFmrEF (ie, left ventricular ejection fraction 41-49\% and signs and/or symptoms of HF) were retrospectively included at one institution from 2016 to 2022. Risk stratification was performed according to WHO-defined BMI groups. The primary endpoint was all-cause mortality at 30 months (median follow-up). Kaplan-Meier, uni- and multivariable Cox proportional regression analyses were applied for statistics. RESULTS: 1832 consecutive patients with HFmrEF were included with a median BMI of 26.7 kg/m2 (IQR 24.0-30.8 kg/m2). Patients with lowest BMI (ie, 18.5-24.9 kg/m2) were associated with highest risk of all-cause mortality at 30 months compared to patients with higher BMI values (40.0\% vs 29.0\% vs 21.4\% vs 20.9\%; log rank p = 0.001; HR = 0.721; 95\% CI 0.656-0.793; p = 0.001). Even after multivariable adjustment, higher BMI values were associated with improved survival at 30 months (HR = 0.963; 95\% CI 0.943-0.985; p = 0.001). In contrast, the risk of HF- related rehospitalization at 30 months was not affected by BMI (log rank p = 0.064). CONCLUSION: In patients hospitalized with HFmrEF, lower BMI was associated with increased risk of all-cause mortality at 30 months, suggesting an obesity paradox in HFmrEF.},
  langid = {english},
  pmcid = {PMC10933520},
  pmid = {38481568},
  keywords = {BMI,body mass index,heart failure with mildly reduced ejection fraction,HFmrEF,mortality,obesity},
  file = {/Users/xx20081/Zotero/storage/3CRC2EQW/Reinhardt et al. - 2024 - Obesity Paradox in Heart Failure with Mildly Reduc.pdf}
}

@article{riceCirculatingActivitiesAngiotensinconverting2006,
  title = {Circulating Activities of Angiotensin-Converting Enzyme, Its Homolog, Angiotensin-Converting Enzyme 2, and Neprilysin in a Family Study},
  author = {Rice, Gillian I. and Jones, Amy L. and Grant, Peter J. and Carter, Angela M. and Turner, Anthony J. and Hooper, Nigel M.},
  year = {2006},
  month = nov,
  journal = {Hypertension (Dallas, Tex.: 1979)},
  volume = {48},
  number = {5},
  pages = {914--920},
  issn = {1524-4563},
  doi = {10.1161/01.HYP.0000244543.91937.79},
  abstract = {The renin-angiotensin system is a key regulator of blood pressure (BP), with inhibitors of angiotensin-converting enzyme (ACE) used clinically to treat hypertension and other cardiovascular conditions. ACE2 is a newly identified member of this system, which converts angiotensin II to angiotensin, and of which the occurrence in plasma has not been investigated. The aim of this study was to determine the heritability of circulating ACE, ACE2, and neprilysin (NEP), which may also be a regulator of BP, in a family study, and to determine covariates that contribute to the variation in plasma activity. ACE, ACE2, and NEP activities were measured in plasma from 534 subjects in the Leeds Family Study using selective fluorogenic substrates. Genetic factors accounted for 24.5\%, 67\%, and 22.7\% of the phenotypic variation in circulating ACE, ACE2, and NEP, respectively. ACE insertion/deletion polymorphism and other measured covariates accounted for 23.8\% of variance in circulating ACE. High-density lipoprotein cholesterol was a significant determinant of circulating ACE2. Measured covariates accounted for 17.3\% of variation in circulating NEP. ACE and NEP were associated with systolic and diastolic BP in univariate analyses; however, only ACE was independently associated with systolic and diastolic BP after accounting for covariates and shared childhood household.},
  langid = {english},
  pmid = {17000927},
  keywords = {Adult,Angiotensin-Converting Enzyme 2,Blood Pressure,Female,Genetic Predisposition to Disease,Humans,Hypertension,Male,Neprilysin,Pedigree,Peptidyl-Dipeptidase A,Sequence Homology Amino Acid},
  file = {/Users/xx20081/Zotero/storage/DFFA89CP/Rice et al. - 2006 - Circulating activities of angiotensin-converting e.pdf}
}

@article{robertsonHigherBodyMass2019,
  title = {Higher {{Body Mass Index}} in {{Adolescence Predicts Cardiomyopathy Risk}} in {{Midlife}}},
  author = {Robertson, Josefina and Schaufelberger, Maria and Lindgren, Martin and Adiels, Martin and Schi{\"o}ler, Linus and Tor{\'e}n, Kjell and McMurray, John and Sattar, Naveed and {\AA}berg, Maria and Rosengren, Annika},
  year = {2019},
  month = jul,
  journal = {Circulation},
  volume = {140},
  number = {2},
  pages = {117--125},
  issn = {1524-4539},
  doi = {10.1161/CIRCULATIONAHA.118.039132},
  abstract = {BACKGROUND: Modifiable lifestyle factors in relation to risk for cardiomyopathy, a common and increasing cause of heart failure in the young, have not been widely studied. We sought to investigate a potential link between obesity, a recognized predictor of early heart failure, in adolescence and being diagnosed with cardiomyopathy in adulthood. METHODS: This was a nationwide register-based prospective cohort study of 1\,668\,893 adolescent men (mean age, 18.3 years; SD, 0.7 years) who enlisted for compulsory military service from 1969 to 2005. At baseline, body mass index (BMI), blood pressure, and medical disorders were registered, along with test results for fitness and muscle strength. Cardiomyopathy diagnoses were identified from the National Hospital Register and Cause of Death Register during an up to 46-year follow-up and divided into categories: dilated, hypertrophic, alcohol/drug-induced, and other. Hazard ratios were calculated with Cox proportional hazards models. RESULTS: During follow-up (median, 27 years; Q1-Q3, 19-35 years), 4477 cases of cardiomyopathy were identified, of which 2631 (59\%) were dilated, 673 (15\%) were hypertrophic, and 480 (11\%) were alcohol/drug-induced. Increasing BMI was strongly associated with elevated risk of cardiomyopathy, especially dilated, starting at levels considered normal (BMI, 22.5-{$<$}25 kg/m2; hazard ratio, 1.38 [95\% CI, 1.22-1.57]), adjusted for age, year, center, and baseline comorbidities, and with a {$>$}8-fold increased risk at BMI {$\geq$}35 kg/m2 compared with BMI of 18.5 to {$<$}20 kg/m2. For each 1-unit increase in BMI, similarly adjusted hazard ratios were 1.15 (95\% CI, 1.14-1.17) for dilated cardiomyopathy, 1.09 (95\% CI, 1.06-1.12) for hypertrophic cardiomyopathy, and 1.10 (1.06-1.13) for alcohol/drug-induced cardiomyopathy. CONCLUSIONS: Even mildly elevated body weight in late adolescence may contribute to being diagnosed with cardiomyopathy in adulthood. The already marked importance of weight control in youth is further strengthened by these findings, as well as greater evidence for obesity as a potential important cause of adverse cardiac remodeling that is independent of clinically evident ischemic heart disease.},
  langid = {english},
  pmcid = {PMC6635044},
  pmid = {31132859},
  keywords = {adolescent,Adolescent,Adult,Body Mass Index,Body Weight,cardiomyopathies,Cardiomyopathies,Cohort Studies,Follow-Up Studies,Humans,Male,Middle Aged,obesity,Obesity,overweight,population groups,Predictive Value of Tests,Prospective Studies,Registries,Risk Factors,Sweden},
  file = {/Users/xx20081/Zotero/storage/SRN8Q7LV/Robertson et al. - 2019 - Higher Body Mass Index in Adolescence Predicts Car.pdf}
}

@article{robinson-cohenGenomeWideAssociationStudy2023a,
  title = {Genome-{{Wide Association Study}} of {{CKD Progression}}},
  author = {{Robinson-Cohen}, Cassianne and Triozzi, Jefferson L. and Rowan, Bryce and He, Jing and Chen, Hua C. and Zheng, Neil S. and Wei, Wei-Qi and Wilson, Otis D. and Hellwege, Jacklyn N. and Tsao, Philip S. and Gaziano, J. Michael and Bick, Alexander and Matheny, Michael E. and Chung, Cecilia P. and Lipworth, Loren and Siew, Edward D. and Ikizler, T. Alp and Tao, Ran and Hung, Adriana M.},
  year = {2023},
  month = sep,
  journal = {Journal of the American Society of Nephrology: JASN},
  volume = {34},
  number = {9},
  pages = {1547--1559},
  issn = {1533-3450},
  doi = {10.1681/ASN.0000000000000170},
  abstract = {SIGNIFICANCE STATEMENT: Rapid progression of CKD is associated with poor clinical outcomes. Most previous studies looking for genetic factors associated with low eGFR have used cross-sectional data. The authors conducted a meta-analysis of genome-wide association studies of eGFR decline among 116,870 participants with CKD, focusing on longitudinal data. They identified three loci (two of them novel) associated with longitudinal eGFR decline. In addition to the known UMOD/PDILT locus, variants within BICC1 were associated with significant differences in longitudinal eGFR slope. Variants within HEATR4 also were associated with differences in eGFR decline, but only among Black/African American individuals without diabetes. These findings help characterize molecular mechanisms of eGFR decline in CKD and may inform new therapeutic approaches for progressive kidney disease. BACKGROUND: Rapid progression of CKD is associated with poor clinical outcomes. Despite extensive study of the genetics of cross-sectional eGFR, only a few loci associated with eGFR decline over time have been identified. METHODS: We performed a meta-analysis of genome-wide association studies of eGFR decline among 116,870 participants with CKD-defined by two outpatient eGFR measurements of {$<$}60 ml/min per 1.73 m 2 , obtained 90-365 days apart-from the Million Veteran Program and Vanderbilt University Medical Center's DNA biobank. The primary outcome was the annualized relative slope in outpatient eGFR. Analyses were stratified by ethnicity and diabetes status and meta-analyzed thereafter. RESULTS: In cross-ancestry meta-analysis, the strongest association was rs77924615, near UMOD / PDILT ; each copy of the G allele was associated with a 0.30\%/yr faster eGFR decline ( P = 4.9{\texttimes}10 -27 ). We also observed an association within BICC1 (rs11592748), where every additional minor allele was associated with a 0.13\%/yr slower eGFR decline ( P = 5.6{\texttimes}10 -9 ). Among participants without diabetes, the strongest association was the UMOD/PDILT variant rs36060036, associated with a 0.27\%/yr faster eGFR decline per copy of the C allele ( P = 1.9{\texttimes}10 -17 ). Among Black participants, a significantly faster eGFR decline was associated with variant rs16996674 near APOL1 (R 2 =0.29 with the G1 high-risk genotype); among Black participants with diabetes, lead variant rs11624911 near HEATR4 also was associated with a significantly faster eGFR decline. We also nominally replicated loci with known associations with eGFR decline, near PRKAG2, FGF5, and C15ORF54. CONCLUSIONS: Three loci were significantly associated with longitudinal eGFR change at genome-wide significance. These findings help characterize molecular mechanisms of eGFR decline and may contribute to the development of new therapeutic approaches for progressive CKD.},
  langid = {english},
  pmcid = {PMC10482057},
  pmid = {37261792},
  keywords = {Apolipoprotein L1,Cross-Sectional Studies,Disease Progression,Genome-Wide Association Study,Genotype,Glomerular Filtration Rate,Humans,Kidney,Protein Disulfide-Isomerases,Renal Insufficiency Chronic}
}

@article{robinson-cohenGenomeWideAssociationStudy2023b,
  title = {Genome-{{Wide Association Study}} of {{CKD Progression}}},
  author = {{Robinson-Cohen}, Cassianne and Triozzi, Jefferson L. and Rowan, Bryce and He, Jing and Chen, Hua C. and Zheng, Neil S. and Wei, Wei-Qi and Wilson, Otis D. and Hellwege, Jacklyn N. and Tsao, Philip S. and Gaziano, J. Michael and Bick, Alexander and Matheny, Michael E. and Chung, Cecilia P. and Lipworth, Loren and Siew, Edward D. and Ikizler, T. Alp and Tao, Ran and Hung, Adriana M.},
  year = {2023},
  month = sep,
  journal = {Journal of the American Society of Nephrology},
  volume = {34},
  number = {9},
  pages = {1547},
  issn = {1046-6673},
  doi = {10.1681/ASN.0000000000000170},
  urldate = {2024-08-14},
  abstract = {Significance Statement~           Rapid progression of CKD is associated with poor clinical outcomes. Most previous studies looking for genetic factors associated with low eGFR have used cross-sectional data. The authors conducted a meta-analysis of genome-wide association studies of eGFR decline among 116,870 participants with CKD, focusing on longitudinal data. They identified three loci (two of them novel) associated with longitudinal eGFR decline. In addition to the known UMOD/PDILT locus, variants within BICC1 were associated with significant differences in longitudinal eGFR slope. Variants within HEATR4 also were associated with differences in eGFR decline, but only among Black/African American individuals without diabetes. These findings help characterize molecular mechanisms of eGFR decline in CKD and may inform new therapeutic approaches for progressive kidney disease.           Background~           Rapid progression of CKD is associated with poor clinical outcomes. Despite extensive study of the genetics of cross-sectional eGFR, only a few loci associated with eGFR decline over time have been identified.           Methods~           We performed a meta-analysis of genome-wide association studies of eGFR decline among 116,870 participants with CKD---defined by two outpatient eGFR measurements of {$<$}60 ml/min per 1.73 m2, obtained 90--365 days apart---from the Million Veteran Program and Vanderbilt University Medical Center's DNA biobank. The primary outcome was the annualized relative slope in outpatient eGFR. Analyses were stratified by ethnicity and diabetes status and meta-analyzed thereafter.           Results~           In cross-ancestry meta-analysis, the strongest association was rs77924615, near UMOD/PDILT; each copy of the G allele was associated with a 0.30\%/yr faster eGFR decline (P = 4.9{\texttimes}10-27). We also observed an association within BICC1 (rs11592748), where every additional minor allele was associated with a 0.13\%/yr slower eGFR decline (P = 5.6{\texttimes}10-9). Among participants without diabetes, the strongest association was the UMOD/PDILT variant rs36060036, associated with a 0.27\%/yr faster eGFR decline per copy of the C allele (P = 1.9{\texttimes}10-17). Among Black participants, a significantly faster eGFR decline was associated with variant rs16996674 near APOL1 (R2=0.29 with the G1 high-risk genotype); among Black participants with diabetes, lead variant rs11624911 near HEATR4 also was associated with a significantly faster eGFR decline. We also nominally replicated loci with known associations with eGFR decline, near PRKAG2, FGF5, and C15ORF54.           Conclusions~           Three loci were significantly associated with longitudinal eGFR change at genome-wide significance. These findings help characterize molecular mechanisms of eGFR decline and may contribute to the development of new therapeutic approaches for progressive CKD.                                          Visual Abstract                      Export},
  langid = {american},
  file = {/Users/xx20081/Zotero/storage/K8MMMCJF/genome_wide_association_study_of_ckd_progression.12.html}
}

@article{robinsonSelectionBiasMissing2014,
  title = {Selection Bias: {{A}} Missing Factor in the {{Obesity Paradox}} Debate},
  shorttitle = {Selection Bias},
  author = {Robinson, Whitney R. and Furberg, Helena and Banack, Hailey R.},
  year = {2014},
  month = mar,
  journal = {Obesity (Silver Spring, Md.)},
  volume = {22},
  number = {3},
  pages = {625},
  issn = {1930-7381},
  urldate = {2024-04-04},
  pmcid = {PMC4102427},
  pmid = {24738156},
  file = {/Users/xx20081/Zotero/storage/8Y9EZ24Z/Robinson et al. - 2014 - Selection bias A missing factor in the Obesity Pa.pdf}
}

@article{rpEdoxabanWarfarinPatients2013,
  title = {Edoxaban versus Warfarin in Patients with Atrial Fibrillation},
  author = {Rp, Giugliano and Ct, Ruff and E, Braunwald and Sa, Murphy and Sd, Wiviott and Jl, Halperin and Al, Waldo and Md, Ezekowitz and Ji, Weitz and J, {\v S}pinar and W, Ruzyllo and M, Ruda and Y, Koretsune and J, Betcher and M, Shi and Lt, Grip and Sp, Patel and I, Patel and Jj, Hanyok and M, Mercuri and Em, Antman},
  year = {2013},
  month = nov,
  journal = {The New England journal of medicine},
  volume = {369},
  number = {22},
  publisher = {N Engl J Med},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1310907},
  urldate = {2023-12-08},
  abstract = {Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 Clinica {\dots}},
  langid = {english},
  pmid = {24251359},
  file = {/Users/xx20081/Zotero/storage/C2TZBLPR/Rp et al. - 2013 - Edoxaban versus warfarin in patients with atrial f.pdf;/Users/xx20081/Zotero/storage/HC3SYRDU/24251359.html}
}

@article{satoRevisitingObesityParadox2023,
  title = {Revisiting the Obesity Paradox in Heart Failure: What Is the Best Anthropometric Index to Gauge Obesity?},
  shorttitle = {Revisiting the Obesity Paradox in Heart Failure},
  author = {Sato, Ryosuke and Von Haehling, Stephan},
  year = {2023},
  month = apr,
  journal = {European Heart Journal},
  volume = {44},
  number = {13},
  pages = {1154--1156},
  issn = {0195-668X, 1522-9645},
  doi = {10.1093/eurheartj/ehad079},
  urldate = {2024-01-16},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/CSYNN8LP/Sato and Von Haehling - 2023 - Revisiting the obesity paradox in heart failure w.pdf}
}

@misc{SemaglutideCardiovascularOutcomes,
  title = {Semaglutide and Cardiovascular Outcomes in Patients with Obesity and Prevalent Heart Failure: A Prespecified Analysis of the {{SELECT}} Trial - {{The Lancet}}},
  urldate = {2025-03-17},
  howpublished = {https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01498-3/fulltext},
  file = {/Users/xx20081/Zotero/storage/P8NJ8ZKZ/fulltext.html}
}

@article{shahBodyMassIndex2014,
  title = {Body {{Mass Index}} and {{Mortality}} in {{Acutely Decompensated Heart Failure Across}} the {{World}}: {{A Global Obesity Paradox}}},
  shorttitle = {Body {{Mass Index}} and {{Mortality}} in {{Acutely Decompensated Heart Failure Across}} the {{World}}},
  author = {Shah, Ravi and Gayat, Etienne and Januzzi, James L. and Sato, Naoki and {Cohen-Solal}, Alain and {diSomma}, Salvatore and Fairman, Enrique and Harjola, Veli-Pekka and Ishihara, Shiro and Lassus, Johan and Maggioni, Aldo and Metra, Marco and Mueller, Christian and Mueller, Thomas and Parenica, Jiri and {Pascual-Figal}, Domingo and Peacock, William Frank and Spinar, Jindrich and {van Kimmenade}, Roland and Mebazaa, Alexandre},
  year = {2014},
  month = mar,
  journal = {Journal of the American College of Cardiology},
  volume = {63},
  number = {8},
  pages = {778--785},
  issn = {0735-1097},
  doi = {10.1016/j.jacc.2013.09.072},
  urldate = {2024-04-04},
  abstract = {Objectives This study sought to define the relationship between body mass index (BMI) and mortality in heart failure (HF) across the world and to identify specific groups in whom BMI may differentially mediate risk. Background Obesity is associated with incident HF, but it is paradoxically associated with better prognosis during chronic HF. Methods We studied 6,142 patients with acute decompensated HF from 12 prospective observational cohorts followed-up across 4 continents. Primary outcome was all-cause mortality. Cox proportional hazards models and net reclassification index described associations of BMI with all-cause mortality. Results Normal-weight patients (BMI 18.5 to 25 kg/m2) were older with more advanced HF and lower cardiometabolic risk. Despite worldwide heterogeneity in clinical features across obesity categories, a higher BMI remained associated with decreased 30-day and 1-year mortality (11\% decrease at 30 days; 9\% decrease at 1 year per 5 kg/m2; p~{$<~$}0.05), after adjustment for clinical risk. The BMI obtained at index admission provided effective 1-year risk reclassification beyond current markers of clinical risk (net reclassification index 0.119, p~{$<$} 0.001). Notably, the ``protective'' association of BMI with mortality was confined to persons with older age ({$>$}75 years; hazard ratio [HR]: 0.82; p~= 0.006), decreased cardiac function (ejection fraction~{$<$}50\%; HR: 0.85; p~{$<$} 0.001), no diabetes (HR: 0.86; p~{$<$} 0.001), and de novo HF (HR: 0.89; p~= 0.004). Conclusions A lower BMI is associated with age, disease severity, and a higher risk of death in acute decompensated HF. The ``obesity paradox'' is confined to older persons, with decreased cardiac function, less cardiometabolic illness, and recent-onset HF, suggesting that aging, HF severity/chronicity, and metabolism may explain the obesity paradox.},
  keywords = {heart failure,obesity,obesity paradox},
  file = {/Users/xx20081/Zotero/storage/VARL88E4/Shah et al. - 2014 - Body Mass Index and Mortality in Acutely Decompens.pdf;/Users/xx20081/Zotero/storage/R2HFWX3V/S0735109713062074.html}
}

@article{shahGenomewideAssociationMendelian2020,
  title = {Genome-Wide Association and {{Mendelian}} Randomisation Analysis Provide Insights into the Pathogenesis of Heart Failure},
  author = {Shah, Sonia and Henry, Albert and Roselli, Carolina and Lin, Honghuang and Sveinbj{\"o}rnsson, Gar{\dh}ar and Fatemifar, Ghazaleh and Hedman, {\AA}sa K. and Wilk, Jemma B. and Morley, Michael P. and Chaffin, Mark D. and Helgadottir, Anna and Verweij, Niek and Dehghan, Abbas and Almgren, Peter and Andersson, Charlotte and Aragam, Krishna G. and {\"A}rnl{\"o}v, Johan and Backman, Joshua D. and Biggs, Mary L. and Bloom, Heather L. and Brandimarto, Jeffrey and Brown, Michael R. and Buckbinder, Leonard and Carey, David J. and Chasman, Daniel I. and Chen, Xing and Chen, Xu and Chung, Jonathan and Chutkow, William and Cook, James P. and Delgado, Graciela E. and Denaxas, Spiros and Doney, Alexander S. and D{\"o}rr, Marcus and Dudley, Samuel C. and Dunn, Michael E. and Engstr{\"o}m, Gunnar and Esko, T{\~o}nu and Felix, Stephan B. and Finan, Chris and Ford, Ian and Ghanbari, Mohsen and Ghasemi, Sahar and Giedraitis, Vilmantas and Giulianini, Franco and Gottdiener, John S. and Gross, Stefan and Gu{\dh}bjartsson, Dan{\'i}el F. and Gutmann, Rebecca and Haggerty, Christopher M. and {van der Harst}, Pim and Hyde, Craig L. and Ingelsson, Erik and Jukema, J. Wouter and Kavousi, Maryam and Khaw, Kay-Tee and Kleber, Marcus E. and K{\o}ber, Lars and Koekemoer, Andrea and Langenberg, Claudia and Lind, Lars and Lindgren, Cecilia M. and London, Barry and Lotta, Luca A. and Lovering, Ruth C. and Luan, Jian'an and Magnusson, Patrik and Mahajan, Anubha and Margulies, Kenneth B. and M{\"a}rz, Winfried and Melander, Olle and Mordi, Ify R. and Morgan, Thomas and Morris, Andrew D. and Morris, Andrew P. and Morrison, Alanna C. and Nagle, Michael W. and Nelson, Christopher P. and Niessner, Alexander and Niiranen, Teemu and O'Donoghue, Michelle L. and Owens, Anjali T. and Palmer, Colin N. A. and Parry, Helen M. and Perola, Markus and {Portilla-Fernandez}, Eliana and Psaty, Bruce M. and {Regeneron Genetics Center} and Rice, Kenneth M. and Ridker, Paul M. and Romaine, Simon P. R. and Rotter, Jerome I. and Salo, Perttu and Salomaa, Veikko and {van Setten}, Jessica and Shalaby, Alaa A. and Smelser, Diane T. and Smith, Nicholas L. and Stender, Steen and Stott, David J. and Svensson, Per and Tammesoo, Mari-Liis and Taylor, Kent D. and {Teder-Laving}, Maris and Teumer, Alexander and Thorgeirsson, Gu{\dh}mundur and Thorsteinsdottir, Unnur and {Torp-Pedersen}, Christian and Trompet, Stella and Tyl, Benoit and Uitterlinden, Andre G. and Veluchamy, Abirami and V{\"o}lker, Uwe and Voors, Adriaan A. and Wang, Xiaosong and Wareham, Nicholas J. and Waterworth, Dawn and Weeke, Peter E. and Weiss, Raul and Wiggins, Kerri L. and Xing, Heming and {Yerges-Armstrong}, Laura M. and Yu, Bing and Zannad, Faiez and Zhao, Jing Hua and Hemingway, Harry and Samani, Nilesh J. and McMurray, John J. V. and Yang, Jian and Visscher, Peter M. and {Newton-Cheh}, Christopher and Malarstig, Anders and Holm, Hilma and Lubitz, Steven A. and Sattar, Naveed and Holmes, Michael V. and Cappola, Thomas P. and Asselbergs, Folkert W. and Hingorani, Aroon D. and Kuchenbaecker, Karoline and Ellinor, Patrick T. and Lang, Chim C. and Stefansson, Kari and Smith, J. Gustav and Vasan, Ramachandran S. and Swerdlow, Daniel I. and Lumbers, R. Thomas},
  year = {2020},
  month = jan,
  journal = {Nature Communications},
  volume = {11},
  number = {1},
  pages = {163},
  issn = {2041-1723},
  doi = {10.1038/s41467-019-13690-5},
  abstract = {Heart failure (HF) is a leading cause of morbidity and mortality worldwide. A small proportion of HF cases are attributable to monogenic cardiomyopathies and existing genome-wide association studies (GWAS) have yielded only limited insights, leaving the observed heritability of HF largely unexplained. We report results from a GWAS meta-analysis of HF comprising 47,309 cases and 930,014 controls. Twelve independent variants at 11 genomic loci are associated with HF, all of which demonstrate one or more associations with coronary artery disease (CAD), atrial fibrillation, or reduced left ventricular function, suggesting shared genetic aetiology. Functional analysis of non-CAD-associated loci implicate genes involved in cardiac development (MYOZ1, SYNPO2L), protein homoeostasis (BAG3), and cellular senescence (CDKN1A). Mendelian randomisation analysis supports causal roles for several HF risk factors, and demonstrates CAD-independent effects for atrial fibrillation, body mass index, and~hypertension. These findings extend our knowledge of the pathways underlying HF and may inform new therapeutic strategies.},
  langid = {english},
  pmcid = {PMC6952380},
  pmid = {31919418},
  keywords = {Adaptor Proteins Signal Transducing,Apoptosis Regulatory Proteins,Atrial Fibrillation,Cardiomyopathies,Carrier Proteins,Case-Control Studies,Coronary Artery Disease,Cyclin-Dependent Kinase Inhibitor p21,Genome-Wide Association Study,Heart Failure,Humans,Mendelian Randomization Analysis,Microfilament Proteins,Muscle Proteins,Risk Factors,Ventricular Function Left},
  file = {/Users/xx20081/Zotero/storage/2RNNXZUL/Shah et al. - 2020 - Genome-wide association and Mendelian randomisatio.pdf}
}

@article{smithAssociationGenomewideVariation2010,
  title = {Association of Genome-Wide Variation with the Risk of Incident Heart Failure in Adults of {{European}} and {{African}} Ancestry: A Prospective Meta-Analysis from the Cohorts for Heart and Aging Research in Genomic Epidemiology ({{CHARGE}}) Consortium},
  shorttitle = {Association of Genome-Wide Variation with the Risk of Incident Heart Failure in Adults of {{European}} and {{African}} Ancestry},
  author = {Smith, Nicholas L. and Felix, Janine F. and Morrison, Alanna C. and Demissie, Serkalem and Glazer, Nicole L. and Loehr, Laura R. and Cupples, L. Adrienne and Dehghan, Abbas and Lumley, Thomas and Rosamond, Wayne D. and Lieb, Wolfgang and Rivadeneira, Fernando and Bis, Joshua C. and Folsom, Aaron R. and Benjamin, Emelia and Aulchenko, Yurii S. and Haritunians, Talin and Couper, David and Murabito, Joanne and Wang, Ying A. and Stricker, Bruno H. and Gottdiener, John S. and Chang, Patricia P. and Wang, Thomas J. and Rice, Kenneth M. and Hofman, Albert and Heckbert, Susan R. and Fox, Ervin R. and O'Donnell, Christopher J. and Uitterlinden, Andre G. and Rotter, Jerome I. and Willerson, James T. and Levy, Daniel and {van Duijn}, Cornelia M. and Psaty, Bruce M. and Witteman, Jacqueline C. M. and Boerwinkle, Eric and Vasan, Ramachandran S.},
  year = {2010},
  month = jun,
  journal = {Circulation. Cardiovascular Genetics},
  volume = {3},
  number = {3},
  pages = {256--266},
  issn = {1942-3268},
  doi = {10.1161/CIRCGENETICS.109.895763},
  abstract = {BACKGROUND: Although genetic factors contribute to the onset of heart failure (HF), no large-scale genome-wide investigation of HF risk has been published to date. We have investigated the association of 2,478,304 single-nucleotide polymorphisms with incident HF by meta-analyzing data from 4 community-based prospective cohorts: the Atherosclerosis Risk in Communities Study, the Cardiovascular Health Study, the Framingham Heart Study, and the Rotterdam Study. METHODS AND RESULTS: Eligible participants for these analyses were of European or African ancestry and free of clinical HF at baseline. Each study independently conducted genome-wide scans and imputed data to the approximately 2.5 million single-nucleotide polymorphisms in HapMap. Within each study, Cox proportional hazards regression models provided age- and sex-adjusted estimates of the association between each variant and time to incident HF. Fixed-effect meta-analyses combined results for each single-nucleotide polymorphism from the 4 cohorts to produce an overall association estimate and P value. A genome-wide significance P value threshold was set a priori at 5.0x10(-7). During a mean follow-up of 11.5 years, 2526 incident HF events (12\%) occurred in 20 926 European-ancestry participants. The meta-analysis identified a genome-wide significant locus at chromosomal position 15q22 (1.4x10(-8)), which was 58.8 kb from USP3. Among 2895 African-ancestry participants, 466 incident HF events (16\%) occurred during a mean follow-up of 13.7 years. One genome-wide significant locus was identified at 12q14 (6.7x10(-8)), which was 6.3 kb from LRIG3. CONCLUSIONS: We identified 2 loci that were associated with incident HF and exceeded genome-wide significance. The findings merit replication in other community-based settings of incident HF.},
  langid = {english},
  pmcid = {PMC3025695},
  pmid = {20445134},
  keywords = {Aged,Aged 80 and over,Black or African American,Cohort Studies,Endopeptidases,Female,Genome-Wide Association Study,Heart Failure,Humans,Incidence,Male,Middle Aged,Polymorphism Single Nucleotide,Risk,Ubiquitin-Specific Proteases,White People},
  file = {/Users/xx20081/Zotero/storage/I2EUT8EK/Smith et al. - 2010 - Association of genome-wide variation with the risk.pdf}
}

@article{smithDiscoveryGeneticVariation2016,
  title = {Discovery of {{Genetic Variation}} on {{Chromosome}} 5q22 {{Associated}} with {{Mortality}} in {{Heart Failure}}},
  author = {Smith, J. Gustav and Felix, Janine F. and Morrison, Alanna C. and Kalogeropoulos, Andreas and Trompet, Stella and Wilk, Jemma B. and Gidl{\"o}f, Olof and Wang, Xinchen and Morley, Michael and Mendelson, Michael and Joehanes, Roby and Ligthart, Symen and Shan, Xiaoyin and Bis, Joshua C. and Wang, Ying A. and Sj{\"o}gren, Marketa and Ngwa, Julius and Brandimarto, Jeffrey and Stott, David J. and Aguilar, David and Rice, Kenneth M. and Sesso, Howard D. and Demissie, Serkalem and Buckley, Brendan M. and Taylor, Kent D. and Ford, Ian and Yao, Chen and Liu, Chunyu and Consortium, Charge-Scd and Consortium, EchoGen and Consortium, Qt-Igc and Consortium, Charge-Qrs and Sotoodehnia, Nona and van der Harst, Pim and Stricker, Bruno H. Ch and Kritchevsky, Stephen B. and Liu, Yongmei and Gaziano, J. Michael and Hofman, Albert and Moravec, Christine S. and Uitterlinden, Andr{\'e} G. and Kellis, Manolis and van Meurs, Joyce B. and Margulies, Kenneth B. and Dehghan, Abbas and Levy, Daniel and Olde, Bj{\"o}rn and Psaty, Bruce M. and Cupples, L. Adrienne and Jukema, J. Wouter and Djousse, Luc and Franco, Oscar H. and Boerwinkle, Eric and Boyer, Laurie A. and {Newton-Cheh}, Christopher and Butler, Javed and Vasan, Ramachandran S. and Cappola, Thomas P. and Smith, Nicholas L.},
  year = {2016},
  month = may,
  journal = {PLOS Genetics},
  volume = {12},
  number = {5},
  pages = {e1006034},
  publisher = {Public Library of Science},
  issn = {1553-7404},
  doi = {10.1371/journal.pgen.1006034},
  urldate = {2025-01-06},
  abstract = {Failure of the human heart to maintain sufficient output of blood for the demands of the body, heart failure, is a common condition with high mortality even with modern therapeutic alternatives. To identify molecular determinants of mortality in patients with new-onset heart failure, we performed a meta-analysis of genome-wide association studies and follow-up genotyping in independent populations. We identified and replicated an association for a genetic variant on chromosome 5q22 with 36\% increased risk of death in subjects with heart failure (rs9885413, P = 2.7x10-9). We provide evidence from reporter gene assays, computational predictions and epigenomic marks that this polymorphism increases activity of an enhancer region active in multiple human tissues. The polymorphism was further reproducibly associated with a DNA methylation signature in whole blood (P = 4.5x10-40) that also associated with allergic sensitization and expression in blood of the cytokine TSLP (P = 1.1x10-4). Knockdown of the transcription factor predicted to bind the enhancer region (NHLH1) in a human cell line (HEK293) expressing NHLH1 resulted in lower TSLP expression. In addition, we observed evidence of recent positive selection acting on the risk allele in populations of African descent. Our findings provide novel genetic leads to factors that influence mortality in patients with heart failure.},
  langid = {english},
  keywords = {Blood,Death rates,DNA methylation,Gene expression,Genetic loci,Genome-wide association studies,Heart failure,Single nucleotide polymorphisms},
  file = {/Users/xx20081/Zotero/storage/2BXNIF7R/Smith et al. - 2016 - Discovery of Genetic Variation on Chromosome 5q22 Associated with Mortality in Heart Failure.pdf}
}

@article{smithItMatterFat2023,
  title = {It's a {{Matter}} of {{Fat}}: {{The Obesity Paradox}} in {{Heart Failure}}},
  shorttitle = {It's a {{Matter}} of {{Fat}}},
  author = {Smith, Hannah R. and Roberts, Lee D. and Witte, Klaus K.},
  year = {2023},
  month = dec,
  journal = {The American Journal of Cardiology},
  volume = {209},
  pages = {247--249},
  issn = {1879-1913},
  doi = {10.1016/j.amjcard.2023.09.117},
  langid = {english},
  pmid = {37884267},
  keywords = {Heart Failure,Humans,Obesity,Obesity Paradox},
  file = {/Users/xx20081/Zotero/storage/5MUXAZ3W/Smith et al. - 2023 - It's a Matter of Fat The Obesity Paradox in Heart.pdf}
}

@article{sunSmallStrongEmerging2023,
  title = {Small but Strong: The Emerging Role of Small Nucleolar {{RNA}} in Cardiovascular Diseases},
  shorttitle = {Small but Strong},
  author = {Sun, Xue and Wang, Gebang and Luo, Wenting and Gu, Hui and Ma, Wei and Wei, Xiaowei and Liu, Dan and Jia, Shanshan and Cao, Songying and Wang, Yu and Yuan, Zhengwei},
  year = {2023},
  month = nov,
  journal = {Frontiers in Cell and Developmental Biology},
  volume = {11},
  pages = {1292925},
  issn = {2296-634X},
  doi = {10.3389/fcell.2023.1292925},
  urldate = {2024-04-12},
  abstract = {Cardiovascular diseases (CVDs) are the leading cause of mortality and disability worldwide. Numerous studies have demonstrated that non-coding RNAs (ncRNAs) play a primary role in CVD development. Therefore, studies on the mechanisms of ncRNAs are essential for further efforts to prevent and treat CVDs. Small nucleolar RNAs (snoRNAs) are a novel species of non-conventional ncRNAs that guide post-transcriptional modifications and the subsequent maturation of small nuclear RNA and ribosomal RNA. Evidently, snoRNAs are extensively expressed in human tissues and may regulate different illnesses. Particularly, as the next-generation sequencing techniques have progressed, snoRNAs have been shown to be differentially expressed in CVDs, suggesting that they may play a role in the occurrence and progression of cardiac illnesses. However, the molecular processes and signaling pathways underlying the function of snoRNAs remain unidentified. Therefore, it is of great value to comprehensively investigate the association between snoRNAs and CVDs. The aim of this review was to collate existing literature on the biogenesis, characteristics, and potential regulatory mechanisms of snoRNAs. In particular, we present a scientific update on these snoRNAs and their relevance to CVDs in an effort to cast new light on the functions of snoRNAs in the clinical diagnosis of CVDs.},
  pmcid = {PMC10682241},
  pmid = {38033868},
  file = {/Users/xx20081/Zotero/storage/6LDTABBF/Sun et al. - 2023 - Small but strong the emerging role of small nucle.pdf}
}

@misc{TirzepatideHeartFailure,
  title = {Tirzepatide for {{Heart Failure}} with {{Preserved Ejection Fraction}} and {{Obesity}} {\textbar} {{New England Journal}} of {{Medicine}}},
  urldate = {2025-01-20},
  howpublished = {https://www.nejm.org/doi/full/10.1056/NEJMoa2410027},
  file = {/Users/xx20081/Zotero/storage/BGXCJ4QE/NEJMoa2410027.html}
}

@article{vinckHeritabilityPlasmaRenin2002,
  title = {Heritability of Plasma Renin Activity and Plasma Concentration of Angiotensinogen and Angiotensin-Converting Enzyme},
  author = {Vinck, W. J. and Fagard, R. H. and Vlietinck, R. and Lijnen, P.},
  year = {2002},
  month = jun,
  journal = {Journal of Human Hypertension},
  volume = {16},
  number = {6},
  pages = {417--422},
  issn = {0950-9240},
  doi = {10.1038/sj.jhh.1001410},
  abstract = {The purpose of the present investigation was to describe the relative impact of genes and environment on the variance of the plasma constituents of the renin angiotensin system. We ascertained 56 male and 80 female adult same-sex twin pairs from the Flemish population. Plasma renin activity (PRA), the concentration of angiotensinogen (AGT) and angiotensin-converting enzyme (ACE) were measured, and path analysis was applied, after transformation toward normality. For PRA and AGT significant heritability was only detected in the male subgroup, with heritability estimates of 66\% and 90\%, respectively. Angiotensin-converting enzyme concentration was determined by additive genes for 43\% of its variance, by shared environmental influences for 42\%, and by specific environmental influences for 15\%. The high heritability found for AGT is compatible with the results of earlier studies linking the M235T polymorphism of the angiotensinogen gene to plasma AGT levels. For PRA, we are the first to show significant heritability. Our results regarding ACE confirm the findings in other populations.},
  langid = {english},
  pmid = {12037697},
  keywords = {Aged,Analysis of Variance,Angiotensinogen,Belgium,Female,Humans,Male,Middle Aged,Peptidyl-Dipeptidase A,Renin,Renin-Angiotensin System}
}

@article{wadeAssessingCausalRole2018,
  title = {Assessing the {{Causal Role}} of {{Body Mass Index}} on {{Cardiovascular Health}} in {{Young Adults}}},
  author = {Wade, Kaitlin H. and Chiesa, Scott T. and Hughes, Alun D. and Chaturvedi, Nish and Charakida, Marietta and Rapala, Alicja and Muthurangu, Vivek and Khan, Tauseef and Finer, Nicholas and Sattar, Naveed and Howe, Laura D. and Fraser, Abigail and Lawlor, Debbie A. and Davey Smith, George and Deanfield, John E. and Timpson, Nicholas J.},
  year = {2018},
  month = nov,
  journal = {Circulation},
  volume = {138},
  number = {20},
  pages = {2187--2201},
  issn = {0009-7322},
  doi = {10.1161/CIRCULATIONAHA.117.033278},
  urldate = {2024-03-08},
  abstract = {Supplemental Digital Content is available in the text.},
  pmcid = {PMC6250296},
  pmid = {30524135},
  file = {/Users/xx20081/Zotero/storage/ECS4WVBU/Wade et al. - 2018 - Assessing the Causal Role of Body Mass Index on Ca.pdf}
}

@article{wadeBMIMortalityUK2018,
  title = {{{BMI}} and {{Mortality}} in {{UK Biobank}}: {{Revised Estimates Using Mendelian Randomization}}},
  shorttitle = {{{BMI}} and {{Mortality}} in {{UK Biobank}}},
  author = {Wade, Kaitlin H. and Carslake, David and Sattar, Naveed and Davey Smith, George and Timpson, Nicholas J.},
  year = {2018},
  month = nov,
  journal = {Obesity (Silver Spring, Md.)},
  volume = {26},
  number = {11},
  pages = {1796--1806},
  issn = {1930-7381},
  doi = {10.1002/oby.22313},
  urldate = {2025-01-22},
  abstract = {Objective The aim of this study was to obtain estimates of the causal relationship between BMI and mortality. Methods Mendelian randomization (MR) with BMI-associated genotypic variation was used to test the causal effect of BMI on all-cause and cause-specific mortality in UK Biobank participants of White British ancestry. Results MR analyses supported a causal association between higher BMI and greater risk of all-cause mortality (hazard ratio [HR] per 1 kg/m2: 1.03; 95\% CI: 0.99-1.07) and mortality from cardiovascular diseases (HR: 1.10; 95\% CI: 1.01-1.19), specifically coronary heart disease (HR: 1.12; 95\% CI: 1.00-1.25) and those excluding coronary heart disease/stroke/aortic aneurysm (HR: 1.24; 95\% CI: 1.03-1.48), stomach cancer (HR: 1.18; 95\% CI: 0.87-1.62), and esophageal cancer (HR: 1.22; 95\% CI: 0.98-1.53), and a decreased risk of lung cancer mortality (HR: 0.96; 95\% CI: 0.85-1.08). Sex stratification supported the causal role of higher BMI increasing bladder cancer mortality risk (males) but decreasing respiratory disease mortality risk (males). The J-shaped observational association between BMI and mortality was visible with MR analyses, but the BMI at which mortality was minimized was lower and the association was flatter over a larger BMI range. Conclusions Results support a causal role of higher BMI in increasing the risk of all-cause mortality and mortality from several specific causes.},
  pmcid = {PMC6334168},
  pmid = {30358150},
  file = {/Users/xx20081/Zotero/storage/K2EPFRV9/Wade et al. - 2018 - BMI and Mortality in UK Biobank Revised Estimates Using Mendelian Randomization.pdf}
}

@article{wildingOnceWeeklySemaglutideAdults2021,
  title = {Once-{{Weekly Semaglutide}} in {{Adults}} with {{Overweight}} or {{Obesity}}},
  author = {Wilding, John P. H. and Batterham, Rachel L. and Calanna, Salvatore and Davies, Melanie and Gaal, Luc F. Van and Lingvay, Ildiko and McGowan, Barbara M. and Rosenstock, Julio and Tran, Marie T. D. and Wadden, Thomas A. and Wharton, Sean and Yokote, Koutaro and Zeuthen, Niels and Kushner, Robert F.},
  year = {2021},
  month = mar,
  journal = {New England Journal of Medicine},
  volume = {384},
  number = {11},
  pages = {989--1002},
  publisher = {Massachusetts Medical Society},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa2032183},
  urldate = {2025-01-20},
  abstract = {This double-blind study randomly assigned adults with obesity (or overweight and with one or more weight-related coexisting conditions) without diabetes to 68 weeks of once-weekly subcutaneous semaglutide (2.4 mg) or placebo, plus lifestyle intervention. Semaglutide therapy was associated with sustained, clinically relevant weight reduction.},
  file = {/Users/xx20081/Zotero/storage/6TC2VVIH/Wilding et al. - 2021 - Once-Weekly Semaglutide in Adults with Overweight or Obesity.pdf}
}

@article{wiviottDapagliflozinCardiovascularOutcomes2019,
  title = {Dapagliflozin and {{Cardiovascular Outcomes}} in {{Type}} 2 {{Diabetes}}},
  author = {Wiviott, Stephen D. and Raz, Itamar and Bonaca, Marc P. and Mosenzon, Ofri and Kato, Eri T. and Cahn, Avivit and Silverman, Michael G. and Zelniker, Thomas A. and Kuder, Julia F. and Murphy, Sabina A. and Bhatt, Deepak L. and Leiter, Lawrence A. and McGuire, Darren K. and Wilding, John P. H. and Ruff, Christian T. and {Gause-Nilsson}, Ingrid A. M. and Fredriksson, Martin and Johansson, Peter A. and Langkilde, Anna-Maria and Sabatine, Marc S. and {DECLARE--TIMI 58 Investigators}},
  year = {2019},
  month = jan,
  journal = {The New England Journal of Medicine},
  volume = {380},
  number = {4},
  pages = {347--357},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1812389},
  abstract = {BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS: We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke. The primary efficacy outcomes were MACE and a composite of cardiovascular death or hospitalization for heart failure. Secondary efficacy outcomes were a renal composite ({$\geq$}40\% decrease in estimated glomerular filtration rate to {$<$}60 ml per minute per 1.73 m2 of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes) and death from any cause. RESULTS: We evaluated 17,160 patients, including 10,186 without atherosclerotic cardiovascular disease, who were followed for a median of 4.2 years. In the primary safety outcome analysis, dapagliflozin met the prespecified criterion for noninferiority to placebo with respect to MACE (upper boundary of the 95\% confidence interval [CI], {$<$}1.3; P{$<$}0.001 for noninferiority). In the two primary efficacy analyses, dapagliflozin did not result in a lower rate of MACE (8.8\% in the dapagliflozin group and 9.4\% in the placebo group; hazard ratio, 0.93; 95\% CI, 0.84 to 1.03; P=0.17) but did result in a lower rate of cardiovascular death or hospitalization for heart failure (4.9\% vs. 5.8\%; hazard ratio, 0.83; 95\% CI, 0.73 to 0.95; P=0.005), which reflected a lower rate of hospitalization for heart failure (hazard ratio, 0.73; 95\% CI, 0.61 to 0.88); there was no between-group difference in cardiovascular death (hazard ratio, 0.98; 95\% CI, 0.82 to 1.17). A renal event occurred in 4.3\% in the dapagliflozin group and in 5.6\% in the placebo group (hazard ratio, 0.76; 95\% CI, 0.67 to 0.87), and death from any cause occurred in 6.2\% and 6.6\%, respectively (hazard ratio, 0.93; 95\% CI, 0.82 to 1.04). Diabetic ketoacidosis was more common with dapagliflozin than with placebo (0.3\% vs. 0.1\%, P=0.02), as was the rate of genital infections that led to discontinuation of the regimen or that were considered to be serious adverse events (0.9\% vs. 0.1\%, P{$<$}0.001). CONCLUSIONS: In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure. (Funded by AstraZeneca; DECLARE-TIMI 58 ClinicalTrials.gov number, NCT01730534 .).},
  langid = {english},
  pmid = {30415602},
  keywords = {Aged,Benzhydryl Compounds,Cardiovascular Diseases,Diabetes Mellitus Type 2,Female,Glucosides,Heart Failure,Hospitalization,Humans,Male,Middle Aged,Sodium-Glucose Transporter 2 Inhibitors}
}

@article{yaghootkarGeneticEvidenceLink2016,
  title = {Genetic {{Evidence}} for a {{Link Between Favorable Adiposity}} and {{Lower Risk}} of {{Type}} 2 {{Diabetes}}, {{Hypertension}}, and {{Heart Disease}}},
  author = {Yaghootkar, Hanieh and Lotta, Luca A. and Tyrrell, Jessica and Smit, Roelof A. J. and Jones, Sam E. and Donnelly, Louise and Beaumont, Robin and Campbell, Archie and Tuke, Marcus A. and Hayward, Caroline and Ruth, Katherine S. and Padmanabhan, Sandosh and Jukema, J. Wouter and Palmer, Colin C. and Hattersley, Andrew and Freathy, Rachel M. and Langenberg, Claudia and Wareham, Nicholas J. and Wood, Andrew R. and Murray, Anna and Weedon, Michael N. and Sattar, Naveed and Pearson, Ewan and Scott, Robert A. and Frayling, Timothy M.},
  year = {2016},
  month = aug,
  journal = {Diabetes},
  volume = {65},
  number = {8},
  pages = {2448--2460},
  issn = {1939-327X},
  doi = {10.2337/db15-1671},
  abstract = {Recent genetic studies have identified some alleles that are associated with higher BMI but lower risk of type 2 diabetes, hypertension, and heart disease. These "favorable adiposity" alleles are collectively associated with lower insulin levels and higher subcutaneous-to-visceral adipose tissue ratio and may protect from disease through higher adipose storage capacity. We aimed to use data from 164,609 individuals from the UK Biobank and five other studies to replicate associations between a genetic score of 11 favorable adiposity variants and adiposity and risk of disease, to test for interactions between BMI and favorable adiposity genetics, and to test effects separately in men and women. In the UK Biobank, the 50\% of individuals carrying the most favorable adiposity alleles had higher BMIs (0.120 kg/m(2) [95\% CI 0.066, 0.174]; P = 1E-5) and higher body fat percentage (0.301\% [0.230, 0.372]; P = 1E-16) compared with the 50\% of individuals carrying the fewest alleles. For a given BMI, the 50\% of individuals carrying the most favorable adiposity alleles were at lower risk of type 2 diabetes (odds ratio [OR] 0.837 [0.784, 0.894]; P = 1E-7), hypertension (OR 0.935 [0.911, 0.958]; P = 1E-7), and heart disease (OR 0.921 [0.872, 0.973]; P = 0.003) and had lower blood pressure (systolic -0.859 mmHg [-1.099, -0.618]; P = 3E-12 and diastolic -0.394 mmHg [-0.534, -0.254]; P = 4E-8). In women, these associations could be explained by the observation that the alleles associated with higher BMI but lower risk of disease were also associated with a favorable body fat distribution, with a lower waist-to-hip ratio (-0.004 cm [95\% CI -0.005, -0.003] 50\% vs. 50\%; P = 3E-14), but in men, the favorable adiposity alleles were associated with higher waist circumference (0.454 cm [0.267, 0.641] 50\% vs. 50\%; P = 2E-6) and higher waist-to-hip ratio (0.0013 [0.0003, 0.0024] 50\% vs. 50\%; P = 0.01). Results were strengthened when a meta-analysis with five additional studies was conducted. There was no evidence of interaction between a genetic score consisting of known BMI variants and the favorable adiposity genetic score. In conclusion, different molecular mechanisms that lead to higher body fat percentage (with greater subcutaneous storage capacity) can have different impacts on cardiometabolic disease risk. Although higher BMI is associated with higher risk of diseases, better fat storage capacity could reduce the risk.},
  langid = {english},
  pmcid = {PMC5386140},
  pmid = {27207519},
  keywords = {Adiposity,Adult,Aged,Body Mass Index,Diabetes Mellitus Type 2,Female,Genetic Predisposition to Disease,Heart Diseases,Humans,Hypertension,Male,Middle Aged,Obesity,Odds Ratio,Risk Factors,Sex Factors,Waist Circumference,Waist-Hip Ratio},
  file = {/Users/xx20081/Zotero/storage/9S96TJLP/Yaghootkar et al. - 2016 - Genetic Evidence for a Link Between Favorable Adip.pdf}
}

@article{yancy2013ACCFAHA2013,
  title = {2013 {{ACCF}}/{{AHA Guideline}} for the {{Management}} of {{Heart Failure}}: {{Executive Summary}}},
  shorttitle = {2013 {{ACCF}}/{{AHA Guideline}} for the {{Management}} of {{Heart Failure}}},
  author = {Yancy, Clyde W. and Jessup, Mariell and Bozkurt, Biykem and Butler, Javed and Casey, Donald E. and Drazner, Mark H. and Fonarow, Gregg C. and Geraci, Stephen A. and Horwich, Tamara and Januzzi, James L. and Johnson, Maryl R. and Kasper, Edward K. and Levy, Wayne C. and Masoudi, Frederick A. and McBride, Patrick E. and McMurray, John J.V. and Mitchell, Judith E. and Peterson, Pamela N. and Riegel, Barbara and Sam, Flora and Stevenson, Lynne W. and Tang, W.H. Wilson and Tsai, Emily J. and Wilkoff, Bruce L.},
  year = {2013},
  month = oct,
  journal = {Circulation},
  volume = {128},
  number = {16},
  pages = {1810--1852},
  publisher = {American Heart Association},
  doi = {10.1161/CIR.0b013e31829e8807},
  urldate = {2025-01-26},
  file = {/Users/xx20081/Zotero/storage/37FRYCHY/Yancy et al. - 2013 - 2013 ACCFAHA Guideline for the Management of Heart Failure Executive Summary.pdf}
}

@article{yanGenomewideAnalysisDisease2018a,
  title = {Genome-Wide Analysis of Disease Progression in Age-Related Macular Degeneration},
  author = {Yan, Qi and Ding, Ying and Liu, Yi and Sun, Tao and Fritsche, Lars G and Clemons, Traci and Ratnapriya, Rinki and Klein, Michael L and Cook, Richard J and Liu, Yu and Fan, Ruzong and Wei, Lai and Abecasis, Gon{\c c}alo R and Swaroop, Anand and Chew, Emily Y and Weeks, Daniel E and Chen, Wei},
  year = {2018},
  month = mar,
  journal = {Human Molecular Genetics},
  volume = {27},
  number = {5},
  pages = {929--940},
  issn = {0964-6906},
  doi = {10.1093/hmg/ddy002},
  urldate = {2024-08-14},
  abstract = {Family- and population-based genetic studies have successfully identified multiple disease-susceptibility loci for Age-related macular degeneration (AMD), one of the first batch and most successful examples of genome-wide association study. However, most genetic studies to date have focused on case--control studies of late AMD (choroidal neovascularization or geographic atrophy). The genetic influences on disease progression are largely unexplored. We assembled unique resources to perform a genome-wide bivariate time-to-event analysis to test for association of time-to-late-AMD with {$\sim$}9 million variants on 2721 Caucasians from a large multi-center randomized clinical trial, the Age-Related Eye Disease Study. To our knowledge, this is the first genome-wide association study of disease progression (bivariate survival outcome) in AMD genetic studies, thus providing novel insights to AMD genetics. We used a robust Cox proportional hazards model to appropriately account for between-eye correlation when analyzing the progression time in the two eyes of each participant. We identified four previously reported susceptibility loci showing genome-wide significant association with AMD progression: ARMS2-HTRA1 (P\,=\,8.1 {\texttimes} 10-43), CFH (P = 3.5 {\texttimes} 10-37), C2-CFB-SKIV2L (P = 8.1 {\texttimes} 10-10) and C3 (P = 1.2 {\texttimes} 10-9). Furthermore, we detected association of rs58978565 near TNR (P = 2.3 {\texttimes} 10-8), rs28368872 near ATF7IP2 (P = 2.9 {\texttimes} 10-8) and rs142450006 near MMP9 (P = 0.0006) with progression to choroidal neovascularization but not geographic atrophy. Secondary analysis limited to 34 reported risk variants revealed that LIPC and CTRB2-CTRB1 were also associated with AMD progression (P {$<$} 0.0015). Our genome-wide analysis thus expands the genetics in both development and progression of AMD and should assist in early identification of high risk individuals.},
  pmcid = {PMC6059197},
  pmid = {29346644},
  file = {/Users/xx20081/Zotero/storage/JVN9MZFY/Yan et al. - 2018 - Genome-wide analysis of disease progression in age.pdf}
}

@misc{yangLimitedOverlapGenetic2023,
  title = {Limited Overlap between Genetic Effects on Disease Susceptibility and Disease Survival},
  author = {Yang, Zhiyu and Pajuste, Fanny-Dhelia and Zguro, Kristina and Cheng, Yipeng and Kurant, Danielle E. and Eoli, Andrea and Wanner, Julian and Jermy, Bradley and FinnGen and research Team, Estonian Biobank and Kanoni, Stavroula and van Heel, David A. and Genes \&amp and Team, Health Research and Hayward, Caroline and Marioni, Riccardo E. and McCartney, Daniel L. and Renieri, Alessandra and Furini, Simone and Consortium, Genomics England Research and M{\"a}gi, Reedik and Gusev, Alexander and Drineas, Petros and Paschou, Peristera and Heyne, Henrike and Ripatti, Samuli and Mars, Nina and Ganna, Andrea},
  year = {2023},
  month = oct,
  pages = {2023.10.10.23296544},
  publisher = {medRxiv},
  doi = {10.1101/2023.10.10.23296544},
  urldate = {2024-08-14},
  abstract = {Understanding disease progression is of a high biological and clinical interest. Unlike disease susceptibility whose genetic basis has been abundantly studied, less is known about the genetics of disease progression and its overlap with disease susceptibility. Considering ten common diseases (N cases ranging from 17,152 to 99,666) across seven biobanks, we systematically compared the genetic architecture of susceptibility and progression, defined as disease-specific mortality. We identified only one locus significantly associated with disease-specific mortality and show that, at a similar sample size, more genome-wide significant loci can be identified in a GWAS of disease susceptibility. Variants that were significantly affecting disease susceptibility were weakly or not associated with disease-specific mortality. Moreover, susceptibility polygenic scores (PGSs) were weak predictor of disease-specific mortality while a PGS for general lifespan was significantly associated with disease-specific mortality for five out of ten diseases. We used theoretical derivation and simulation to propose plausible explanations for our empirical observations and account for potential index-event bias. Overall, our findings point to little similarity in genetic effects between disease susceptibility and disease-specific mortality and suggest that either larger sample sizes or different measures of progression are needed to identify the genetic underpinning of disease progression.},
  archiveprefix = {medRxiv},
  copyright = {{\copyright} 2023, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/VE5E2Z2A/Yang et al. - 2023 - Limited overlap between genetic effects on disease.pdf}
}

@article{yengoMetaanalysisGenomewideAssociation2018,
  title = {Meta-Analysis of Genome-Wide Association Studies for Height and Body Mass Index in {$\sim$}700000 Individuals of {{European}} Ancestry},
  author = {Yengo, Loic and Sidorenko, Julia and Kemper, Kathryn E. and Zheng, Zhili and Wood, Andrew R. and Weedon, Michael N. and Frayling, Timothy M. and Hirschhorn, Joel and Yang, Jian and Visscher, Peter M. and {GIANT Consortium}},
  year = {2018},
  month = oct,
  journal = {Human Molecular Genetics},
  volume = {27},
  number = {20},
  pages = {3641--3649},
  issn = {1460-2083},
  doi = {10.1093/hmg/ddy271},
  abstract = {Recent genome-wide association studies (GWAS) of height and body mass index (BMI) in {$\sim$}250000 European participants have led to the discovery of {$\sim$}700 and {$\sim$}100 nearly independent single nucleotide polymorphisms (SNPs) associated with these traits, respectively. Here we combine summary statistics from those two studies with GWAS of height and BMI performed in {$\sim$}450000 UK Biobank participants of European ancestry. Overall, our combined GWAS meta-analysis reaches N~{$\sim$}700000 individuals and substantially increases the number of GWAS signals associated with these traits. We identified 3290 and 941 near-independent SNPs associated with height and BMI, respectively (at a revised genome-wide significance threshold of P~{$<~$}1~{\texttimes}~10-8), including 1185 height-associated SNPs and 751 BMI-associated SNPs located within loci not previously identified by these two GWAS. The near-independent genome-wide significant SNPs explain {$\sim$}24.6\% of the variance of height and {$\sim$}6.0\% of the variance of BMI in an independent sample from the Health and Retirement Study (HRS). Correlations between polygenic scores based upon these SNPs with actual height and BMI in HRS participants were {$\sim$}0.44 and {$\sim$}0.22, respectively. From analyses of integrating GWAS and expression quantitative trait loci (eQTL) data by summary-data-based Mendelian randomization, we identified an enrichment of eQTLs among lead height and BMI signals, prioritizing 610 and 138 genes, respectively. Our study demonstrates that, as previously predicted, increasing GWAS sample sizes continues to deliver, by the discovery of new loci, increasing prediction accuracy and providing additional data to achieve deeper insight into complex trait biology. All summary statistics are made available for follow-up studies.},
  langid = {english},
  pmcid = {PMC6488973},
  pmid = {30124842},
  keywords = {Body Height,Body Mass Index,Body Weight,Female,Genome Human,Genome-Wide Association Study,Humans,Male,Polymorphism Single Nucleotide,Quantitative Trait Loci,White People},
  file = {/Users/xx20081/Zotero/storage/F2Q2B374/Yengo et al. - 2018 - Meta-analysis of genome-wide association studies f.pdf}
}

@article{yusufEffectsCandesartanPatients2003,
  title = {Effects of Candesartan in Patients with Chronic Heart Failure and Preserved Left-Ventricular Ejection Fraction: The {{CHARM-Preserved Trial}}},
  shorttitle = {Effects of Candesartan in Patients with Chronic Heart Failure and Preserved Left-Ventricular Ejection Fraction},
  author = {Yusuf, Salim and Pfeffer, Marc A. and Swedberg, Karl and Granger, Christopher B. and Held, Peter and McMurray, John J. V. and Michelson, Eric L. and Olofsson, Bertil and Ostergren, Jan and {CHARM Investigators and Committees}},
  year = {2003},
  month = sep,
  journal = {Lancet (London, England)},
  volume = {362},
  number = {9386},
  pages = {777--781},
  issn = {1474-547X},
  doi = {10.1016/S0140-6736(03)14285-7},
  abstract = {BACKGROUND: Half of patients with chronic heart failure (CHF) have preserved left-ventricular ejection fraction (LVEF), but few treatments have specifically been assessed in such patients. In previous studies of patients with CHF and low LVEF or vascular disease and preserved LVEF, inhibition of the renin-angiotensin system is beneficial. We investigated the effect of addition of an angiotensin-receptor blocker to current treatments. METHODS: Between March, 1999, and July, 2000, we randomly assigned 3023 patients candesartan (n=1514, target dose 32 mg once daily) or matching placebo (n=1509). Patients had New York Heart Association functional class II-IV CHF and LVEF higher than 40\%. The primary outcome was cardiovascular death or admission to hospital for CHF. Analysis was done by intention to treat. FINDINGS: Median follow-up was 36.6 months. 333 (22\%) patients in the candesartan and 366 (24\%) in the placebo group experienced the primary outcome (unadjusted hazard ratio 0.89 [95\% CI 0.77-1.03], p=0.118; covariate adjusted 0.86 [0.74-1.0], p=0.051). Cardiovascular death did not differ between groups (170 vs 170), but fewer patients in the candesartan group than in the placebo group were admitted to hospital for CHF once (230 vs 279, p=0.017) or multiple times. Composite outcomes that included non-fatal myocardial infarction and non-fatal stroke showed similar results to the primary composite (388 vs 429; unadjusted 0.88 [0.77-1.01], p=0.078; covariate adjusted 0.86 [0.75-0.99], p=0.037). INTERPRETATION: Candesartan has a moderate impact in preventing admissions for CHF among patients who have heart failure and LVEF higher than 40\%.},
  langid = {english},
  pmid = {13678871},
  keywords = {Adolescent,Adult,Aged,Angiotensin Receptor Antagonists,Antihypertensive Agents,Benzimidazoles,Biphenyl Compounds,Cardiovascular Diseases,Double-Blind Method,Female,Follow-Up Studies,Heart Failure,Hospitalization,Humans,Male,Middle Aged,Outcome Assessment Health Care,Placebos,Stroke Volume,Tetrazoles,Treatment Outcome,Ventricular Function Left},
  file = {/Users/xx20081/Zotero/storage/DBUH4AU9/Yusuf et al. - 2003 - Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejectio.pdf}
}

@article{zhengRecentDevelopmentsMendelian2017b,
  title = {Recent {{Developments}} in {{Mendelian Randomization Studies}}},
  author = {Zheng, Jie and Baird, Denis and Borges, Maria-Carolina and Bowden, Jack and Hemani, Gibran and Haycock, Philip and Evans, David M. and Smith, George Davey},
  year = {2017},
  journal = {Current Epidemiology Reports},
  volume = {4},
  number = {4},
  pages = {330--345},
  issn = {2196-2995},
  doi = {10.1007/s40471-017-0128-6},
  abstract = {PURPOSE OF REVIEW: Mendelian randomization (MR) is a strategy for evaluating causality in observational epidemiological studies. MR exploits the fact that genotypes are not generally susceptible to reverse causation and confounding, due to their fixed nature and Mendel's First and Second Laws of Inheritance. MR has the potential to provide information on causality in many situations where randomized controlled trials are not possible, but the results of MR studies must be interpreted carefully to avoid drawing erroneous conclusions. RECENT FINDINGS: In this review, we outline the principles behind MR, as well as assumptions and limitations of the method. Extensions to the basic approach are discussed, including two-sample MR, bidirectional MR, two-step MR, multivariable MR, and factorial MR. We also consider some new applications and recent developments in the methodology, including its ability to inform drug development, automation of the method using tools such as MR-Base, and phenome-wide and hypothesis-free MR. SUMMARY: In conjunction with the growing availability of large-scale genomic databases, higher level of automation and increased robustness of the methods, MR promises to be a valuable strategy to examine causality in complex biological/omics networks, inform drug development and prioritize intervention targets for disease prevention in the future.},
  langid = {english},
  pmcid = {PMC5711966},
  pmid = {29226067},
  keywords = {Databases and automation tools for causal inference,Disease progression,Drug development,Hypothesis-free causality,Mendelian randomization},
  file = {/Users/xx20081/Zotero/storage/LDQUCHG7/Zheng et al. - 2017 - Recent Developments in Mendelian Randomization Studies.pdf}
}

@article{ziaeianEpidemiologyAetiologyHeart2016,
  title = {Epidemiology and Aetiology of Heart Failure},
  author = {Ziaeian, Boback and Fonarow, Gregg C.},
  year = {2016},
  month = jun,
  journal = {Nature Reviews. Cardiology},
  volume = {13},
  number = {6},
  pages = {368--378},
  issn = {1759-5010},
  doi = {10.1038/nrcardio.2016.25},
  abstract = {Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of {$>$}37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience numerous symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance, and fluid retention. Although the underlying causes of HF vary according to sex, age, ethnicity, comorbidities, and environment, the majority of cases remain preventable. HF is associated with increased morbidity and mortality, and confers a substantial burden to the health-care system. HF is a leading cause of hospitalization among adults and the elderly. In the USA, the total medical costs for patients with HF are expected to rise from US\$20.9 billion in 2012 to \$53.1 billion by 2030. Improvements in the medical management of risk factors and HF have stabilized the incidence of this disease in many countries. In this Review, we provide an overview of the latest epidemiological data on HF, and propose future directions for reducing the ever-increasing HF burden.},
  langid = {english},
  pmcid = {PMC4868779},
  pmid = {26935038},
  keywords = {Cost of Illness,Health Care Costs,Heart Failure,Humans,Incidence,Prevalence,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/RZUN6Q6Z/Ziaeian and Fonarow - 2016 - Epidemiology and aetiology of heart failure.pdf}
}

@article{zinmanEmpagliflozinCardiovascularOutcomes2015,
  title = {Empagliflozin, {{Cardiovascular Outcomes}}, and {{Mortality}} in {{Type}} 2 {{Diabetes}}},
  author = {Zinman, Bernard and Wanner, Christoph and Lachin, John M. and Fitchett, David and Bluhmki, Erich and Hantel, Stefan and Mattheus, Michaela and Devins, Theresa and Johansen, Odd Erik and Woerle, Hans J. and Broedl, Uli C. and Inzucchi, Silvio E. and {EMPA-REG OUTCOME Investigators}},
  year = {2015},
  month = nov,
  journal = {The New England Journal of Medicine},
  volume = {373},
  number = {22},
  pages = {2117--2128},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1504720},
  abstract = {BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS: We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, as analyzed in the pooled empagliflozin group versus the placebo group. The key secondary composite outcome was the primary outcome plus hospitalization for unstable angina. RESULTS: A total of 7020 patients were treated (median observation time, 3.1 years). The primary outcome occurred in 490 of 4687 patients (10.5\%) in the pooled empagliflozin group and in 282 of 2333 patients (12.1\%) in the placebo group (hazard ratio in the empagliflozin group, 0.86; 95.02\% confidence interval, 0.74 to 0.99; P=0.04 for superiority). There were no significant between-group differences in the rates of myocardial infarction or stroke, but in the empagliflozin group there were significantly lower rates of death from cardiovascular causes (3.7\%, vs. 5.9\% in the placebo group; 38\% relative risk reduction), hospitalization for heart failure (2.7\% and 4.1\%, respectively; 35\% relative risk reduction), and death from any cause (5.7\% and 8.3\%, respectively; 32\% relative risk reduction). There was no significant between-group difference in the key secondary outcome (P=0.08 for superiority). Among patients receiving empagliflozin, there was an increased rate of genital infection but no increase in other adverse events. CONCLUSIONS: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. (Funded by Boehringer Ingelheim and Eli Lilly; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.).},
  langid = {english},
  pmid = {26378978},
  keywords = {Aged,Benzhydryl Compounds,Cardiovascular Diseases,Cause of Death,Diabetes Mellitus Type 2,Female,Glucosides,Hospitalization,Humans,Hypoglycemic Agents,Intention to Treat Analysis,Kaplan-Meier Estimate,Male,Middle Aged,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/96S7G77H/Zinman et al. - 2015 - Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.pdf}
}
